BLOOD GLUCOSE A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Blood Glucose: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-497-00151-9 1. Blood Glucose-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on blood glucose. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON BLOOD GLUCOSE ...................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Blood Glucose................................................................................ 6 E-Journals: PubMed Central ....................................................................................................... 65 The National Library of Medicine: PubMed ................................................................................ 66 CHAPTER 2. NUTRITION AND BLOOD GLUCOSE .......................................................................... 113 Overview.................................................................................................................................... 113 Finding Nutrition Studies on Blood Glucose............................................................................. 113 Federal Resources on Nutrition ................................................................................................. 114 Additional Web Resources ......................................................................................................... 115 CHAPTER 3. ALTERNATIVE MEDICINE AND BLOOD GLUCOSE .................................................... 117 Overview.................................................................................................................................... 117 National Center for Complementary and Alternative Medicine................................................ 117 Additional Web Resources ......................................................................................................... 120 General References ..................................................................................................................... 124 CHAPTER 4. DISSERTATIONS ON BLOOD GLUCOSE ...................................................................... 125 Overview.................................................................................................................................... 125 Dissertations on Blood Glucose.................................................................................................. 125 Keeping Current ........................................................................................................................ 127 CHAPTER 5. PATENTS ON BLOOD GLUCOSE ................................................................................. 129 Overview.................................................................................................................................... 129 Patents on Blood Glucose........................................................................................................... 129 Patent Applications on Blood Glucose ....................................................................................... 158 Keeping Current ........................................................................................................................ 194 CHAPTER 6. BOOKS ON BLOOD GLUCOSE..................................................................................... 195 Overview.................................................................................................................................... 195 Book Summaries: Federal Agencies............................................................................................ 195 Chapters on Blood Glucose......................................................................................................... 245 Directories.................................................................................................................................. 248 CHAPTER 7. MULTIMEDIA ON BLOOD GLUCOSE .......................................................................... 251 Overview.................................................................................................................................... 251 Video Recordings ....................................................................................................................... 251 Audio Recordings....................................................................................................................... 252 CHAPTER 8. PERIODICALS AND NEWS ON BLOOD GLUCOSE ....................................................... 255 Overview.................................................................................................................................... 255 News Services and Press Releases.............................................................................................. 255 Newsletters on Blood Glucose.................................................................................................... 257 Newsletter Articles .................................................................................................................... 257 Academic Periodicals covering Blood Glucose ........................................................................... 258 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 261 Overview.................................................................................................................................... 261 U.S. Pharmacopeia..................................................................................................................... 261 Commercial Databases ............................................................................................................... 262 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 267 Overview.................................................................................................................................... 267 NIH Guidelines.......................................................................................................................... 267 NIH Databases........................................................................................................................... 269 Other Commercial Databases..................................................................................................... 271 APPENDIX B. PATIENT RESOURCES ............................................................................................... 273
viii Contents
Overview.................................................................................................................................... 273 Patient Guideline Sources.......................................................................................................... 273 Finding Associations.................................................................................................................. 280 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 283 Overview.................................................................................................................................... 283 Preparation................................................................................................................................. 283 Finding a Local Medical Library................................................................................................ 283 Medical Libraries in the U.S. and Canada ................................................................................. 283 ONLINE GLOSSARIES................................................................................................................ 289 Online Dictionary Directories ................................................................................................... 290 BLOOD GLUCOSE DICTIONARY............................................................................................ 291 INDEX .............................................................................................................................................. 373
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with blood glucose is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about blood glucose, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to blood glucose, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on blood glucose. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to blood glucose, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on blood glucose. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON BLOOD GLUCOSE Overview In this chapter, we will show you how to locate peer-reviewed references and studies on blood glucose.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and blood glucose, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “blood glucose” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Blood Glucose Monitoring Update Source: Diabetes Self-Management. 19(1): 46-52. January-February 2002. Contact: Available from R.A. Rapaport Publishing, Inc. 150 West 22nd Street, New York, NY 10011. (800) 234-0923. Website: www.diabetes-self-mgmt.com. Summary: In the 1970's, home blood glucose monitoring revolutionized the treatment of diabetes by providing the feedback required to manage diabetes. In the 1980's, the equipment improved, but was still fairly complicated and expensive to use on a regular basis. In the 1990's home blood glucose monitoring became a standard of care. This article brings readers up to date on blood glucose monitoring (self monitoring of blood glucose, or SMBG). The author notes that there has been further progression in glucose monitoring technology toward greater accuracy and elimination of most of the annoying
4
Blood Glucose
parts of the process. For example, some meters no longer require a fingerstick, some no longer require the user to handle test strips, and at least one no longer requires the user to code the meter for each new batch of test strips. One sidebar lists meters by brand name and features. The author also explains data management software, which is now a standard feature for almost all meters. The author concludes by reviewing strategies to avoid common errors, including the use of defective or outdated strips, soiled meters, and exposing the meter to extremes of heat and cold. The article closes with a list of twelve steps to accurate and easy SMBG. 1 table. •
Self-Monitoring of Blood Glucose: The Basics Source: Clinical Diabetes. 20(1): 45-47. 2002. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: Self monitoring of blood glucose (SMBG) is an important component of modern therapy for diabetes mellitus. The goal of SMBG is to collect detailed information about blood glucose levels at many time points to enable maintenance of a more constant glucose level by more precise regimens, including adjustment of dietary intake, physical activity, and insulin doses. This article reviews the basics of SMBG for health care providers who will be working with patients with diabetes. The author discusses SMBG use and frequency and the specifics of different types and brands of meters. One table summarizes the more popular blood glucose meters, including their weight, the required blood sample size, test time, memory, and special features. The author concludes that SMBG is recommended for all patients treated with insulin and is desirable for all patients with diabetes. Judicious use of SMBG data can help to improve glycemic control, select an antidiabetes regimen, and provide powerful feedback to patients wishing to improve metabolic control. 1 table. 6 references.
•
Bedside Blood Glucose Monitoring in Hospitals Source: Diabetes Care. 25(Supplement 1): S110. January 2002. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: The modern management of hospitalized patients with diabetes includes capillary blood glucose (sugar) determinations at the bedside. The rapidity with which results can be obtained, and therapeutic decisions made, can improve management and conceivably shorten hospital stays. This article presents the American Diabetes Association position statement on bedside blood glucose monitoring in hospitals. Use of bedside blood glucose monitoring requires clear administrative responsibility for the procedure, a well-defined policy or procedure manual, a training program for those personnel doing the testing, quality control procedures, and regularly scheduled equipment maintenance. 1 reference.
•
Programmable Meters: The Handy Blood Glucose Meter Meets the 21st Century Source: Diabetes Forecast. 55(5): 65-68. May 2002. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article helps readers with diabetes understand programmable blood glucose meters. The author first introduces a person with diabetes who uses five
Studies
5
different meters (one at home, one in each of the family cars, one at his office, one in his briefcase) and who uses computer software to reconcile all the data collected by these five meters. Every couple of weeks, the man hooks his meters up, one by one, to his computer and obtains his data as easy to read charts and graphs. The author then describes the benefits of getting this type of data, and the equipment that would be required. Other features available on most software programs include modal readings, physician tracking fields, and the ability to average blood glucose readings by time of day, mealtime, or even day of the week. The author then considers why so few people with diabetes (estimated at less than 1 percent) use these programs with their blood glucose meters. One side bar offers details about deciding which programmable blood glucose meter to purchase; another sidebar lists the contact information for eight manufacturers of blood glucose meters that interact with computer software. •
Impact of Self-Monitoring of Blood Glucose on Self-Efficacy and Pregnancy Outcomes in Women with Diet-Controlled Gestational Diabetes Source: Diabetes Educator. 28(3): 435-443. May-June 2002. Contact: Available from American Association of Diabetes Educators. 100 West Monroe Street, 4th Floor, Chicago, IL 60603-1901. (312) 424-2426. Summary: This article reports on a study undertaken to examine the effects of selfmonitoring of blood glucose (SMBG) on feelings of self-efficacy, dietary compliance, and pregnancy outcomes in women with diet-controlled gestational diabetes mellitus (GDM). The study included 58 women with GDM and a fasting blood glucose level less than 95 milligrams per deciliter (mg/dL) who were randomly assigned to 2 groups. The experimental group measured their blood glucose levels 4 times daily using a reflectance meter with memory. Metabolic status was assessed in the control group by periodic monitoring at prenatal visits. Otherwise the management protocol was identical for both groups. The Diabetes Empowerment Scale was completed at study entry and at 37 weeks gestation to assess feelings of self-efficacy. Dietary compliance was assessed at each visit. Both groups of women achieved excellent glucose control; only 1 woman in each group required insulin therapy. There were no significant differences with regard to feelings of self-efficacy, dietary compliance, birth weight, gestational age at delivery, Apgar scores, and neonatal complications. Rates of macrosomia (large size baby), delivery by cesarean section, and occurrence of birth trauma were similar. The authors conclude that SMBG appears to have little effect on maternal feelings of self-efficacy, dietary compliance, or pregnancy outcomes in women with diet-controlled GDM. 7 tables. 20 references.
•
Self-Monitoring of Blood Glucose Source: Clinical Diabetes. 20(1): 48. 2002. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This patient education fact sheet reviews self monitoring of blood glucose (SMBG), the use of a home glucose meter to check and track blood glucose (sugar) levels. Designed for patients with diabetes, the fact sheet answers six common questions, covering the indications for SMBG, choosing a blood glucose meter, who should check their blood glucose, how often blood glucose levels should be checked, how to learn to use a blood glucose meter, and how the results of SMBG will be utilized. The fact sheet briefly describes how the results will let the health care provider and patient tailor the diabetes treatment plan to help avoid high or low blood glucose
6
Blood Glucose
levels (hyperglycemia and hypoglycemia, respectively). The fact sheet is designed to be photocopied and distributed to patients.
Federally Funded Research on Blood Glucose The U.S. Government supports a variety of research studies relating to blood glucose. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to blood glucose. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore blood glucose. The following is typical of the type of information found when searching the CRISP database for blood glucose: •
Project Title: AGING AND MEMORY Principal Investigator & Institution: Gold, Paul E.; Professor; Psychology; University of Illinois Urbana-Champaign Henry Administration Bldg Champaign, Il 61820 Timing: Fiscal Year 2003; Project Start 01-DEC-1996; Project End 31-JUL-2008 Summary: (provided by applicant): Administration of glucose enhances learning and memory in rodents and humans, and is especially effective in reversing age-related impairments in memory. This research project will examine whether age-related changes in the regulation of blood and brain glucose contribute to age-related impairments of learning and memory. Training is often accompanied by increases in circulating epinephrine levels, with subsequent increases in circulating glucose levels, in a manner related to endogenous modulation of learning and memory. Recent evidence suggests that, in aged male Fischer 344 rats, there is an uncoupling between epinephrine release from the adrenal medulla and subsequent increases in blood glucose levels, resulting in diminished responses of circulating glucose levels to training. The reduced responses of blood glucose levels may significantly influence brain processes important for learning and memory. In the brain, extracellular glucose levels in the hippocampus are depleted while rats are tested on a hippocampus dependent spontaneous alternation task. As compared to young adult rats, aged rats perform poorly on this task and exhibit exaggerated depletion of glucose in the hippocampus during behavioral testing. Injections (i.p.) of glucose block the depletion in the hippocampus and also enhance performance on the alternation task in aged rats. Together, these findings suggest that altered control of glucose levels in blood and brain during aging may contribute to agerelated impairments of memory. Using young and old rats, the proposed experiments will examine the contribution of age-related changes in responses of glucose to training to age-related changes in learning and memory. Proposed experiments will examine
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
7
changes in circulating and brain glucose responses to training in aged rats, assessing the relationship of these changes to learning and memory. The experiments will determine whether the depletion of extracellular glucose levels in the hippocampus, prominent in aged rats, is evident also in the striatum and prefrontal cortex. These experiments include measures of changes in extracellular brain glucose levels during training with and without treatments that enhance learning and memory in aged rats and also assess the efficacy in enhancing learning and memory of microinjections of glucose directly into those brain areas in which glucose is depleted by training. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTAGONISTS OF A2B RECEPTORS IMPROVE INSULIN SENSITIVITY Principal Investigator & Institution: Figler, Robert A.; Adenosine Therapeutics, Llc Charlottesville, Va 22902 Timing: Fiscal Year 2004; Project Start 15-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): This is a phase II SBIR grant to develop a new therapy for the treatment of type II diabetes. Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation of selective antagonists of A2B adenosine receptors (A2BAR). Dr. Kathryn LaNoue of Penn State University discovered that A2BAR blockers lower blood glucose in insulin resistant animals. A use patent to this discovery has been licensed to ATL. In the phase I portion of this grant we found that novel highly selective A2BAR blockers lower blood glucose in mice or rats, but the efficacy of the early compounds was limited, probably due to very low aqueous solubility and low bio availability. A new family of antagonist that has much higher solubility has recently been formulated at ATL and found to be very effective in lowering blood glucose. In a continuing collaboration between ATL and the LaNoue laboratory, we now propose to identify a therapeutic candidate for the treatment of diabetes. More compounds will be screened for potency and selectivity in radio ligand binding assays. Promising compounds will be screened to determine their potency and efficacy in bioassays to lower blood glucose in insulin resistant animals. The most active compounds will be evaluated for oral activity and for pharmacokinetic and pharmacodynamic properties. A few compounds will be evaluated in euglycemic clamp studies with Zucker rats. Our goal is to identify a lead compound that has good characteristics as a potential new drug. If we identify such a compound our plan is to partner with a large pharmaceutical company for clinical trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ASSESMENT OF A CHRONIC SUBCUTANEOUS GLUCOSE SENSOR Principal Investigator & Institution: Ward, W Kenneth.; Legacy Health System 1919 Nw Lovejoy St Portland, or 97209 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: (provided by applicant): In the United States, diabetes mellitus is the leading cause of end-stage kidney failure, blindness in adults under age 65, and is the second leading cause (after trauma) of limb amputation. Poorly-controlled glucose levels are the major cause of these complications, but tight glycemic control is difficult to safely achieve using present technology. While a continuously-functioning glucose sensor would assist in safely achieving tight glucose control, such devices are typified by instability and loss of output over time due to the formation of foreign-body scar tissue, which eventually surrounds the sensors. Miniaturized sensors could be implanted
8
Blood Glucose
under the skin with minimal discomfort. It is possible that the surrounding scar capsule could be made much more "friendly" to a glucose sensor by the slow release of growth factor compounds from the sensor surface. The hypothesis is that such compounds would reduce the scar fibrosis and generate many blood vessels in the capsule. These blood vessels are important to the long-term function of the sensor given its need for continuous glucose and oxygen delivery. A study will initially be performed in order to ascertain the optimal dosage of the growth factor. Then the growth factor (or saline control) will be slowly released over one month from miniaturized pumps into the tissue, which directly contacts the sensor. The thickness of the capsule and the formation of new blood vessels will measured by standard histologic staining techniques and by endothelial Factor Vifi immunohistochemistry. Another major problem of glucose sensors is short-term drift. It is frequently observed but poorly understood. It now appears that it may be possible to obtain stable readings from simultaneous recordings of multiple sensor electrodes. The technique which will be used to separate the accurate electrode signals from the inaccurate (outlying) signals is from the field of median statistics and is called the ZMAD method of Rousseeauw. The ZMAD data processing will be performed prospectively and continuously. In addition, the sensors and their transmitters will be miniaturized with the help of a biotelemetry company, MiniMitter. The body can be hostile to compounds which coat implanted devices. We will compare two promising polyurethanes as sensor coats: a carbonate based- vs. ether-based polymer. We will compare their long term function in studies using rabbits, which will be also be used to ascertain the effect of the growth factors and the real-time data processing. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CARDIOVASCULAR DISEASE IN THE PIMA INDIANS Principal Investigator & Institution: Howard, Barbara V.; President; Medstar Research Institute Hyattsville, Md 20783 Timing: Fiscal Year 2002; Project Start 30-SEP-1988; Project End 31-MAY-2005 Summary: MedStar (formerly Medlantic) Research Institute proposes to continue its participation in the Strong Heart Study to manage the Arizona field center and the core laboratory. For the field center, this proposal describes methodology for 1) morbidity and mortality surveillance of the original Strong Heart Study cohort (1099 surviving out of 1500 original men and women ages 45-74 years in Phase I); 2) recruitment and examination of 30 families of at least 30 members, each 15 years and older; and 3) reexamination of the 900 family members from the Phase Ill pilot study. The Arizona field center comprises three American Indian communities: Gila River, Salt River, and Ak Chin. The Arizona center had a 71% recruitment rate in Phase I and 90%+ completion rates in Phases II and III. Morbidity and mortality surveillance obtained data on 99% of the participants. The core laboratory will provide accurate, reliable, stable, and comparable phenotypic measures of coronary heart disease risk factors in blood and urine samples. Measurements to be made for the family cohort include lipoprotein profile, glucose, HbA1c, insulin, LDL size, fibrinogen, PAI-1, apoE phenotype, apoB, apoA1, chemistry profile, and urinary albumin and creatinine. In addition, some exciting new markers of evolving importance in the etiology of atherosclerosis will be evaluated on stored baseline samples using a case-cohort design. sVCAM and endothelin-1 will be measured in approximately 400 definite cardiovascular disease cases and suitable controls. TSH also will be measured in these samples to allow evaluation of its role in cardiovascular disease in American Indians. The core laboratory will store blood, urine, and DNA in a safe and organized manner for effective inventory
Studies
9
so that the resources will be retrievable for other scientists and the American Indian communities. Laboratory performance during the previous exams has been excellent, with high completion rates and precision and accuracy exceeding those of most core laboratories. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CASEIN COATED CAP PARTICLES FOR ORAL INSULIN DELIVERY Principal Investigator & Institution: Morcol, Tulin; Biosante Pharmaceuticals, Inc 4600 Highlands Pky, Ste A&B Smyrna, Ga 30082 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2004 Summary: (provided by applicant): Parenteral administration of insulin via the subcutaneous route is the only commercially available therapy to treat insulindependent diabetes mellitus. Multiple daily injections are required to manage and maintain blood glucose control due to its relatively short duration of action (4 to 8 hours). Oral insulin would provide an attractive alternative. However, successful development of an oral insulin formulation has been hampered by the numerous and complex barriers to protein absorption inherent to the gastrointestinal tract. A novel delivery system has emerged that may overcome these obstacles. The design of this delivery system incorporates an understanding of the complex barriers to oral insulin absorption and results in the production of biodegradable, insulin-impregnated, calcium phosphate / polyethylene glycol microparticles coated with casein. The characterization of particle size and morphology, their associated physicochemical properties, and the critical factors affecting these parameters will assist in formula optimization and process development. Thus, the aims of Phase I are to prepare a lot of casein coated, insulinladen microparticles utilizing the most current manufacturing process; to fully characterize them in terms of particle size, particle morphology, % loading of insulin, insulin activity, relative component composition, moisture content, stability against digestive enzymes, pH-dependent dissolution characteristics, and storage stability; and to demonstrate a dose-dependent reduction in blood glucose with concomitant increase in serum insulin levels in rodents. Furthermore, modification and adaptation of the delivery system to another orally challenged therapeutic protein, such as human growth hormone, would demonstrate general utility of the delivery system. The long-range goal of this research is to develop a novel, safe, efficacious, long-acting, oral delivery system for insulin demonstrating a dose dependency with reduced variability that may be applicable to other therapeutically relevant proteins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CEREBRAL RESPONSES TO INSULIN-INDUCED HYPOGLYCEMIA Principal Investigator & Institution: Seaquist, Elizabeth R.; Associate Professor; Medicine; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 03-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): The overall goal of this project is to define the cerebral response to insulin-induced hypoglycemia. In diabetes, hypoglycemia limits our ability to achieve normoglycemia and thereby reduce the long-term complications of the disease. Recurrent episodes of hypoglycemia also lead to the clinical syndrome of hypoglycemia unawareness in which patients lose their ability to detect hypoglycemia until neuroglycopenia occurs. How the brain adapts to recurrent hypoglycemia is uncertain, but greater understanding of this process will provide insights into how we
10
Blood Glucose
can better treat patients with diabetes. In this investigation, we will directly examine how the human brain responds to hypoglycemia in vivo using high field magnetic resonance imaging and 13C magnet resonance spectroscopy. We will take advantage of the relationship between cerebral blood flow and neuronal activation to determine if glucose sensing regions can be identified in humans and to determine if the response of the brain to hypoglycemia is altered by antecedent glycemia in diabetes. We will also determine if insulin has effects on the brain that are independent of glycemia. The hypotheses we intend to examine and the aims of the studies planned to address each hypothesis are below. Hypothesis #1: During hypoglycemia, regions of the brain with an abundance of glucose sensing neurons such as the hypothalamus, amygdala, and brainstem will increase blood flow at a higher glucose concentration than will other brain regions. Aim #1: To determine blood and brain glucose concentrations at which regional cerebral blood flow is increased during hypoglycemia. Hypothesis #2: Cerebral blood flow will increase during hypoglycemia at the same brain glucose but at different blood glucose concentration in patients with poorly controlled diabetes, patients with type 1 diabetes and hypoglycemia and in healthy volunteers.Aim #2A: To determine the blood and brain glucose concentrations at which regional cerebral blood flow increases during hypoglycemia in patients with poorly controlled diabetes and compare these values to those measured in healthy volunteers.Aim #2B: To determine the blood and brain glucose concentrations at which regional cerebral blood flow increases during hypoglycemia in patients with type 1 diabetes and hypoglycemia unawareness and compare these values to those measured in healthy volunteers. Hypothesis #3: Insulin has effects independent of glucose on cerebral blood flow.Aim #3: To determine if cerebral blood flow is altered by changes in serum insulin concentrations. Aim #4: To determine if insulin alters neuronal activation as measured event-related potentials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COMPLEMENT IN THE VASCULAR COMPLICATIONS OF DIABETES Principal Investigator & Institution: Halperin, Jose A.; None; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2006 Summary: (provided by applicant): The major goal of this proposal is to investigate glycated human CD59 as a surrogate bio-marker and predictor of vascular diabetic complications, with special focus on diabetic nephropathy and peripheral and cardiovascular disease. CD59 is a key complement regulatory membrane protein that specifically inhibits formation of the membrane attack complex of complement (MAC), a transmembrane pore that triggers the release of growth factors and cytokines that stimulate cell proliferation, inflammation and thrombosis. Human CD59 is inactivated by glycation because it contains in its active site a glycation motif formed by amino acid residues K41-H44, as determined by NMR analysis of the human CD59 structure and site directed mutagenesis studies. We proposed that glycation-inactivation of CD59 leads first to increased MAC deposition in diabetic tissues and then to increased MACinduced release of growth factors and cytokines that synergistically with other hyperglycemia induced pathways promote the diverse tissue damage responsible for the vascular complications that characterize human diabetes. Consistent with this hypothesis, glycated CD59 and activated complement proteins including MAC are found in glomeruli, nerves, blood vessels and failed vein grafts from diabetic but not from nondiabetic patients. Importantly, we have shown that a soluble form of CD59, both glycated and non-glycated, can be measured in human urine and plasma by
Studies
11
established ELISAs. Glycated CD59 levels seem to correlate with the level of glycemic exposure. These extensive preliminary data make it imperative to assess whether glycated CD59 represents a pathogenically relevant biomarker of diabetic vascular complications. Specifically we will investigate whether glycated CD59 in plasma and/or urine identifies sub-populations at risk of developing vascular complications of diabetes (Specific Aim 1), discriminates persons with impaired glucose tolerance who have a higher risk of cardiovascular disease (Specific Aim 2), and predicts the risk of developing diabetic nephropathy (Specific Aim 3) and/or the risk of vein graft failure after peripheral by-pass surgery (Specific Aim 4). Successful accomplishment of these Specific Aims will provide a novel biomarker of diabetic vascular complications; it will also open new avenues for the early treatment and perhaps prevention of those diabetic complications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTINUOUS GLUCOSE SENSORS IN YOUTH: BIOBEHAVIORAL STUDY Principal Investigator & Institution: Wysocki, Tim T.; Chief; Nemours Children's Clinic 807 Children's Way Jacksonville, Fl 322078482 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: (prepared by applicant): Intensive therapy for youths with type 1 diabetes mellitus (DM) yields higher HbA1c and more frequent severe hypoglycemia (SH) than for adults. The advent of continuous glucose sensors (CGS) could yield medical and psychological benefits for these youths. The investigators submit that many patients may not realize these benefits and that psychosocial features of patients and families will affect the outcomes of adding CGS to DM therapy. To maximize the therapeutic benefits of CGS, we need clinically useful information about its glycemic and psychological effects and about psychological influences on its therapeutic utility. This information would be useful in selecting candidates for this technology and for assisting patients and families in achieving positive outcomes from its use. This application addresses four specific aims: 1.) Evaluation of the effects of 12 month?s use of a CGS device (GlucoWatch Biographer, Cygnus, Inc.) on HbA1G, the Kovatchev Low Blood Glucose Index and the frequency of severe hypoglycemia; 2.) Identification of behavioral and psychological consequence of CGS use; 3.) Analysis of psychosocial predictors of metabolic and psychological outcomes; and 4.) Evaluation of glycemic profiles of healthy youths without DM, construction of a normative glycemic profile for use in future studies and comparison of the glycemic profiles of youths with and without diabetes. Specific Aims 1 through 3 will be addressed in a randomized, controlled trial of three intensive therapy regimens that are based on different glucose monitoring methods: SMBG patients will receive current intensive therapy with four to six self-monitored blood glucose tests daily; CGS with Feedback patients will augment SMBG by using a CGS device that gives immediate glucose feedback and alarms for high, low, and rapidly falling levels; CGS without Feedback patients will augment SMBG by using the same CGS device with the feedback and alarm functions disabled. Patients and parents will complete periodic assessments of demographic factors and general and diabetes-specific psychological factors. Statistical analyses will include multivariate analyses of variance, survival analysis and individual growth modeling techniques. Specific Aim 4 will be addressed by studying a demographically similar sample of 240 healthy children and adolescents who will use the GlucoWatch Biographer without feedback for a total of 144 hours during a two-week period. The project results will enhance clinical adoption of CGS technology.
12
Blood Glucose
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTRACEPTIVE IN WOMEN WITH PRIOR GESTATIONAL DIABETES Principal Investigator & Institution: Xiang, Anny H.; Preventive Medicine; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2004; Project Start 01-JAN-2004; Project End 31-DEC-2005 Summary: (provided by applicant): This application is submitted in response to PA-02077, "Secondary Analyses in Diabetes, Digestive and Kidney Diseases". We propose to analyze data from an existing observational cohort database to assess the impact of different types of contraception on the risk of diabetes and on glucose levels, blood pressure and serum lipids in Latino women with prior gestational diabetes mellitus (GDM). We have previously shown that those women are at high risk of developing type 2 diabetes during their reproductive years. They require effective contraception because a) pregnancy planning is required to minimize the risk of conceiving with undetected hyperglycemia, which imparts a risk of congenital malformations to the baby and (b) additional pregnancies increase their risk of diabetes. Contraception should be safe regarding effects on glycemia and risk of diabetes, as well as on blood pressure and lipid levels, which can be elevated in association with the insulin resistance that is common in women with GDM. Using data from a subset of the current cohort available through 1994, we found that low-dose combination oral contraceptives (OCs) did not increase the risk of diabetes, but that a progestin-only oral preparation did increase that risk. Effects on lipids and blood pressure were not evaluated. Approximately 20% of hormonal contraception users in our patients elect to use an injectable progestin preparation, depomedroxyprogesterone acetate (DMPA) for longterm contraception. The impact of that preparation on the risk of diabetes is unknown. Accordingly, we now propose to use an expanded version of the cohort, including all patients through 1998 when accrual ended, to assess the impact of DMPA as compared to OCs and non-hormonal contraception, on the risk of diabetes and on glucose levels, blood pressure and lipid levels. Survival analysis will be use to compare diabetes rates among forms of contraception. Generalized linear models will be used to compare effects on glucose, blood pressure and lipid levels. Successful completion of these analyses will provide novel and clinically important information about the safety of several forms of hormonal contraception that are crucial for young Latino women at high risk for type 2 diabetes. The observational results will also be important to the design of future direct comparisons of different forms of contraception in this high-risk population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DEVELOPMENT NUTRACEUTICAL
OF
AN
ANTI-DIABETES
BOTANICAL
Principal Investigator & Institution: Ilic, Nebojsa; Phytomedics, Inc. 65 Stults Rd Dayton, Nj 08810 Timing: Fiscal Year 2002; Project Start 20-SEP-2002; Project End 31-MAR-2003 Summary: (provided by applicant): This is a revised proposal for the pre-clinical development of PMI-5011, a standardized botanical extract, developed by Phytomedics Inc. and Rutgers University. PMI-5011 effectively lowers blood glucose in insulin deficient and insulin resistant animals, does not cause hypoglycemia, and is safe and non-toxic. All data suggest that PMI-5011 is an efficacious nutritional supplement for
Studies
13
those suffering from diabetes or prediabetic conditions. Preliminary results demonstrate that PMI-5011 specifically affects hepatic gene expression in diabetic rats and promotes insulin mediated glucose uptake by muscle tissues as potential means of normalizing glycemia. Phytomedics will use the SBIR funds to complete the necessary pre-clinical investigation of PMI-5011 and to produce a sufficient supply of the standardized and optimized PMI-5011 material for the remaining preclinical and clinical testing. Phytomedics will also confirm the identity of the active ingredients of PMI-5011 and determine optimal hydroponic greenhouse methods for the source plant cultivation. Phytomedics will conduct limited clinical trials of PMI-5011 in Phase 2 of this proposal. Phase 3 of this proposal will involve the full-scale commercialization of PMI-5011 with a commercial partner, using PMI-5011 exclusively supplied by Phytomedics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SENSORS
DEVELOPMENT
OF
GENETICALLY-ENCODED
GLUCOSE
Principal Investigator & Institution: Altenberg, Guillermo A.; Physiology and Biophysics; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2004 Summary: (provided by applicant): In most living organisms, including animals, plants and bacteria, glucose is employed as energy source, for energy storage and in the synthesis of essential biological molecules. Glucose measurements are critical to elucidate the basic characteristics of glucose distribution at the cellular and subcellular level under normal conditions and in disease states. This is particularly important because in diabetes mellitus, one of the most common chronic diseases in humans, alterations in glucose metabolism (not well understood at the cell level) are the most important factor. Currently, there is no glucose sensor suitable for measuring glucose in cells and the sensors available for clinical and industrial applications are frequently unsatisfactory. This proposal presents a novel approach to develop glucose sensors based on the use of autofluorescent proteins (proteins that fluoresce in the absence of cofactors) and the glucose binding properties of the enzyme glucokinase (hexokinase IV), the glucose sensor protein of the pancreas. The most useful autofluorescent proteins derive from the green fluorescent protein from the jellyfish Aequoria victoria and the red fluorescent protein from a coral of the Discosoma genus (red fluorescent protein). Our plan is to develop a sensor that will be: 1) Suitable for "in vitro" measurements of glucose concentration, and 2) Genetically-encoded for targeting to specific cells and subcellular compartments, as well as specific cells and tissues of transgenic animals. The sensor can also be evaluated as the backbone for a continuous minimally invasive glucose monitoring system in diabetic patients. We plan to engineer glucose sensors by fusion of glucokinase to autofluorescent proteins. We will purify the sensor proteins expressed in E. coil, analyze their properties (fluorescence properties, response to glucose, specificity) and test their usefulness for measuring glucose in living cells. Although the goal of the project is to obtain a sensor for measurements in cells, to foster basic research under normal and disease conditions, potentially the new sensors can be adapted to industrial (e.g., glucose measurements in fruit juices) and medical (monitoring glycemia in diabetes mellitus) uses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
14
•
Blood Glucose
Project Title: DIET THERAPY IN DIABETES MANAGEMENT OF MEXICAN AMERICANS Principal Investigator & Institution: Briones, Esperanza R.; Univ of Texas-Pan American Edinburg, Tx Timing: Fiscal Year 2002; Project Start 01-JUN-1977; Project End 31-JUL-2006 Summary: (provided by applicant): Diabetes in Hispanic Americans is a serious health problem. It affects 1.2 million or 10.6% of the Mexican American population. Approximately 24% of Mexican Americans in the U.S. between the ages of 45-74 have diabetes. In Hispanic adults, diabetes is primarily type 2, and its incidence is correlated with the occurrence of obesity. The purpose of the study is to conduct a two and half (21/2) year randomized trial of a culturally appropriate dietary and lifestyle education intervention designed for Mexican Americans with type 2 diabetes residing in Rio Grande Valley. Both males and females, with type 2 diabetes will be recruited, with two age subgroups, ages 45-59 and 60 and above. Eligible participants will be randomized into two groups. Group 1 will receive the conventional dietary counseling and group 2 will receive additional sessions and follow-up. The specific objectives of the study are: to assess the effectiveness of a culturally appropriate intervention to improve participants' adherence to dietary modifications, medication schedules, and promote sustained improvements in lifestyle behaviors; to assess the anthropometric measurements, health habits, and nutrient consumption of subjects at baseline and after dietary and educational sessions; to determine fasting serum glucose and glycosylated hemoglobin in assessing the level of diabetes control; and to assess the lipid profile (serum cholesterol, triglycerides, high density lipoprotein cholesterol) which are associated with the development of coronary heart disease in diabetes. Statistical calculations will be used to evaluate the differences between the two groups. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DIETARY GLYCEMIC LOAD, BODY WEIGHT, AND BLOOD LIPIDS Principal Investigator & Institution: Ma, Yunsheng; Medicine; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, Ma 01655 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): The overall goal of this 2 year proposal is to examine the association of glycemic load (GL), derived from 24-hour dietary recalls, with body weight and blood lipids (including total cholesterol, LDL, HDL, and triglycerides), and to study seasonal and short-term variation of GL in a free-living healthy population. Results from short-term experimental studies and a limited number of observational studies suggest that GL, a measure of the quality and quantity of carbohydrate in foods, may be related to body weight and serum lipids, and GL potentially should be considered in dietary recommendations. However, neither the glycemic index (GI) nor GL is considered in the dietary guidelines of the American Heart Association, the U.S Department of Agriculture, or the American Diabetes Association. We will use dietary data collected from the Seasonal Variation in Blood Cholesterol Levels (SEASONS) (NHLBI: R01-HL52745) (1. Ockene - P.I.) study, in which 641 healthy adults in central Massachusetts were followed quarterly (baseline and four consecutive quarters: five sampling points in all) during this a one-year observational study. A total of fifteen 24hour dietary and physical activity recalls were collected for each subject, with serum lipids and body weight measured five times. Serum lipids and body weight were measured once per quarter and three 24-hour recalls were administered (two weekdays and one weekend day) per quarter. If GL is found to be associated with body weight
Studies
15
and blood lipids, a randomized clinical trial will be designed to evaluate the effects of a GL-based nutritional intervention program on hyperlipidemic patients. The methodology of this proposed study will involve several steps: 1) Data summarization of 9,067 24- hour diet recall records, 2) GL calculation and calculation of overall GI index, 3) Analysis of the relationship of GL to body weight and blood lipids, 4) Estimation of seasonal and short-term variations in GL, 5) Analysis of GL by meal type and identification of the top ten food contributors, 6) Analysis of the association of overall GI with body weight and blood lipids, and 7) Final report and manuscript preparation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIFFERENTIATING BONE MARROW STEM CELLS TO CURE DIABETES Principal Investigator & Institution: Ramiya, Vijayakumar K.; Ixion Biotechnology, Inc. Box 13, 13709 Progress Blvd Alachua, Fl 32615 Timing: Fiscal Year 2002; Project Start 15-MAR-2002; Project End 31-DEC-2002 Summary: (Scanned from the Applicant's Abstract): Type 1 diabetes is a polygenic, chronic metabolic disease characterized by the progressive ablation of insulin-producing beta cells by autoimmunity. Regular insulin injections do not maintain blood glucose near normal levels at all times and consequently patients develop serious secondary clinical complications. While pancreatic and islet transplantations consistently establish euglycemic states and significantly reduce long-term complications, availability of the grafts is severely limited. Thus, there is an urgency to develop a beta cell/islet replacement therapy for Type 1 diabetic patients. The mammalian hematopoietic stem cells (HSCs) produce at least 8 distinct lineages of mature blood cells while mesenchymal stem cells (MSCs) produce multiple lineages of mature cells. The wealth of information on the growth and differentiation of these stem cells is vast, and purified HSCs are routinely used in the clinical setting and both HSCs and MSCs are commercially available for research purposes. Thus, investigating the feasibility of differentiating human HSCs and MSCs into pancreatic pathway will be of immense importance in curing Type 1 diabetes, and in the realization of autologous stem cellderived insulin producing cell/islets for implantation. In this SBIR Phase I proposal, we will specifically: (1) characterize human bone marrow derived CD34+ HSCs and CD34MSCs for the expression of developmental genes involved in the generation of islets/pancreas following treatments with various factors in vitro; and (2) determine the functional capability of the differentiated cells in vitro. A successful completion of the Phase I study will lay the foundation for a more detailed Phase II grant proposal that will involve in vivo functional studies in diabetic animal models. PROPOSED COMMERCIAL APPLICATION: This research project has the potential to produce glucose-responsive insulin producing cells/islets for implantion into every single insulin?dependent Type 1 & 2 diabetics. All that would be required from the individuals is their peripheral blood, or bone marrow samples. Also, cells that are at different stages of differentiation can be used for drug discovery research related to mesenchymal and pancreatic systems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DOES HYPERGLYCEMIA PREDICT PANCREATIC CANCER DIAGNOSIS? Principal Investigator & Institution: Chari, Suresh T.; Mayo Clinic Coll of Medicine, Rochester 200 1St St Sw Rochester, Mn 55905
16
Blood Glucose
Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): Pancreatic cancer causes glucose intolerance and diabetes in up to 80% of patients. Pancreatic cancer induced diabetes (PaCDM) is often asymptomatic, of short duration (50 years of age may have PaCDM. We propose to establish whether newly elevated fasting blood glucose (FBG) is indicative of underlying pancreatic cancer as evidenced by diagnosis of pancreatic cancer within 3 years of the FBG measurement. If so, this would provide an entirely novel approach to screening for sporadic pancreatic cancer. We hypothesize that the 3-year likelihood of diagnosis of pancreatic cancer will be high in subjects: a) equal to or > 50 years of age with newly elevated FBG, b) with elevated fasting glucose who have known risk factors for pancreatic cancer (e.g. smoking), and/or c) who manifest an abrupt increase in FBG in serial measurements over time. We will identify visits to Mayo Clinic between years 1988 to 2002 by subjects equal to or >50 years of age who resided in its surrounding catchment area and had a routine physical examination that included a FBG. Preliminary data reveal that about 150,000 different subjects made >300,000 such visits during this time period providing >1 million person-years of follow-up. We will electronically retrieve clinical, and laboratory data and examine 3-year follow-up from date of FBG measurement to identify those diagnosed with pancreatic cancer. We expect 340 to 510 pancreatic cancer events in this cohort. Our Specific Aims are: Aim 1A). To test if FBG drawn during routine physical examination predicts likelihood of underlying pancreatic cancer and to test for non-linearity of this association. Aim 1B) To establish a FBG threshold that predicts a high 3-year likelihood of diagnosis of pancreatic cancer. Aim 2). To estimate the extent to which known risk factors for pancreatic cancer (age, smoking, obesity and family history) modify the likelihood of underlying pancreatic cancer in subjects with FBG greater than the threshold defined by Aim 1B. Aim 3). To test if patterns of change in serial measurements of FBG over time predict likelihood of underlying pancreatic cancer. The clinical and research implications of this study are considerable. These data may lead to delineation of individuals who have a high likelihood of existing pancreatic cancer, and who may be ideal candidates for more intensive screening or early detection regimens. The research described in this application is 100% relevant to pancreatic cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DPT-1 TRIALNET: CLINICAL CENTERS Principal Investigator & Institution: Raskin, Philip; Internal Medicine; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2002; Project Start 29-SEP-2001; Project End 31-AUG-2008 Summary: (provided by applicant) Type 1 diabetes affects more than one million individuals in the United States and many more worldwide. Type 1 diabetes arises in genetically predisposed individuals as a consequence of immune-mediated destruction of the pancreatic islet insulin-secreting beta-cells. The onset of clinical symptoms of diabetes represents the endpoint of a chronic progressive decline in beta-cell function and occurs when the majority of beta-cells have been lost. First-degree relatives of individuals with Type 1 diabetes are ten-fold more likely to develop the disease than the general population. The disease, which can begin at any age, characteristically begins in childhood or in young adults. The present treatment for Type 1 diabetes, which includes the early use of insulin, rigid dietary intervention, and frequent blood glucose monitoring, when implemented properly, can delay or prevent the horrible long-term complications of diabetes (i.e. blindness, renal failure, and amputation). However, proper diabetes treatment is quite difficult to do, expensive, and very invasive to the
Studies
17
diabetic patient?s lifestyle. Diabetes is also a major factor in health care costs. Is it possible to prevent Type 1 diabetes? To date, several immune interventions have been tried in genetically susceptible individuals without success. Other trials have been attempted to intervene early in the course of Type 1 diabetes, in order to preserve betacell function. These immune interventions have likewise failed. Thus, the identification of agents that either prevent the disease or slow its progression would result in major health care cost savings and reduce complications related to diabetes in addition to the huge individual savings in terms of not having the disease. Our long-term goal is to prevent the development of Type 1 diabetes through the use of innovative immunebased therapies designed to prevent the development of the disease in genetically predisposed individuals. The objectives of this application, in pursuit of that goal and in response to the RFA, is completion of the DPT-1 protocol and the development of TrialNet, an enhanced network to develop and test innovative interventions to prevent or slow the progression of Type 1 diabetes. One such innovative approach to slow the progression of Type 1 diabetes is our proposed pilot protocol, "Thiazolidinediones Preserve C-Peptide in Type 1 Diabetes." The proposed work is innovative because it utilizes a drug that has a proven safety profile and is already widely used for the treatment of Type 2 diabetes but also is an immune modulator. Our Center has the experience, the personnel, and access to the appropriate patients to be a successful member of TrialNet and to be able to successfully complete our proposed pilot protocol or others that TrialNet may bring forward. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DYNAMIC FMRI ANALYSES OF HYPOGLYCEMIA UNAWARENESS Principal Investigator & Institution: Liu, Yijun; Assistant Professor; Psychiatry; University of Florida Gainesville, Fl 32611 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 31-JUL-2004 Summary: (provided by applicant): We propose a functional MRI (fMRI) study to probe the timing and location of neuro-hormonal interaction following food ingestion in humans. The proposal presents an explorative fMRI project by developing in vivo methods to characterize brain activity during hypoglycemia induced by prolonged fasting. We will examine brain responses during a real-time transition from fasting hypoglycemia to normoglycemia attained by eating (i.e., by oral glucose intake), focusing on the hypothalamus and its associated neural circuits. In particular, this project underscores two novel dynamic imaging approaches for tracing the time course of brain-hormone interaction during the transition. These approaches, namely (1) temporal clustering analysis (TCA) and (2) within-condition interregional covariance analysis (WICA), are critical to the timing of neuronal events that are interacting with hormonal processes, such as glucose-insulin regulation. Modeling of both temporal and spatial information about brain-hormone interaction will be our first step toward establishing a functional marker of hypoglycemia unawareness. By the functional marker we mean noninvasively -measured neuroendocrinal signals in response to a physiological challenge, such as fasting or eating. We hypothesize that alteration of such signals is implicated in the development of hypoglycemia unawareness, as in insulindependent diabetes mellitus (IDDM) accompanied by recurrent hypoglycemia. Although the ultimate goal of this project is to directly test this hypothesis in patient population under long-term intensive insulin treatment, which may require large-scale clinical trials, the current R21 proposal aims to develop new fMRI methodology involving a small number of subjects imaged under well-controlled conditions. While functional imaging methods may reflect a departure from traditional, symptom-
18
Blood Glucose
dependent assessment of hypoglycemia unawareness (e.g., cognitive task testing or objective neurophysiological evaluation), it is still important to correlate fMRI analyses with routine clinical measurements, such as counterregulatory hormone levels by blood sampling. This correlation may provide information for delineating the neural bases about how internal biochemical signals give rise to the awareness of hunger or satiation, and for understanding the phenomenon of hypoglycemia unawareness. Two specific aims are to be accomplished in this two-year project: Aim 1. Development of a fastingeating fMRI paradigm by correlating functional imaging signal with biochemical measurement; and Aim 2. Development of both temporal and spatial reference systems for the in vivo modeling of glycemia regulation and hypoglycemia unawareness. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EDUCATION AND GROUP SUPPORT FOR DIABETIC HISPANICS Principal Investigator & Institution: Brown, Sharon A.; Professor; None; University of Texas Austin 101 E. 27Th/Po Box 7726 Austin, Tx 78712 Timing: Fiscal Year 2002; Project Start 01-AUG-1994; Project End 31-MAR-2003 Summary: Type 2 diabetes is three to five times more prevalent in Mexican Americans than in non-Hispanic whites and ranks as the third and fourth leading cause of death in Hispanic females and males, respectively. In Starr County, Texas, type 2 diabetes affects 50 percent of the adult Hispanic population. The Starr County Diabetes Education Study (1994-1998) sought to improve the health of diabetic Mexican Americans and their families with a culturally-relevant, community-based intervention of: (1) three months of instruction on nutrition, home glucose monitoring, exercise, etc.; and (2) nine months of group support to promote behavioral changes. Primary indicators of intervention effectiveness were diabetes knowledge and health beliefs, health behaviors, HbA1c, and FBS. Preliminary findings suggested that the intervention had a positive impact, statistically and clinically significant, on metabolic control. HbA1c and FBS were reduced significantly by the third month of the one-year intervention, and these changes were maintained at six-months and at one-year. The proposed continuation will adapt and test a three-month version of the current one-year intervention to determine if the shortened version, applicable to clinical practice, attains the same positive health outcomes in this Mexican American population. To identify key components of the current strategy, investigators will hold focus groups with subjects of the current study to explore differences between those who successfully integrated self-care components of the intervention and who experienced significant improvements in metabolic control and those who were not as successful. Following the focus groups, the current intervention will be revised and tested with a prospective, longitudinal, randomized, pretest/posttest control group design. 256 diabetic subjects and their family members will be randomly assigned to the shortened intervention (treatment) or the one-year intervention (control). In addition, a predictive model will be tested to explain metabolic control in subjects receiving longitudinal care versus compressed care. The proposed continuation is a critical step in translating this culturally-appropriate intervention into clinical practice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECT OF AGE AND GLYCEMIA ON TRANSCRIPTION FACTORS Principal Investigator & Institution: Fukagawa, Naomi K.; Associate Professor of Medicine; Medicine; University of Vermont & St Agric College 340 Waterman Building Burlington, Vt 05405
Studies
19
Timing: Fiscal Year 2002; Project Start 01-JUN-2000; Project End 31-MAY-2005 Summary: This application is for a Mentored Research Scientist Development Award in Aging through which the candidate, an experienced clinical investigator, will learn state-of-the-art techniques in cell physiology, cell imaging and signaling under the mentorship of Dr. Brooke Mossman. The goal will be to determine whether oxidative stress associated with aging and/or high glucose contributes to alterations in vascular smooth muscle cell (VSMC) apoptosis or proliferation. The research plan will focus on age- and glycemia-related effects on activation of the redox-sensitive transcription factors Nuclear Factor kappa B (NF-kappaB) and Activator Protein-1 (AP-1), testing the hypotheses that 1) aging and/or high glucose will induce mitochondrial oxidative stress in VSMC; 2) aging is associated with dysregulation of NF-kappaB and AP-1 activation; and 3) an imbalance between VSMC apoptosis and proliferation, i.e. phenotypic endpoints regulated by redox- sensitive transcription factors, will contribute to the development of vascular disease. Specific aims of the proposal will be to determine: 1) whether high glucose media causes mitochondrial oxidative stress in VSMC from old (22-24 mos) and young (6-8 mos) Fischer 344 rats using cell imaging of oxidative probes (dichlorofluorescin derivatives); 2) whether age, glucose or hydrogen peroxide (H2O2), conditions or agents associated with oxidative stress, alters mitochondrial gene integrity and expression that may influence cell function or viability; 3) whether VSMC from old compared to young rats exhibit differences in baseline or inducible redox-sensitive transcription factors by determining the effect of high glucose media or exogenously administered H2O2 on DNA binding and transcriptional activation of NF-kappaB and AP-1; and 4) whether aging and/or high glucose induces changes in the activation of NF-kappaB or AP-1 which are causally related to the development of apoptosis or proliferation in VSMC. In these latter studies, we will first quantitate the effect of different concentrations of H2O2 (as a positive control) and of glucose on apoptosis and proliferation. We will then block the separate pathways using transient transfection techniques with dominant negative mutant constructs to determine if the phenotypic expression can be altered. The data obtained will permit future studies aimed at interventions targeted to defined signaling pathways to attenuate the deleterious effects of oxidative stress in vivo. The long-term goal will be to apply the tools and approaches learned through the support of this award to examine the effect of oxidative stress and transcriptional regulation on muscle protein synthesis in vivo in humans. The mentor has an extensive background in the investigation of reactive oxygen species as mediators of cell injury and of signal transduction, and a successful track record of training undergraduate and graduate students, postdoctoral fellows, and faculty. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFECTS OF STRESS ON BEHAVIOR AND GLUCOSE IN TYPE 1 DM Principal Investigator & Institution: Helgeson, Vicki S.; Professor; Psychology; CarnegieMellon University 5000 Forbes Ave Pittsburgh, Pa 15213 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): The goal of this research is to use daily diary methods to link stress and social interactions to mood, self-care behaviors, and blood glucose levels among adolescents (ages 14-16) with Type 1 diabetes. Previous research has relied on retrospective reports of stress rather than on-line measures. Eighty-eight adolescents (44 male, 44 female) will carry palm pilots for two separate 48-hour periods, which will prompt them every two hours during the day to complete a 2-minute questionnaire. The questionnaire will assess mood, stress, social interactions (conflict, social barriers), and self-care behaviors. Four prompts will also request that blood
20
Blood Glucose
glucose levels are tested and recorded. Adolescents will wear the Actical, an accelerometer that measures frequency, duration, and intensity of movement during the same days of assessment. With this methodology, we can link stress and aspects of social interactions to mood, specific self-care behaviors, and blood glucose in a momentto-moment fashion. A second goal of the study is to examine whether individual difference variables moderate these relations. We will examine whether sex influences these relations, as interpersonal stress is associated with more negative health consequences for females than males. We also will examine whether unmitigated communion (focus on others to exclusion of self) influences these relations, as relationship stressors and social barriers to self-care behavior may be more strongly tied to negative outcomes for people high in unmitigated communion. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENDOTHELIAL PRECONDITIONING AND ISCHEMIC BRAIN INJURY Principal Investigator & Institution: Keep, Richard F.; Associate Professor; Neurosurgery; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2003; Project Start 25-JUL-1996; Project End 31-MAY-2008 Summary: (provided by applicant): Ischemic preconditioning (IPC) has proved to be one of the most effective methods of reducing ischemic brain damage in animal models of stroke. Attention has focused on the mechanisms by which neurons may be protected by such preconditioning. However, we have found that IPC also protects the endothelium, which forms the blood-brain barrier, from ischemic damage. 'Ischemic' preconditioning also protects cerebral endothelial cells in vitro from oxygen glucose deprivation induced injury indicating that there can be direct preconditioning of the endothelium. Damage to the cerebral endothelium may potentiate ischemic brain injury in a number of ways and determining mechanisms to reduce endothelial damage is particularly pertinent at the moment considering the role of endothelial injury (hemorrhagic transformation) in limiting the use of tissue plasminogen activator for the treatment of ischemic stroke. We will examine the mechanisms involved in cerebral endothelial preconditioning both in vivo (rat middle cerebral artery occlusion) and in vitro (primary cultures of rat cerebral microvessel endothelial cells). The in vitro experiments will facilitate exploration of the mechanisms involved in preconditioning while assuring that the preconditioning acts directly on the endothelium. The in vivo experiments will ensure that the mechanisms elucidated in vitro also occur in the whole animal as well as allowing an assessment of the effects of preconditioning on other parameters (such as blood flow, capillary morphology and infarction). Overall the proposal has three main goals. 1) Determine the time course of preconditioning and the extent of its effects on the endothelium (Specific Aim 1). 2) Determine the events that can trigger endothelial preconditioning (Specific Aim 2). 3) Determine what mechanisms are triggered to protect the endothelium (Specific Aim 3). These experiments should provide information on: A) Endogenous defense mechanisms that protect the cerebral endothelium from ischemic injury and which may be therapeutic targets. B) The role of endothelial preconditioning in the effects of IPC on the brain. C) The role of endothelial injury in the overall effects of ischemia on the brain. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
21
Project Title: ENGRAFTMENT OF PANCREATIC PROGENITORS Principal Investigator & Institution: Sarvetnick, Nora E.; Associate Member; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2005 Summary: (provided by applicant): Insulin dependent diabetes mellitus results from the autoimmune destruction of the pancreatic beta cells. Once these crucial cells are lost they cannot be regained since the adult pancreas lacks the ability for regrowth. Therefore, IDDM patients are dependent on the possibility of receiving new endocrine cells to cure their disease. One therapy for IDDM patients is the possibility of utilizing islet progenitor cells for the in vivo or in vitro growth of new pancreatic islets. Indeed these cells could represent a limitless supply of differentiated beta cells for IDDM patients. However the exact identity of islet progenitor cells remains unknown despite dramatic progress in the area of islet ontogeny in recent years. Our laboratory has defined a novel cell surface antigen that is expressed on a cell population in the regenerating pancreas as well as in the normal adult small intestine, facilitating their purification. In this application we show that sorted intestinal cells give rise to insulinproducing cells following in vivo transfer experiments. This work suggests that stem cells that can give rise to functional islets can exist in the normal adult gut. Importantly, we have found in our preliminary studies that the transfer of sorted adult intestinal cells into STZ-treated diabetic mice significantly improves their blood glucose levels. The overall goal of this application is to develop these findings into a new therapy for clinical IDDM patients. This application is Bench to Bedside Partnership between investigators at Scripps Research Institute: Drs. Sarvetnick, Kritzik, Solomon, and Dabernat; Whittier Institute: Dr. Alberto Hayek; City of Hope National Medical Center Islet Cell Resource Center: Dr. Fouad Kandeel, and an outside consultant: Dr. Ronnda Bartel. The experiments proposed are designed to optimize conditions for the expansion of these intestinal-derived progenitor cells in vitro, an important consideration given the limited supply of donor cells. We will utilize the expanded cells in transfer experiments to assess their differentiation potential in vivo. Subsequently, we will define conditions for the intestinal cells to incorporate and expand in diabetic mice, optimizing conditions for their transfer, incorporation, and differentiation in the recipient. The proposed studies will allow the development of a new strategy for the isolation and expansion of intestinal islet progenitor cells, and their subsequent use in the treatment of diabetic conditions, which are clearly important goals for the establishment of therapies for IDDM patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN DIABETES Principal Investigator & Institution: Burge, Mark R.; Assistant Professor; Medicine; University of New Mexico Albuquerque Controller's Office Albuquerque, Nm 87131 Timing: Fiscal Year 2004; Project Start 01-FEB-2004; Project End 31-DEC-2008 Summary: (provided by applicant): Hypoglycemia is the principal barrier to the achievement of target glycemic goals in type 2 diabetes. Alcohol consumption is very prevalent in our society and a proven cause of hypoglycemia. Population studies suggest that elderly, insulin requiring type 2 diabetes patients are particularly vulnerable to severe hypoglycemia and that this problem accounts for an estimated $50 million or more in healthcare costs in the USA each year. We hypothesize that low dose ethanol significantly increases the vulnerability to overnight hypoglycemia and impairs
22
Blood Glucose
the recovery of plasma glucose in elderly, insulin requiring patients with type 2 diabetes. Our preliminary studies suggest that low dose ethanol impairs recovery from day time insulin-induced hypoglycemia in type 2 diabetes patients but not in age matched healthy control subjects. The proposed studies will examine the effects of low dose ethanol on overnight glucose regulation in elderly, insulin requiring type 2 diabetes patients and will establish the mechanism of these impairments through a series of systematic evaluations. Specifically, these studies will document suppression of the dawn phenomenon by ethanol, and/or exacerbation of a deficient counterregulatory response to hypoglycemia during sleep, especially growth hormone. Specific mechanisms for the suppression of growth hormone to be examined include that evening ethanol (3) inhibits peak overnight ghrelin secretion and/or (4) reduces pituitary sensitivity to GHRH. Additionally, these studies will characterize (5) the dose response characteristics of ethanol on overnight glucose homeostasis and will (6) carefully evaluate the effect of the timing of ethanol administration in relation to meal ingestion on overnight hypoglycemic vulnerability. To address these aims, we will assess the effect of moderate doses of orally administered ethanol or placebo on overnight growth hormone release, ghrelin, total IGF- 1, free IGF- 1, insulin-like growth factor binding protein 1 (IGFBP- 1) concentrations, glucose production and other parameters of glucose homeostasis among elderly control subjects versus elderly, insulin requiring subjects with type 2 diabetes. These important studies will provide a scientific basis for the prevention of overnight hypoglycemia (and the attendant cost savings) by providing mechanistic insights into the causes of nocturnal hypoglycemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EVALUATION OF A NON-INVASIVE GLUCOSE MONITOR Principal Investigator & Institution: Buchert, Janusz M.; Infratec, Inc. 539 Danbury Rd Wilton, Ct 06897 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JUL-2005 Summary: (provided by applicant): Sixteen million people in the United States live with the chronic disease diabetes; approximately 5 -10% are children. The seminal Diabetes Control & Complications Trial (DCCT) concluded that frequent glucose monitoring is necessary to reduce the complications of this disease. However, all glucose monitors available require invasive techniques with the most widely used method of selfmonitoring, obtaining blood from a finger stick, causing pain and discomfort which results in poor compliance. The development of a novel, hand-held, non-invasive glucose monitor will provide diabetics with the means for testing their glucose level more frequently, improving their quality of life, and reducing the costs and complications of this chronic disease. This application proposes the development, calibration and clinical validation of an advanced prototype based on a proprietary method of mid-infrared Thermal Emission Spectroscopy (TES). The method and instrument are based on the discovery that natural mid-infrared emissions, from the tympanic membrane, consist of spectral information of blood analytes. In recent years, infrared (IR) spectroscopy has emerged as a potential analytical method of choice for non-invasive glucose monitoring. The specific aims of this Phase I proposal are to develop the optical system and to integrate sensors into an ergonomic form for diabetic self-monitoring. The subsequent clinical studies are designed to demonstrate that a universal calibration for real time accurate measurements is possible for predictive results. The device will be calibrated and validated across a range of glucose concentrations from 40 to 400 mg/dL, using a total of 52 diabetic and normal subjects in hyperglycemic and hypoglycemic protocols. A trained nurse will perform the
Studies
23
measurements. Subsequently, 19 diabetic subjects will test themselves using the hyperglycemic protocol in a full predictive study. The hypotheses will test that the intraindividual correlation coefficient of the non-invasive predicted serum glucose compared with the clinical laboratory serum glucose measurement will be greater than 0.85, and less than 1 percent of the measurements will fall outside the clinically acceptable range on the Clarke Error Grid. Successful conclusion of Phase I milestones will lead to Phase II clinical studies and modifications for younger pediatric subjects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EVALUATION OF DIABETES SELF-MANAGEMENT CONSULTANT CARE Principal Investigator & Institution: Anderson, Robert M.; Professor, Senior Research Scientist; Medical Education; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 20-AUG-2002; Project End 31-JUL-2006 Summary: (provided by applicant): Evaluation of Diabetes Self-Management Consultant CareThe overall objective of this study is to develop, implement and evaluate the effectiveness of a collaborative care intervention to improve blood glucose control and diabetes-related quality of life for subjects with type 2 diabetes being cared for in two different health care systems. The effectiveness of their diabetes Self Management Consultant (SMC) Collaborative Care intervention will be evaluated by comparing it with a randomized usual care control group for subjects with type 2 diabetes.Specific Aims 1. Develop a diabetes Self-Management Consultant (SMC) intervention designed to improve blood glucose control and diabetes-related quality of life for adults with type 2 diabetes. 2. Recruit SMCs, Primary Care Physicians (PCP)s, and subjects for the study. 3. Pilot test the feasibility of all major elements of the SMC intervention including data collection and self-management consultant protocols and activities with a small number of subjects. 4. Implement the intervention in both the Detroit Department of Health and the University of Michigan Department of Family Medicine. 5. Conduct a randomized clinical trial to evaluate the relative effectiveness of the SMC intervention compared to usual care in improving blood glucose control and diabetes-related quality of life. 6. Identify variables (e.g., program site, demographic, psychosocial, resource, and health) that predict which subjects benefit from participating in the SMC intervention. 7. Estimate the cost-effectiveness of the SMC intervention, relative to the cost of usual care, in the short-term, from the perspective of the health care insurer. 8. Estimate the expected effect the SMC intervention has on end-stage subject outcomes (both microvascular and macrovascular complications) and long-term costs through the use of Monte Carlo simulation models. 9. Disseminate the results, materials, and protocols developed for this study, nationally, and provide training and technical assistance to health care professionals who wish to use the SMC intervention (or parts of it) in local settings.HypothesisThe SMC intervention will be more effective than usual care in improving blood glucose control and diabetes-related quality of life. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EVOLUTION OF CARDIOVASCULAR RISK WITH NORMAL AGING Principal Investigator & Institution: Berenson, Gerald S.; Professor and Director; Tropical Med & Parasitology; Tulane University of Louisiana New Orleans, La New Orleans, La 70112 Timing: Fiscal Year 2002; Project Start 15-MAY-2000; Project End 31-AUG-2005
24
Blood Glucose
Summary: (Adapted from the Applicant's Abstract): The cardiovascular (C-V) system is one of the organ systems most affected by the aging process. Significant differences in CV morbidity and mortality occur by race and gender that influence longevity. The proposed research involves a biracial (black-white) population that has been followed for C-V risk factors and lifestyles in the Bogalusa Heart Study over the past 25 years. The specific aim of the research is to characterize traits (intrinsic aging vs. The risk factor burden) in a population reaching middle age that influence the subclinical C-V disease process in normal aging. The extensive data base collected since childhood provides information related to silent underlying C-V disease and aging. The study cohort includes 1,200 individuals born between 1959 and 1969, who were examined at least four times since childhood. The cohort will be examined for: 1) C-V risk factor variables comprising obesity measures, blood pressure, lipids, lipoproteins, apoliproproteins, homocysteine, glucose, insulin, fibrinogen, plasminogen activator inhibitor 1, intercellular adhesion molecules -1, C-reactive protein, lipid peroxides and microalbuminuria; 2) lifestyle and psychosocial variables such as tobacco and alcohol use, physical activity, diet, and life change events; 3) subclinical changes of the heart and vasculature (outcome variables) observed by echo-Doppler measurements of cardiaccarotid structure and function and brachial and radial artery compliance; and 4) selected longevity-associated allele markers, like apoE. These variables (except for the allele markers) will be measured at two points in time, with a 3-year interval. In addition, a family history of longevity and health history information on study subjects and their parents and grandparents will be obtained to evaluate familial risk characteristics of the cohort. The proposed studies will provide insights into the interaction of normal aging and predisposing factors that influence the subclinical C-V disease process in a blackwhite population reaching middle age. Understanding the evolution of C-V risk in normal aging can lead to more rational programs for successful aging and longevity and C-V disease prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EXERCISE, DIABETES, AND CORONARY SMOOTH MUSCLE CALCIUM Principal Investigator & Institution: Sturek, Michael S.; Professor and Chair; Dalton Research Center; University of Missouri Columbia 310 Jesse Hall Columbia, Mo 65211 Timing: Fiscal Year 2002; Project Start 01-APR-1999; Project End 31-MAR-2003 Summary: Our long-term goal is to determine if exercise training attenuates the excess coronary artery disease (CAD) in diabetes and the vascular smooth muscle (VSM) Ca (Cam) signaling mechanisms involved. In our porcine model of diabetic dyslipidemia coronary arteries show increases in contraction to prostaglandin F2alpha (PGF) and Cam responses to endothelin-1 (ET). Exercise of normal swine decreases Ca release from the sarcoplasmic reticulum (SR) and increases Ca influx, while decreasing ET-induced contraction and DNA synthesis. However, ET-induced contraction does not require Ca release that is dependent on tyrosine kinase, a signal for cell growth. Overall hypothesis: after exercise training increased ET-induced Ca influx attenuates contraction, while decreased SR Ca release attenuates growth of smooth muscle. Design: low fat control pigs (C), high fat fed (HF), and alloxan diabetic and high fat fed (D) pigs are maintained for 20 and 30 wk to study the progression of CAD and compared to D pigs exercise trained (D plus EX). Specific Aims are to test the hypotheses that in diabetes: 1) Exercise improves glycemic and lipidemic status. Diabetes will be defined by measures of blood glucose, glycated protein, insulin, etc. HDL, LDL, VLDL, triglycerides, apoproteins, glycated LDL, and ET will define features of diabetic dyslipidemia. 2) Exercise
Studies
25
attenuates the increase in CAD. Intravascular ultrasound will assess atheroma and vasoconstrictor responses to PGF and ET in vivo. Histology and contractile tension responses of coronary rings to PGF and ET will provide in vitro measures of CAD. 3) Exercise attenuates the conversion of VSM from the contractile (cVSM) to synthetic (sVSM) phenotype. sVSM cell phenotype will be identified using digital imaging microscopy by the Cam response to UTP, perinuclear SR, DNA, smooth muscle actin, desmin, and vimentin. 4) Exercise attenuates the increased contraction of cVSM by increasing ET receptor-dependent Ca influx. Mn and Ba influx used as Ca surrogates will assess Ca influx. Subsarcolemmal Ca localization relative to ryanodine receptors will be digitally imaged. 5) Exercise attenuates the increased ET-induced Cam amplitude and nuclear Ca localization by decreasing tyrosine kinase-dependent Ca release from the SR. Imaging will assay in single cells the relative content and spatial distribution of ET, ryanodine, and IP3 receptors, tyrosine phosphorylation, DNA and Cam. Significance: the first study of Ca localization mechanisms involved in the excess CAD in diabetic dyslipidemia and the therapeutic effects of exercise on CAD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FLUORESCENT MICROSHELLS
GLUCOSE
SENSORS
FROM
POLYION
Principal Investigator & Institution: Mcshane, Michael J.; Assistant Professor; Biomedical Engineering; Louisiana Tech University Ruston, La 71272 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Non-invasive glucose monitoring is desired to reduce the pain of blood sampling, which is an important step toward improved control of blood glucose for diabetics. Poor control results in debilitating complications, but the bother associated with testing typically leads to low patient compliance with recommended monitoring frequencies. The concept of implantable fluorescent sensors that can be monitored transdermally would be an attractive solution to the problem, but many obstacles to practical use have been identified. This work aims to use polyelectrolyte microcapsules to overcome drawbacks of previously proposed systems. Methods for fabricating these structures have been developed over the past few years, with precision control over mechanical and chemical properties, thus, "tuning" of the structures to fit different applications may be possible. Recent work has produced fundamental knowledge on the properties of these nanostructured capsules, yet there has been little reported by way of practical application. Since biomedical applications have not been pursued, no work has been done to assess the biocompatibility of the materials used. An interdisciplinary research team will evaluate the potential for polyelectrolyte microcapsules to function as carriers for fluorescence sensing chemistry using an integrative approach to sensor design that considers material, chemical, optical, and biological properties. The work will clarify basic questions regarding the process of encapsulation, then use these data to engineer sensor properties that will possess clinically relevant response characteristics. The stability of the structures will be assessed over time in increasingly physiological conditions, and methods to overcome problems with fouling and enzyme degradation will be identified to allow progress to continue. Finally, the biocompatibility of the materials used will be studied from molecule to device level, in vitro and in vivo, to determine baseline host response and risk factors for device failure. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
26
•
Blood Glucose
Project Title: GENETIC ANALYSIS OF CVD RISK FACTORS Principal Investigator & Institution: Maccluer, Jean W.; Scientist; Southwest Foundation for Biomedical Res San Antonio, Tx 782450549 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 31-MAY-2007 Summary: (provided by the applicant): The objective of Project 1 is to detect, map and characterize polymorphic genes that contribute to variation in risk of cardiovascular disease (CVD). The focus in this Program Project (the San Antonio Family Hearth Study, SAFHS) is on extended Mexican American families ascertained without regard to disease status. During the current grant period each family member is being genotyped for 414 short tandem repeat markers in a 10 centimorgan map. Using genome screen data from the first ten genotyped families (Pedigree Set A, with nearly 500 individuals), QTLs have been detected and mapped that influence leptin, fat mass, BMI, insulin, 2 hour glucose, LDL-3-C, HDL-C, HDL2a unesterified cholesterol, evidence for linkage, additional, more closely spaced markers are being typed for use in finer scale mapping strategies. Identification of the functional alleles for a few of the best characterized of these genes will be pursued in Project 3. In Project 1, taking advantage of the resource of families with extensive genotypic and phenotypic data that has been created in the past ten years, linkage analyses will be pursued for phenotypes that exhibit substantial heritabilities but for which significant linkages were not detected in Pedigree Set A (e.g., apolipoproteins, selected lipoproteins size classes, fasting glucose, 2-hour insulin, fibrinogen, C-reactive protein, and measures of carotid intima-media thickness). Linkage signals also will be strengthened and refined for other QTLs for which significant evidence of linkage already has been detected (e.g., QTLs for BMI on chromosome 17, HDL-C on chromosome 16, insulin/glucose ratio on chromosome 3, and HDL2a unesterfied cholesterol on chromosome 8). These analyses will incorporate additional markers, and associations will be sought with polymorphisms in positional candidate genes. Several new phenotypes related to the role of adipose tissue as an endocrine organ will be examined, and the pleiotropic effects of QTLs detected in the current and proposed grant periods, on other CVD risk factors will be characterized. The longitudinal data being accumulated for the families in the SAFHS will be exploited to examine genetic effects on age-related changes in CVD risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETIC EPIDEMIOLOGY OF HYPERTENSION IN AFRICAN AMERICAN Principal Investigator & Institution: Rotimi, Charles N.; Associate Professor and Director; Howard University Washington, Dc 20059 Timing: Fiscal Year 2002; Project Start 01-JUN-1977; Project End 31-JUL-2006 Summary: The goal of this project in genomic research is to contribute to the growing attempts to fill a major void in resources available to the research community for dissecting the pathophysiology of hypertension (HTN) and related complications in African Americans. It is well documented that A experience one of the highest incidence of HTN in the world. Epidemiologic studies have demonstrated the important role of environmental factors including diet (e.g., high salt intake), lifestyle (e.g., lack of physical activity) and psycho-socio stressors (e.g., employment difficulty) in the etiology of HTN. However, a proportion of the total variance remains unexplained. Because of the importance of family history and observed differential susceptibility to HTN, it is now widely accepted that the etiology of HTN is the result of complex interplay of genetics and the environment. Based on an on-going family study, we propose to recruit
Studies
27
a population of 350 AA families with 5 or more members (n> 1,750 persons) in Washington, DC. During a clinical exam, we will collect demographic data, measure BP, height, weight, fat mass, fat free mass, waist and hip circumference. Blood will be drawn for assays of physiologic intermediates including components of the renin-angiotensin aldosterone system (RAAS-Angiotensinogen-AGT, angiotensin-converting enzyme aldosterone system (RAAS-Angiotensinogen-AGT, angiotensin-converting enzyme-ACE and aldosterone), endothelin 1, C-reactive protein (CRP), sodium potassium, calcium, albumin, creatinine, glucose, insulin and leptin. Genomic DNA will be extracted. We propose to evaluate the association and linkage between BP, HTN and genes of the RAAS (ACE, AGT and angiotensin II receptor type 1), epithelial sodium channel beta subunit, endothelial nitric oxide synthase, CRP, endothelin 1, and beta2-adrenergic receptor. We will evaluate single nucleotide polymorphisms (SNP) variations in candidate genes and determine if variation in each SNP and in constructed haplotype, explain variations in BP and HTN risk. In addition, DNA will be stored for future application to conduct genome-wide scan with the goal of identifying novel genomic regions in linkage and association with BP and HTN in AA. Identified novel genomic regions may inform our understanding of the etiology of HTN in other human populations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC LOCUS EXTENDING LIFE AND REDUCING INSULIN Principal Investigator & Institution: Harrison, David E.; Senior Staff Scientist; Jackson Laboratory 600 Main St Bar Harbor, Me 04609 Timing: Fiscal Year 2002; Project Start 01-JAN-2001; Project End 31-DEC-2005 Summary: Maximum life spans are significantly increased in mice by Leg 1a, a genetic variant in Mus m molossinus (MOLD) on chromosome 8 near microsatellite marker D8Mit171. The same chromosome region reduces blood insulin without affecting glucose levels or normal growth. Defining this gene that retards mammalian aging may suggest clinical treatments to improve health in old age. Aim 1 tests if Leg1a has effects on aging like those already defined for caloric restriction (CR) by comparing four groups of 84 mice: Leg1a carriers and non-carriers, each with a fed ad lib group and a CR group. At 4 and 24 months of age, biological aging will be assessed with a battery of nonharmful measures including blood insulin and glucose, T cell subset distributions, wound healing and collagen denaturation. In addition, growth will be followed from weaning, and life spans and pathology will be determined. Splenic T cell telomere lengths will be tested in separate groups. Aim 2 maps Leg1a to a 1 cM region, and tests if Leg1 is the locus that regulates insulin. Progeny will be produced from 10 males; each with a different chromosomal recombination carrying a unique subset of MOLD alleles in the 10 cM region now defined. For statistical power, each male will produce 84 progeny carrying the recombination and 84 non-carrier controls with no MOLD alleles in the 10 cM region. Insulin and glucose levels will be tested at 4 months in these mice, and life spans of the longest-lived 18 and 40 percent will be compared to map Leg1a to a 1 cM region. If the long-lived recombinant groups all have low insulin, it will strongly support the hypothesis that Leg1a regulates insulin. Aim 3 uses the progeny of Aim 2 to map the locus regulating insulin to within 1 cM. Subsequently, progeny from 10 males with recombinations within this 1 cM region will be used to refine the map location to 0.1 cM (roughly 10 genes), comparing 79 carriers of each recombination with 79 noncarrier progeny. Candidate genes will be tested to see whether MOLD alleles differ from those of NZW, LP and BALB. The gene will ultimately be identified by homologous recombination.
28
Blood Glucose
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLIAL CELL GLYCOGEN AND STRESS-INDUCED DEPRESSION Principal Investigator & Institution: Bonsall, Robert W.; Associate Professor; Psychiatry and Behavioral Scis; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): In this exploratory project, we propose to test a new hypothesis that deficiencies in the brain's reserves of energy make it vulnerable to stress and constitute a risk factor in the development of depression. Normal brain function is dependent on the expenditure of large amounts of energy (up to 20 percent of all energy needs in the human) and most of this energy is consumed in maintaining electrical potentials and ionic gradients across neuronal cell membranes. Exposure to stressful conditions induces greatly increased energy consumption in specific areas of the brain, and the ability of a neuron to respond normally to stressors and to survive the excited state that stressors produce is dependent on surrounding glial cells providing energy in the form of glucose and glucose metabolites. The glial cell's ability to provide energy sources to neurons is not only dependent on the transport of glucose from the blood but also on the mobilization of its own glycogen energy reserves. In response to excitatory neurotransmitters, glial cells break down glycogen into glucose and lactic acid and export them to neurons. We will determine if depression results when the brain is exposed to stressful conditions of sufficient intensity and duration as to deplete the glial glycogen reserve in specific regions of the brain. Depleted glial cells would then be unable to provide nearby neurons with sufficient glucose and lactic acid, and neuroprotective responses to the energy deficit would reduce local neural activity and cause symptoms of depression. We present new data using a well-established animal model of depression that support the glycogen hypothesis. These data indicate that stressful conditions sufficient to cause behavioral depression not only deplete cerebral glycogen but also cause a profound metabolic deficit. In the planned experiments, we shall (a) examine the effects of depression-inducing stressors on levels of glycogen in different brain areas, (b) monitor brain glucose and lactic acid release during exposure to the stressor and during the development and recovery from behavioral depression, and (c) examine the neurochemical and behavioral effects of manipulating brain glycogen levels. Results will provide entirely new insights into the mechanisms of stress induced depression and should suggest new approaches to the treatment and prevention of this devastating disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GLP-1 IN NORMAL AND ABNORMAL GLUCOSE TOLERANCE Principal Investigator & Institution: D'alessio, David A.; Associate Professor of Medicine; Internal Medicine; University of Cincinnati 2624 Clifton Ave Cincinnati, Oh 45221 Timing: Fiscal Year 2003; Project Start 30-SEP-1999; Project End 31-JAN-2004 Summary: The overall goal of this proposal is to determine the role of the insulinotropic GI hormone glucagon-like peptide 1 (GLP-1) in persons with normal glucose tolerance, and with type 2 diabetes. In normal subjects the action of GLP-1 and other gut factors accounts for 30-60 percent of the insulin secreted after eating. This effect is severely impaired in persons with type 2 diabetes suggesting defects in the secretion or action of gut peptides. In addition to its action on the -cell, we have recently observed a novel effect of GLP-1 to suppress endogenous glucose production (EGP) independent of its
Studies
29
effects on islet hormone secretion. When given to persons with type 2 diabetes in pharmacologic amounts, GLP-1 normalizes both fasting and post-prandial hyperglycemia, and so has potential as a therapeutic agent. Therefore, it is important to understand the mechanisms by which GLP-1 lowers blood glucose levels in persons with diabetes, and whether defects in the secretion or action of the hormone contribute to the pathogenesis of diabetes. The specific aims of this project are to determine: 1) the mechanism by which GLP-1 normalizes fasting hyperglycemia in diabetic subjects. 2) whether GLP-1 suppresses EGP by inhibition of glycogenolysis, gluconeogenesis, or both. 3) whether the deficient incretin effect in persons with type 2 diabetes is due to decreased levels of GLP-1, or impaired sensitivity of insulin secretion to GLP-1. To address these aims: 1) Glucose turnover will be measured in diabetic subjects before and during GLP-1 infusions, to determine the contributions of islet hormones, and islet hormone-independent effects of GLP-1 to lower blood glucose. 2) EGP will be measured in healthy subjects, and rates of gluconeogenesis and glycogenolysis determined before and after GLP-1 using the 2H2O method. 3) Secretion, and metabolism of GLP-1 in diabetic and control subjects will be compared using a new assay we have developed with greatly increased specificity for GLP-1. In addition, GLP-1 will be infused over a wide range of doses to measure the sensitivity of the insulin response in diabetic and control subjects. The results of these studies will expand the understanding of glucose homeostasis, and promote the development of new strategies to treat type 2 diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLU6PASE AND 6P2K/FBASE GENE REGULATION IN SEPSIS Principal Investigator & Institution: Maitra, Subir R.; Emergency Medicine; State University New York Stony Brook Stony Brook, Ny 11794 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2004 Summary: Sepsis is that critical condition of the patient which, if uncorrected, leads to death. The initial hyperglycemia seen in sepsis is followed by hypoglycemia with concomitant hyperlacticacidemia. Glucose-6-phosphatase (Glu-6-Pase) is a key enzyme in the homeostatic regulation of blood glucose concentration, which catalyses the final step in gluconeogenesis and glycogenolysis. Another important enzyme for regulation of gluconeogenesis is 6-phosphofructo-2-kinase/fructose-2,6bisphosphatase (6PF2K/FBPase), which is responsible for the production and hydrolysis of fructose-2,6bisphosphate (Fru-2,6- P2), a modulator of glycolytic to gluconeogenic flux. We have demonstrated that gene expression of Glu-6-Pase and 6PF2K/FBPase are reciprocally modulated during hyperglycemic phase of hemorrhagic shock. In this proposal, we are focusing on the regulation of expression of these two genes as models of hormonal counter-regulation during sepsis. In addition to studying the hormonal regulation of these genes in sepsis, we also propose to determine the hormonal response elements of these genes by promoter analysis. Sepsis will be induced in fasted, anesthetized rats by cecal ligation and puncture (CLP) method and will be observed for 0.5 h, 3 h, and 20 h periods. Control rats will undergo sham operation and will be observed for the same time. The liver and kidney from control and CLP rats will be freeze-clamped in liquid nitrogen and stored at -70 degrees C for future assay of glucose-6- phosphate, fructose-6phosphate, glucose-6-phosphate dehydrogenase activity, Glu-6-Pase and 6PF2K/FBPase enzyme activity and gene expression. Blood samples will be collected at the same time periods to assay glucose, corticosterone, insulin and glucagon concentration in the plasma. Relatively selective pharmacologic antagonists of hormones and cytokines will be administered prior to CLP to observe their effects on Glu-6-Pase and 6PF2K/FBPase gene expression. Hepatocytes will be isolated from control and CLP rats and will be
30
Blood Glucose
incubated with agonists to observe their effects on Glu-6-Pase and 6PF2K/FBPase gene expression. Freshly prepared, primary cultures of hepatocytes will be transfected and then incubated with hormones and hormonal response element will be confirmed by DNA footprinting. The results of this study are essential to understand the molecular basis of deranged metabolism in sepsis. Understanding the mechanism might be useful for developing appropriate therapeutic intervention during sepsis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUCOSE MEDIATION OF NORADRENERGIC ACTIVITY IN VMH Principal Investigator & Institution: Beverly, Joseph L.; Associate Professor; Animal Sciences; University of Illinois Urbana-Champaign Henry Administration Bldg Champaign, Il 61820 Timing: Fiscal Year 2002; Project Start 30-SEP-2000; Project End 31-AUG-2005 Summary: (Applicant's abstract): Circulating glucose concentration is monitored and maintained at appropriate concentrations by the central nervous system (CNS). Physiological and behavioral responses to glucose imbalances have been described, but the key mechanism by which fluctuations in glucose status are recognized and appropriate counter-regulatory responses initiated is not known. The immediate objective of the proposed research is to identify underlying neurochemical mechanisms in the ventral hypothalamus that sense changes in plasma glucose and initiate counterregulatory responses to restore glucose status. Noradrenergic activity in the ventromedial hypothalamus (VMH) has been demonstrated to influence blood glucose through effects on the autonomic nervous system, behavior, and neuroendocrine system. We have reported a consistent activation of noradrenergic systems in the VMH during hypoglycemia. The specific aims of this application are to determine the glycemic thresholds for the activation of noradrenergic systems in the VMH, to evaluate the effect of changes in interstitial fluid glucose concentrations in the VMH on noradrenergic activation, to determine if the activation of noradrenergic systems in the VMH is mediated through local intrinsic neurons within the VMH, to the effect of recurrent hypoglycemia on the noradrenergic activation in the VMH, and determine if increased levels of circulating leptin alter sensitivity of noradrenergic response to hypoglycemia. Intravenous catheters and microdialysis probes will be used to simultaneously monitor plasma glucose and concentrations of extracellular neurotransmitters in the VMH. Our hypothesis is that glucose responsive neurons in the VMH respond to changes in extracellular glucose concentrations that reflect circulating plasma glucose and activates noradrenergic inputs to the hypothalamus. The activation of these neurons is dynamic, so that the glycemic threshold for activating NE systems in the VMH will be altered by recurrent episodes of hypoglycemia. Further, we propose that leptin affects the sensitivity of glucose response neurons to interstitial glucose concentrations thereby altering the glycemic threshold for activation of glucoregulatory systems in the VMH. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EXPRESSION
GLUCOSE
REGULATION
OF
PANCREATIC
ISLET
GENE
Principal Investigator & Institution: Robertson, R Paul.; Scientific Director and Ceo; Pacific Northwest Research Institute 720 Broadway Seattle, Wa 98122 Timing: Fiscal Year 2002; Project Start 01-DEC-1985; Project End 31-MAR-2006
Studies
31
Summary: (provided by applicant) The overall goal of this proposal is to examine the hypothesis that the adverse effects of prolonged exposure of pancreatic islets to supraphysiologic glucose concentrations (i.e. glucose toxicity) is mediated at least in part by glucose oxidation and the subsequent generation of reactive oxygen species (ROS) that can impair insulin gene expression and beta cell function. The four specific aims are: Specific Aim #1: To determine whether intervention with antioxidants after establishment of hyperglycemia in ZDF rats is successful in decreasing plasma markers for oxidative stress, and, if so, also in decreasing plasma glucose levels and restoring islet PDX-1 and insulin mRNA, insulin content, and glucose-induced insulin secretion. We will also determine whether discontinuation of antioxidant treatment is followed by reversion to the pretreatment level of hyperglycemia and defects in beta cell function. Specific Aim #2: To determine whether progression of type 2 diabetes mellitus in db/db mice is accompanied by disruption of the balance between reactive oxygen species and islet antioxidant enzyme gene expression, enzyme levels, and enzyme activity and defects in PDX-1 and insulin gene expression, and to determine whether db/db mice transgenically modified to overexpress intraislet antioxidant enzymes as a preventive measure are protected from glucose toxicity-induced progression of type 2 diabetes. Specific Aim #3: To determine whether prolonged exposure of pancreatic islets to supraphysiologic glucose concentrations disrupts the intracellular balance between reactive oxygen species (ROS) and anti-oxidant enzyme gene expression, enzyme levels, and enzyme activity, thereby causing defective insulin gene expression and to determine whether in vitro overexpression of antioxidant enzymes islets prevents adverse effects of supraphysiologic glucose concentrations on PDX-1 and insulin gene expression, insulin content, and glucose-induced insulin secretion. Specific Aim #4: To ascertain whether measures of oxidative stress correlate positively with the level of hyperglycemia and negatively with residual beta cell function in type 2 diabetic patients; whether the intervention of improving glycemic control in type 2 diabetic patients leads to decreases in markers of oxidative stress and improvements in beta cell function; and whether interventional treatment with an antioxidant drug without changing current conventional drugs used for glycemic control diminishes hyperglycemia and improves beta cell function in poorly controlled type 2 diabetic patients. The methods used to achieve these specific aims will involve studies of insulin secretion, insulin content, PDX-1 and insulin mRNA levels, antioxidant enzyme levels and activity, and blood and islet markers for oxidative stress. We will conduct experiments using ZDF rats and antioxidant drugs, rat and human islets with adenoviral infection of cells to overexpress antioxidant enzymes, and db/db mice made transgenic to overexpress antioxidant enzymes, both singly and in combination. At the conclusion of these studies, we hope to have determined whether chronic oxidative stress is a mechanism of action for glucose toxicity in islets. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUCOSE SENSOR/TISSUE INTERACTIONS ENGINEERING Principal Investigator & Institution: Moussy, Francis; Associate Professor; Mechanical Engineering; University of South Florida 4202 E Fowler Ave Tampa, Fl 33620 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): A major obstacle to the widespread application of implantable glucose sensors is that they progressively lose function after a relatively short period of time in vivo. This loss of function is in part a consequence of inflammation and fibrosis resulting from the tissue trauma caused by the sensor implantation and by reactions within the tissue. For an implantable glucose sensor, mere
32
Blood Glucose
tissue toleration of the device is not sufficient; the sensor must also remain functional. It must be emphasize that although it is known that tissue reactions plays an important role in loss of sensor's function, the specific contribution of each tissue reactions (i.e. inflammation, fibrosis and loss of vasculature) has not yet been determined nor quantified. Furthermore, little work has been done so far on controlling these reactions to implanted biosensors. Based on the preceding information, we have developed the following hypotheses. Grant Hypotheses: We hypothesize that inflammation, fibrosis and loss of vasculature affect both the transport properties and the local concentration of glucose around the implanted sensor. As a result, implanted glucose sensors progressively lose function and become unreliable after implantation. We further hypothesize that our experiments and mathematical models will show that all threetissue reactions play a significant role in the loss of sensor function. However, we also hypothesize that use of an anti-inflammatory drug delivery system, with an anti-fibrotic decorated surface hydrogel, and VEGF gene transfer can enhance the function and lifespan of the implanted sensors by decreasing inflammation and fibrosis, as well as by enhancing neovascularization. To test these hypotheses, we propose to use the current electrochemical Nation-based glucose sensor developed in our laboratory and all in vivo experiments will be conducted in the rat model. Therefore, the goals of this proposal will be: 1) to determine the specific contributions of inflammation, fibrosis and blood vessel density on the sensor's loss of function, using in vitro and in vivo studies as well as mathematical models, and 2) to control these reactions using a combination of approaches (decorated hydrogels, drug delivery and gene transfer) to enhance the glucose sensor's function and lifetime in vivo. Our overall goal for this proposal is to have a glucose sensor that can be implanted and provide reliable and continuous monitoring for at least 4 weeks. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUCOSE SENSORS AND HYPOGLYCEMIA IN CHILDREN WITH DM Principal Investigator & Institution: Tsalikian, Eva; Associate Professor of Pediatrics; Pediatrics; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): Intensive therapy is currently accepted as the standard of care to reduce the risk of long term complication in patients with diabetes of all ages. However, intensive therapy is frequently complicated by hypoglycemia. In comparison to adults, young children and adolescents have even more lifestyle characteristics that make them prone to hypoglycemia, which then becomes a dangerous complication and a major limiting factor of intensive treatment and good diabetes control. With current home glucose monitoring capabilities it is difficult to accurately define the true incidence, duration, and severity of hypoglycemia in children with diabetes. A continuous glucose monitoring system (CGMS) has recently become available as a tool to more closely examine blood glucose patterns, by recording up to 288 glucose measurements a day (864 glucose readings over a 72 hour period). The purpose of the proposed study is to elucidate the extent of hypoglycemia and the factors that contribute to hypoglycemia in children with and without diabetes. In this descriptive study, four age groups of children will be studied: defined by children 2-6, 610, 10-14, and 14-18 years of age. Grouping by age will assure an appropriate sample of children of different ages, as well as a large prepubertal cohort. Eighteen children with diabetes will be included in each age group for a total of 72 patients with diabetes. Nine children without diabetes will serve as controls for each age group in order to study the
Studies
33
normal physiologic glucose variability. During the four years of data collection, subjects will participate for one to three years, depending on the time of enrollment. They will be fitted with the CGMS for three days, quarterly, alternating week, and weekend intervals. Data will be obtained on the child?s medical history, blood glucose levels, genotyping, and dietary intake. Activity will be monitored by accelerometry. Cognitive functioning, school performance, behavior, and adjustment to diabetes will be measured as potential factors contributing to the risk of hypoglycemia. In summary, CGMS in children with diabetes will provide valuable information on hypoglycemia frequency and severity, and the risk factors associated with this serious complication of intensive diabetes management in children. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUCOSE SENSORS IN CHILDREN WITH TYPE I DIABETES Principal Investigator & Institution: Chase, Peter H.; Professor; B Davis Ctr/Childhood Diabetes; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: (prepared by applicant): The specific aim of this application is to determine if glucose control can be safely improved in children with type 1 diabetes as a result of using continuous glucose monitoring (CGM). In an initial feasibility trial, accuracy of the two CGM devices will be compared to venous glucose levels in a Pediatric GCRC. Children with and without diabetes will spend 24 hours in the GCRC. This will also help to sort out children with diabetes (1 in 30) who have excessive skin reactions to the GlucoWatch, or who cannot tolerate subcutaneous CGM sensors. The children with diabetes will then be randomized to a feasibility three-month trial of either using the GlucoWatch Biographer or the MiniMed CGMS or serving as a control. Children will be selected for the feasibility and the two-year study who are either using intensive diabetes management or who are committed to moving toward intensive diabetes management. They must be willing to do at least four self-blood glucose monitoring (SBGM) tests each day. They will be randomized to two years of treatment, including six months of using four GlucoWatch Biographers per week (two day/two night), six months of using the MiniMed CGMS, and a six month control period. Primary end points will be change in HbA1c levels and the incidence of hypoglycemia. HbA1c levels will be determined initially and every three months, or at one and three months in the feasibility trial, with a goal of achieving HbA1c values less than seven percent. The incidence of all hypoglycemic events and of severe hypoglycemia will be compared for the three treatment groups in the three-month feasibility and the two-year longer trial. In addition, each person will serve as their own control in the longer trial as they are randomized to each of the three study groups. Secondary end points will be episodes of ketoacidosis, change in BMI, numbers of sensors used, insulin dose, use of an insulin pump, use of carbohydrate counting, number of SBGM tests done per day and changes in Fear of Hypoglycemia and Quality of Life Questionnaires. Quality of Life and Fear of Hypoglycemia Questionnaires will be used to evaluate psychological factors in both the factors in both the feasibility and the two-year trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GLYCEMIC INDEX, OBESITY, INSULIN RESISTANCE AND CVD RISK Principal Investigator & Institution: Ludwig, David S.; Assistant Professor of Pediatrics; Children's Hospital (Boston) Boston, Ma 021155737
34
Blood Glucose
Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2006 Summary: (provided by applicant): The prevalence of obesity has risen dramatically among children in the U.S. since the 1960s. Effective treatment of childhood obesity is widely recognized as instrumental to public health efforts to combat type 2 diabetes and heart disease. Evidence from animal studies, short-term human studies and epidemiology suggests that diets designed to minimize the rise in postprandial blood glucose, that is low glycemic index, may be useful in the treatment of obesity and related complications. This project proposes two studies involving obese adolescent subjects age 13 to 18 years: 1) a randomized controlled trial examining the effectiveness and practicality of a low glycemic index diet in the treatment of obesity and prevention of related complications; 2) a cross-over feeding study investigating the physiological effects of weight-maintaining diets differing in glycemic index on insulin resistance and CVD risk factors under controlled conditions. Study 1 involves 90 subjects randomly assigned to receive standard dietary treatment or a macronutrient-controlled low glycemic index diet. Each subject and at least one parent will received intensive nutritional counseling for 6 months, with follow-up for an additional 6 months. Both diet groups will receive identical treatment intensity, behavioral modification and physical activity recommendations. The primary endpoint will be change in percent body fat by dexa-scan at 12 months; other outcomes include insulin resistance and CVD risk factors. Compliance will be assessed by interviewer-administered, 24-hour dietary recalls. Study 2 involves 24 subjects who will be randomly assigned to received marconutrient-controlled low or high glycemic index diets prepared in a metabolic kitchen for 4 weeks. Subjects will be admitted to the GCRC at baseline and at the end of each dietary treatment for measurement of insulin sensitivity by hyperinsulinemic euglycemic clamp, endothelium-dependent flow-mediated dilation of the brachial artery and other cardiovascular disease-related outcomes. The two studies are expected to provide complementary information regarding the effects of dietary glycemic index on childhood health. The project's key personnel and consultants include individuals with a diversity of expertise and perspective, ensuring a rigorous and impartial evaluation of study hypotheses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEPATIC MECHANISM FOR CONTROL OF FOOD INTAKE Principal Investigator & Institution: Friedman, Mark I.; Associate Director; Monell Chemical Senses Center 3500 Market St Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 01-JAN-1986; Project End 31-MAR-2004 Summary: (Adapted From The Applicant's Abstract): Feeding behavior is controlled in part by post-absorptive fuel metabolism. In order for fuel metabolism to affect feeding, the brain must be informed. The liver monitors fuel metabolism and generates signals that the brain uses to control feeding behavior. The overall goal of this project is to understand the operation of this hepatic control of food intake. The experiments proposed in this application will provide important information about hepatic mechanisms that control feeding behavior, and thus will contribute to a fuller understanding of the etiology of overeating, obesity and anorexia, and to the development of appropriate strategies for their prevention and treatment. Two aims of this project pertain to the neural substrate for the transmission and processing of the hepatic hunger signal(s). Experiments will be performed to: 1) locate the neurons involved in the transmission and processing of hepatic metabolic hunger signals; and 2) determine where different peripheral metabolic hunger signals are integrated to control feeding behavior. Three aims of the project address questions concerning the hepatic
Studies
35
mechanism that mediates satiety in glucose and fat. To address these issues experiments will be conducted to determine whether: 1) the difference in glucose concentration in the blood vessels supplying the liver (hepatic artery and hepatic portal vein) generates a satiety signal; 2) the sensory neurons in the vagus nerves mediate the satiating effect of high concentrations of hepatic portal vein glucose; and 3) the satiating effect of fat is due to its metabolism in the liver. Another aim of this project pertains to which cell types in the liver are the source of hepatic signals that control feeding behavior. To address this, an experiment will be performed to determine whether a metabolic hunger signal originates from hepatocytes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIF-1 AS A THERAPEUTIC TARGET IN DIABETIC RETINOPATHY Principal Investigator & Institution: Ihnat, Michael A.; University of Oklahoma Hlth Sciences Ctr Health Sciences Center Oklahoma City, Ok 73126 Timing: Fiscal Year 2002; Project Start 16-SEP-2002; Project End 31-AUG-2007 Summary: Diabetic retinopathy is a major complication of diabetes and a leading cause of blindness. In its later stages this disease is characterized by a hyperproliferation of retinal blood vessels, or angiogenesis. Hypoxia inducible factor -1 (HIF-1) is a transcription factor that is rapidly induced in response to hypoxia and regulates the expression of several genes critical to angiogenesis and glucose regulation. HIF-1 has been shown to be significantly increased in the retina in response to hypoxia and to advanced glycation products (AGEs), altered macromolecules associated with diabetes. The overall hypothesis driving these studies is that inhibition of angiogenesis through the specific disruption of HIF-1 is a novel, early target for potentially controlling proliferative retinopathy. The goal of specific aim one is to target HIF-lalpha, a critical subunit of HIF-1, at the messenger RNA level through the use of ribozymes, or catalytic pieces of RNA. The goal of specific aim two is to find specific peptide inhibitors of the interaction between the HIF-1alpha and the HIF-1beta (ARNT) subunit using phage peptide display. Both the ribozymes and the peptides will be introduced locally into the retina using adenovirus. The effect of these agents on angiogenesis and on downstream targets of HIF-1 (VEGF, PAl-l) will be examined using an oxygen-induced mouse ischemia model. Using these molecular approaches we seek to define a role for HIF-1 in proliferative diabetic retinopathy and to determine whether this transcription factor represents a valid target for therapy in this disease state. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HYPOGLYCEMIA PREVENTION
&
DRIVING:INCIDENCE,
MECHANISMS,
Principal Investigator & Institution: Cox, Daniel J.; Psychiatric Medicine; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2003; Project Start 01-JAN-1982; Project End 31-JAN-2006 Summary: (provided by applicant): Intensive insulin therapy for Type 1 Diabetes Mellitus (T1DM) is associated with an increased risk of hypoglycemia. Our past NIHfunded research, investigating the biopsychobehavioral causes and effects of hypoglycemia, has yielded important and unique, albeit post hoc, findings about hypoglycemia and driving in T1DM. We demonstrated that mild hypoglycemia (e.g., 65 mg/dl) impairs cognitive-motor, judgment and driving performance. Additionally, our 11-site retrospective survey of 600 drivers with and 300 drivers without diabetes found that those with T1DM had twice as many auto crashes and violations and experienced
36
Blood Glucose
hypoglycemic stupor 4 times as often while driving than either T2DM or nondiabetic drivers (p's<.01); Post hoc analyses revealed that T1DM drivers who had crashed/hypoglycemic stupor in the previous 2 years had a lower Blood Glucose (BG) threshold for deciding when not to drive, were less likely to measure BG before driving, were more likely to have mild hypoglycemia while driving, and were less likely to have carbohydrates in the car (p's<.03). Finally, our previous research demonstrates that judgment about driving when BG is low can be improved, and number of moving vehicle violations and crashes can be reduced, through psycho-behavioral interventions. Based on these findings, we propose the first, a priori, prospective, multi-center investigation of hypoglycemia and driving in T1DM drivers who are thought to be at High vs. Low risk for driving mishaps. This study has three phases: Phase 1 will involve recruiting 275 High and 275 Low risk T1DM drivers, from three diverse sites in the U.S., and prospectively tracking diabetes self-management behaviors and driving mishaps over a 12-month period. Phase 2 will be intensive and experimental UVA field and hospital-based studies investigating the physiological, behavioral and psychological parameters of driving and self-regulation during euglycemia and hypoglycemia. Phase 3 will include the pilot testing of an intervention aimed at preventing hypoglycemiarelated driving mishaps. The proposed research is designed to: A) document the frequency of hypoglycemia-related driving mishaps, e.g., driving errors that may or may not result in a crash or citation; B) determine mechanisms underlying these mishaps, testing a diabetes-specific causal model we have developed; and C) create a database on which to begin to develop an intervention program intended to reduce the factors associated with hypoglycemia-related driving mishaps; and, D) pilot test an intervention designed to reduce risk of driving mishaps due to hypoglycemia. Ultimately, this research may enhance driving safety for people with T1DM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTION
HYPOGLYCEMIA
AND
AUTONOMIC
NERVOUS
SYSTEM
Principal Investigator & Institution: Freeman, Roy; Associate Professor of Neurology; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2008 Summary: The Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study have documented unequivocally that improved glycemic control decreases the incidence and progression of microvascular complicatons of diabetes. The implementation of regimens to rigorously control blood sugar in diabetic patients has led to an increased incidence of severe iatrogenic hypoglycemic events that have limited glycemic management of diabetes mellitus. Recent antecedent iatrogenic hypoglycemia impairs the neuroende:rine and autonomic response to subsequent hypoglycemia - a disorder known as hypoglycemia associated autonomic failure - thus increasing the predisposition to severe hypoglycemia. It is not known whether antecedent hypoglycemia has more general effects on autonomic nervous system function. Impaired autonomic function is associated with increased mortality and morbidity in individuals with diabetes mellitus. If hypoglycemia induces generalized autonomic dysfunction it may further increase the mortality and morbidity associated with diabetes mellitus. The goal of this research is to understand the mechanisms of hypoglycemia associated autonomic failure. The proposed studies test the hypothesis that antecedent hypoglycemia not only impairs the counterregulatory response to subsequent hypoglycemia but also impairs cardiovascular autonomic function in nonhypoglycemic individuals. These studies will examine those markers of cardiovascular
Studies
37
autonomic function that, when impaired, are associated with increased morbidity and mortality in patients with diabetes. Furthermore, we hypothesize that antecedent hypoglycemia causes a rise in serum cortisol and that cortisol activation of glucocorticoid receptors mediates the development of hypoglycemia associated autonomic failure. The specific aims for the proposal are to assess autonomic control of cardiovascular function following antecedent euglycemia and hypoglycemia. In addition, we will determine whether administration of a glucocorticoid receptor antagonist, mifepristone, prior to antecedent hypoglycemia improves the autonomic and neuroendocrine response to subsequent hypoglycemia in healthy men and women. Thus, the broad long term objectives of the proposal are to fully understand the mechanisms and consequences of hypoglycemia associated autonomic failure with the ultimate goal of finding an efficacious treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMAGING PANCREATIC B-CELL FUNCTION BY MAGNETIC RESONANCE Principal Investigator & Institution: Roman, Brian B.; Research Assistant Professor; Physiology and Biophysics; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): The use of MRI imaging as a non-invasive tool to assess encapsulated pancreatic beta cell viability is proposed. The immunoisolation of transplanted islets has emerged as a promising method of treating Type I Diabetes, and is potentially the only strategy that provides both the safety of avoiding immunosuppressant drugs and the effectiveness of measuring blood glucose as accurately as only living cells can. Since the device functions as an implantable homeostatic sensor-release system, it is fundamental for the encapsulated cells to be able to respond promptly to fluctuations in glucose concentrations of the interstitial fluid in order to retain a physiologic dynamic response. Currently, efficacy of the biocapsule is assessed indirectly by measuring serum glucose levels, and although insulin secretion may remain constant, levels of ATP, glucose consumption and lactate production may change, and may be indicators of irreversible damage to the encapsulated cells. In this proposal, NMR spectroscopy and microimaging will be used to analyze the physical and physiological status of the pancreatic beta cells. A novel MR imaging method is proposed to non-invasively assess cell activation. Pancreatic b-cells activated by increased glucose levels induce Ca2+ uptake through L-type voltage-gated Ca2+ channels. Mn2+ acts as a Ca2+ analog and enters cells through L-type voltage gated channels. Additionally, Mn2+ is a MR relaxation agent and reduces the T1 of water, resulting in a change in image contrast. Therefore beta cells activated by increased glucose in the presence of Mn2+ will demonstrate a change in MR signal intensity compared to non-activated cells. Using the high spatial resolution abilities of MRI, this approach will allow us to directly image beta cell function and viability. Simultaneously it will be possible to apply localized spectroscopic techniques to construct metabolic profiles of activated versus non-activated regions. In concert, these techniques will provide means to understand beta cell function, factors influencing successful islet transplantation, and the further development of encapsulated pancreatic beta cells necessary for a bioartificial pancreas. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
38
•
Blood Glucose
Project Title: INDIVIDUALIZING DIABETES CARE FOR OLDER PEOPLE Principal Investigator & Institution: Huang, Elbert S.; Instructor of Medicine; Medicine; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2004; Project Start 01-FEB-2004; Project End 31-JAN-2008 Summary: (provided by applicant): Type 2 diabetes mellitus is a substantial health care burden for individuals over 65 but little clinical research has been specifically devoted to establishing preventive care guidelines for this population. Preventive care goals need to be individualized for older patients, a process that requires accounting for all treatment effects, patient heterogeneity, and individual preferences. I am a general internist who seeks to develop a career at the intersection of diabetes and geriatrics that is focused on the evaluation and individualization of diabetes care goals for older patients, using a decision modeling approach. In four years, I would like to be able to conduct a series of decision-analytic studies using available trial and epidemiological data that illustrate how patient heterogeneity and preferences should influence the setting and prioritization of prevention goals such as the control of blood glucose, blood pressure, and serum cholesterol. In order to reach this long-term goal, I will obtain additional research training and experience in multiple disciplines through formal coursework, one-on-one mentoring, and completion of a series of modeling projects and a patient survey over the next four years. The faculty and resources of the University of Chicago make it a rich environment for career development in aging-related research. This research plan is composed of four specific aims: 1) To develop a model of type 2 diabetes designed to analyze the effectiveness and cost-effectiveness of varying levels of glucose control for subjects over the age of 65; 2) To evaluate the impact of patient heterogeneity on the effectiveness and cost-effectiveness of varying levels of glucose control for older subjects; 3) To assess older patients' preferences regarding life with diabetes treatments and complications and to evaluate the effect of preferences on the effectiveness and cost-effectiveness of glucose control strategies; 4) To begin to evaluate the effectiveness and cost-effectiveness of non-glycemic control related treatments in older subjects. Optimizing the individualization of comprehensive diabetes care has the potential to dramatically reduce complications and improve quality of life for older patients. The development and evaluation of a glucose control module and the collection of patient preference data will be crucial to future decision-analytic studies of comprehensive diabetes care in older patients. Along with more research training, these studies will also help me reach my overall goal of becoming an independent investigator in the areas of geriatric diabetes and cost-effectiveness analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INFLUENCE ADOLESCENCE
OF
INSULIN
ON
BP
CHANGE
DURING
Principal Investigator & Institution: Sinaiko, Alan R.; Professor of Pediatrics; Pediatrics; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 05-MAY-1995; Project End 31-MAY-2004 Summary: (Adapted from the Investigator's Abstract) This research application is a continuation of a project initiated in 1995 to study insulin resistance in children. The primary objectives are (1) to define the relation of insulin resistance (defined by the euglycemic insulin clamp) during childhood and adolescence to the development of the insulin resistance syndrome (i.e., hypertension, dyslipidemia, obesity, and insulin resistance) in young adulthood; and (2) to define the relation of the insulin resistance syndrome within families and the importance of genetics to that relation. The original
Studies
39
cohort consists of 357 children who have had two euglycemic insulin clamp studies (at mean ages 13 and 15 years). The specific aims are: to (1) repeat anthropometric and blood pressure measurements at mean ages 18, 19, and 20 and obtain insulin clamps, lipid levels, echocardiograms, and DEXA at mean age 21 in the children; and (2) obtain the measurements, blood and DNA samples, echocardiogram, and insulin clamp in the parents and siblings of the children. Statistical genetics methods will be used to estimate heritability and genetic correlations among the insulin resistance syndrome traits. These data will address the hypotheses that 1) insulin resistance in childhood will predict insulin resistance and cardiovascular risk factors in young adulthood; 2) insulin resistance in parents will be associated with insulin resistance and cardiovascular risk factors in their children; 3) in fat children, BMI and insulin resistance at mean age 13 will predict cardiovascular risk, but in thin children only insulin resistance will be a similar predictor; 4) insulin resistance has significant heritability; and 5) there are significant genetic correlations between insulin resistance and the insulin resistance traits. It is anticipated that at least 300 of the original cohort of 357 who have had two euglycemic insulin clamps will complete the five years of this continuation. The investigators state that the significance of this project lies in its potential to define the factors influencing development of the insulin resistance syndrome and provide the basic clinical data required to begin to study genetic patterns of cardiovascular disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INSTRUMENTAL DESIGNS FOR NEAR INFRARED GLUCOSE MONITORS Principal Investigator & Institution: Arnold, Mark A.; Professor; Chemistry; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2004; Project Start 15-MAY-2004; Project End 31-MAR-2008 Summary: (provided by applicant): Two novel solid-state instrumental designs are described for use in the noninvasive measurement of blood glucose. Both instruments implement transmission measurements of near-infrared light through a tissue sample and allow the encoding of multivariate calibration models in hardware. Each instrument is based on the sequential measurement of pre-defined combinations of near- infrared wavelengths that are specified in the form of filter bandpass functions. In the two designs, these filter profiles are generated with either a digital micromirror array (MMA) or an acousto-optic tunable filter (AOT F). The MMA allows the specification of filter profiles of arbitrary complexity, while the AOTF allows the generation of filters with simpler square-wave shapes. A computational model and numerical optimization procedures are described for use in defining optimal filter profiles that result in the measurement of unique spectral patterns that are selective for blood glucose. These filter profiles are analogous to the components extracted by multivariate calibration models from contiguous spectral data acquired by a conventional spectrometer. Performing these discrete filter-based measurements gains both throughput and multiplex advantages, and allows the creation of rugged instrumental designs that are compatible with noninvasive blood glucose measurements made by diabetic patients outside the controlled environment of the laboratory. Both in vitro experiments and in vivo studies with a rat model are proposed for use in characterizing the performance and analytical utility of these instrumental designs. The experimental and computational work will be directed to the overall goal of developing a noninvasive nocturnal hypoglycemic alarm. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
40
•
Blood Glucose
Project Title: INSULIN ACTION IN MUSCLE & FAT CELL Principal Investigator & Institution: Lawrence, John C.; Professor; Pharmacology; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2002; Project Start 01-APR-1981; Project End 31-MAR-2006 Summary: Insulin lowers blood glucose by stimulating glucose uptake and storage in various target tissues, the most important being liver, skeletal muscle, and fat. The failure to respond appropriately to insulin results in a rise in blood sugar. Type II diabetes mellitus develops if beta cells become unable to release enough insulin to compensate for the insulin resistance. Determining the processes involved in the normal response to insulin will be essential for understanding insulin resistance, and the overall objective of this project is to define mechanisms involved in the actions of insulin in skeletal muscle and fat cells. Initial aims are to investigate the stimulation of glycogen synthesis by insulin. This effect is of particular importance in the control of blood glucose levels, as most of the glucose taken up following a meal is deposited as glycogen in skeletal muscle. Experiments in Aim 1 are proposed to investigate both the mechanism through which insulin activates glycogen synthase (GS), the enzyme that synthesizes glycogen from uridine diphosphoglucose (UDPG), and the importance of increasing GS activity in the stimulation of glycogen synthesis. Treating rats with insulin results in a marked decrease in muscle UDPG, implying that the activity of UDPG pyrophosphorylase (PPL) may limit the rate of glycogen synthesis. Objectives of Aim 2 are to determine whether UDPG PPL is subject to hormonal and/or metabolic control, and to investigate the potential limiting role of UDPG PPL in glycogen synthesis in rodent and human muscles. In the last two Aims we will investigate new targets of insulin action. We have recently discovered an adipocyte protein, designated betaip140, which is phosphorylated in response to insulin and coimmunoprecipitates with the beta isoform of protein kinase B (PKB). By purifying betaip140 and sequencing peptides by tandem mass spectrometry, we have shown that betaip140 is the product of the Kiaa0188 gene, recently identified by genetic fine mapping as a candidate gene for the fld mouse phenotype. Mice homozygous for the fld gene exhibit insulin resistance, glucose intolerance, and markedly diminished adipose tissue mass. Aim 3 is to investigate the potential interactions between betaip140 and PKBbeta, to define the mechanisms controlling betaip140 phosphorylation, and to determine the role of betaip140 in insulin action. Many other proteins that are phosphorylated in response to insulin can be detected, but have not been identified. This represents a serious gap in our understanding of insulin action, since at least some of the proteins are likely to represent downstream targets that are involved in the important metabolic responses to insulin. The objective of Aim 4 is to identify these new targets. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INSULIN RESISTANCE AND CNS FUNCTION IN TYPE 2 DIABETES Principal Investigator & Institution: Craft, Suzanne; Professor; Psychiatry and Behavioral Scis; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2005 Summary: (provided by applicant): Type 2 diabetes mellitus (T2DM) is caused by insulin resistance (IR) and inadequate insulin secretion. T2DM affects one in five Americans over age 60 and has been associated with verbal memory deficits in older patients. These deficits are consistent with growing evidence that insulin contributes to the functioning of the hippocampus and adjoining medial temporal structures supporting memory. Furthermore, the hypothalamic-pituitary-adrenal (HPA) axis,
Studies
41
commonly dysregulated in insulin resistant persons, interacts with the hippocampus and may influence memory. Therefore, IR may contribute to T2DM-related memory impairment. The proposed studies will examine the effects of improving IR on central nervous system (CNS) functions in T2DM and impaired glucose tolerance (IGT). Three hypotheses will be tested: that improving insulin sensitivity will (1) enhance memory and other cognitive functions, (2) increase cerebral glucose metabolism in the hippocampus and adjoining medial temporal structures, and (3) normalize cerebrospinal fluid (CSF) levels of insulin and the CSF-to-plasma insulin ratio. We will also characterize the effects of improving IR on plasma and CSF levels of amyloid peptides, which are regulated in part by circulating insulin. In a Core Study, newly diagnosed persons with T2DM and IGT will be randomized to receive the insulin sensitizer rosiglitazone (4 mg bid), the insulin secretagogue nateglinide (120 mg tid), or placebo for 16 weeks. Cognitive measures and blood samples for neuroendocrine assays will be obtained at baseline, treatment weeks 8 and 16, and after 8 weeks of washout. It is predicted that both agents will enhance memory, and that rosiglitazone will produce a greater degree of enhancement than nateglinide. A subset of Core Study subjects will receive either positron emission tomography (PET) imaging or lumbar puncture (LP) to obtain CSF at baseline and treatment week 16. In addition, a healthy control group will receive only baseline PETs or LPs. Significant findings will provide converging evidence that JR can adversely influence various CNS functions and suggest that an important therapeutic goal in IGT and T2DM is to improve insulin sensitivity. Furthermore, results of these studies should point to new avenues of research, such as examination of the cellular effects of IR on cerebral glucose metabolism and their relationship to cognition. Finally, these studies have the potential to elucidate relationships between T2DM and other disorders in which memory is impaired, such as Alzheimer?s disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: L-TYPE CA2+ CHANNEL MODULATION OF BETA CELL FUNCTION Principal Investigator & Institution: Hockerman, Gregory H.; Associate Professor; Medicinal Chem/Molecular Pharm; Purdue University West Lafayette West Lafayette, in 479072040 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-JAN-2009 Summary: (provided by applicant): In type II diabetes, the insulin secreting beta cells of pancreatic islets fail to secrete insulin in sufficient quantities to maintain normal blood glucose levels. The resulting hyperglycemia can Iead to many serious complications. Therefore, understanding the mechanisms that mediate insulin secretion could lead to new therapies to prevent the onset and complications of Type II diabetes. Two Subclasses of L-type Calcium channels, Cav1.2 and Cav1.3 are expressed in pancreatic beta cells. A "knock in" method to introduce Cav1.2 and Cav1.3 mutant channels that are insensitive to the dihydropyridine (DHP) class of L-type channel blockers into the insulinoma cell line INS-1 has been described. In this system, the endogenous L-type channels can be "shut off" with DHP drugs, thus pharmacologically isolating either Cav1.2 of Cav1.3 channels. Using this system, it is shown that Cav1.3 but not Cav1.2 channels can mediate glucose-stimulated insulin secretion, but that both channels can mediate KCI stimulated insulin secretion. Furthermore, the intracellular loop between homologous domains III and IV (II-III loop) of Cav1.3 but not Cav1.2 completely inhibits glucose-stimulated insulin secretion when over-expressed in INS-1 cells. To elucidate the mechanism and structural determinants of the specificity of Cav1.3 coupling glucose-stimulated insulin secretion in INS-1 cells, this proposal will: 1. Determine the mechanism whereby glucose stimulated insulin secretion is specifically coupled to
42
Blood Glucose
Cav1.3. 2. Identify the molecular determinants of the preferential coupling of Cav1.3 to glucose-stimulated insulin secretion. 3. Identify proteins that interact with intracellular domains of Cav1.3 and mediate the specificity for glucose-induced insulin secretion. 4. Define functional roles for the distal C-terminal tails of Cav 1.2 and Cav1.3 in INS-1 cells. Although much of this work will be done in the INS-1 cell model, adenovirus vectors will be used to introduce mutant channels and channel fragments into primary rat beta cells to repeat key experiments in this more physiologically relevant system. This proposal will utilize techniques such as patch clamp whole-cell electrophysiology, confocal microscopy, and total internal reflection microscopy. This proposal is consistent with the PI's long-term goal of understanding L-type calcium channel modulation and cellular function. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MANAGING DIABETES: USE OF A DIGITAL INTERCOM SYSTEM Principal Investigator & Institution: Flax, Stephen W.; Flextech Systems, Inc. 333 Bishops Way, Ste 109 Brookfield, Wi 53005 Timing: Fiscal Year 2003; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: (provided by applicant): The long-term objective of this project is to develop a new and novel medical monitoring device aimed at benefiting a large class of diabetic individuals. The new device is being called an "Assisted Self- Management Monitor." There are many diseases, such as diabetes, which are considered "self-managed" diseases. With diabetes, it is expected that patients measure and monitor their own blood glucose levels, their own medication administration, and their own diet and exercise programs. When patients properly and actively manage their own disease, they will minimize the disease progression. Otherwise, the effects can be tragic in terms of disease progression and health care costs. Mismanaged diabetes will eventually put the patient at risk for coronary artery disease, stroke, kidney failure, blindness, and peripheral vascular disease. Furthermore, there is often a significant time lag between when a patient collects self-care information and when a medical staff is made aware of that information. The new device underdevelopment is designed to actually monitor and evaluate how well patients are self-managing their disease, and then provide feedback to the care staff and the patient when irregularities are detected. Initially, the system is intended to help diabetic patients living in an assisted living setting. The new device will automatically transfer a patient's glucose reading and medication usage information from his or her quarters to a central station. There, the information will be compared to a personal profile that has been developed for each individual patient. When something of concern is detected, the monitor will notify the care staff with an appropriate message on a computer screen. However, the resident will also be notified with a prerecorded voice message that pertains to the given condition. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MONITORING PREGNANT WOMEN WITH GDM VIA THE INTERNET Principal Investigator & Institution: Homko, Carol J.; Medicine; Temple University 406 Usb, 083-45 Philadelphia, Pa 19122 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): Gestational diabetes mellitus (GDM), which complicates between 3 and 5% of all pregnancies, is associated with an increase in perinatal morbidity. A significant relationship between maternal glycemic control and
Studies
43
macrosomia as well as other adverse pregnancy outcomes has been clearly established. Therefore intensive management regimens, which aim to normalize blood glucose levels, are the mainstay of therapy in these pregnancies. Such an approach requires close medical surveillance with frequent communications between the health care provider and the woman with diabetes. However, current methods of surveillance, including frequent clinic visits and multiple telephone contacts, are labor intensive, costly, and not always uniformly applied particularly among inner city underserved populations. The purposed project enlists interactive technology between the health care provider and the patient at home to allow frequent monitoring of health status, to provide advice and education via a direct communication system. It is our hypothesis that the increased communication facilitated by this network will empower inner city women with GDM to take a more active role in their management, thereby improving maternal glucose control and leading to reductions in birth weight and ultimately other adverse outcomes. This preliminary study will attempt to determine if pregnant women with GDM can interact successfully with their health care providers via the diabetes health network. Eighty women with GDM will be randomized to one of two groups. Women in both groups will monitor their blood glucose levels four times a day, perform fetal movement counting three times day, and record insulin doses and episodes of hypoglycemia. Women in the experimental group will transmit their blood glucose levels and fetal movement counts to their health care providers via the diabetes health network three times a week. Women in the control group will record this information in a logbook, which will be reviewed by the medical team at prenatal visits. Key outcome variables will include infant birth weight, maternal blood glucose control and feelings of self-efficacy. Secondary outcome variables will include rate of macrosomia, neonatal morbidities, and admission to the Neonatal Intensive Care Unit. We expect this program to improve communications between patient and health care providers, enhance women's feelings of self-efficacy, improve glucose control and reduce birth weight. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEAR-CONTINUOUS GLUCOSE MONITORING IN PEDIATRICS Principal Investigator & Institution: Buckingham, Bruce A.; Pediatrics; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: (prepared by applicant): The investigators propose to develop a systematic approach to evaluating near continuous glucose sensors in children and adolescents. This approach can be used in the assessment of current sensors now available to the public, and for future sensors that become available during this project. Accuracy will be determined using normal controls and children with diabetes. Initial accuracy measurements will be performed in a CRC using a laboratory quality measurement of glucose. The sensors will then be assessed in the home environment to determine their usefulness in detecting changes in blood glucose levels and improving diabetes management. The investigators will collect detailed record of food intake, and a continuous record of physical activity will be obtained using an accelerometer as well as psychological assessments. These data will be integrated to evaluate the multiple factors leading to hypoglycemia and variability in blood glucose levels, as well as provide effective tools for improving diabetes management. In the future these data will be valuable in developing algorithms that incorporate this information into a closed loop insulin delivery system. Aim 1 is to determine the accuracy of near-continuous glucose monitors in normal children. This will allow assessment of the possible physiologic effects, such as sleep and physical activity on glucose levels. These studies will also
44
Blood Glucose
allow determination of the incidence of sensor readings in the hypoglycemic range despite normal blood glucose levels. Aim 2 is to determine the accuracy of nearcontinuous glucose sensors in children with diabetes. Particular attention will be given to the detection of hypoglycemia, especially nocturnal hypoglycemia, and the accuracy of sensors during physical activity. Aim 3 is to assess hypoglycemia in a contemporaneous population of children with Type 1 diabetes using near continuous glucose monitoring. This will be an observational study in a home environment. Aim 4 is to assess the long-term effectiveness of near continuous glucose monitoring on decreasing the frequency and severity of hypoglycemic reactions, and improving glycemic control. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROENDOCRINOLOGY OF PUBERTY Principal Investigator & Institution: Foster, Douglas L.; Professor & Research Scientist; Obstetrics and Gynecology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 01-MAR-1984; Project End 31-JAN-2005 Summary: When nourishment is inadequate or energy expenditure is great, fertility is reduced in the adult, and puberty is delayed in the developing individual. This suppression of reproductive activity is not understood mechanistically. We believe this to be an integrative problem at this stage of inquiry that requires both physiologic and pharmacologic approaches to answer broad questions about how the brain discriminates how well nourished and how mature the body is. Our broad objective is to understand the physiological mechanisms by which changes in nutrition and metabolism control reproduction, specifically the signals, sensors, and pathways whereby blood-borne information regulates GnRH secretion. To progress further in understanding the relationship between growth, metabolism and production of high frequency GnRH pulses during development, we must first determine how energy metabolism regulates GnRH secretion. To progress further in understanding the relationship between growth , metabolism and production of high frequency GnRH pulses during development, we must first determine how energy metabolism regulates GnRH secretion in the adult. Thus, we will first evaluate how changes in glucose availability and leptin modify GnRH secretion during adulthood and then determine if such a mechanism might be timing puberty during growth. The sheep will be used because its large size and long lifespan permits individuals to be studied longitudinally through their development and permits detailed studies in adults. Importantly, it is well suited for the characterization of hypophysiotrophic hormone patterns. Specific Aim 1 will determine if the hindbrain and the liver contain sensors that transmit information about glucose availability to regulated GnRH secretion. We will both increase and decrease availability locally in each site to establish their function and their interrelationships. Specific Aim 2 will determine the role of leptin as a signal to regulate the pulsatile secretion of GnRH. This will be achieved through central administration of leptin during both acute fasting and chronic low nutrition. Although widely studied in feeding behavior, we have little understanding of its physiologic role in regulating GnRH secretion. Specific Aim 3 will assess "nutritional stress" as a cause hypogonadotropism through reduced GnRH secretion by monitoring of stress peptides in the pituitary portal circulation and by antagonizing their action during acute fasting and chronic low nutrition. Specific Aim 4 will determine if glucose availability times the pubertal GnRH increase by using the power of our large animal model in which we can chronically administer metabolically important signals such as insulin and leptin.
Studies
45
Understanding the metabolic control of GnRH secretion has broad application both to growth and maturation and to other physiologic conditions in which reduced GnRH secretion may contribute to infertility because of altered energy metabolism. These include dietary malnutrition from eating disorders; during high-energy expenditure, as in exercise- induced amenorrhea and lactational anovulation; during type 1-diabetesinduced infertility. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUTRAL LIPID DYSREGULATION OF THE PANCREATIC BETACELL Principal Investigator & Institution: Poitout, Vincent; Associate Professor; Pacific Northwest Research Institute 720 Broadway Seattle, Wa 98122 Timing: Fiscal Year 2002; Project Start 01-JUN-2001; Project End 31-MAY-2005 Summary: (Scanned from the applicant's description) Type 2 diabetes mellitus is characterized by chronic hyperglycemia and is often associated with elevated plasma lipid levels. The overall objective of this proposal is to ascertain the mechanisms whereby prolonged exposure to elevated levels of fatty acids (FA) affects pancreatic beta-cell function in Type 2 diabetes. Previously, we have demonstrated that prolonged exposure to FA impairs insulin gene expression only in the presence of high glucose, and that this is associated with increased neutral lipid synthesis. Specific Aim I: To identify the metabolic intermediate(s) generated along the pathway of neutral lipid synthesis responsible for the impairment of insulin secretion and gene expression upon prolonged exposure to FA. Isolated rat islets, HIT-T15, and betaHC-l3 cells will be cultured for 1 to 7 days in the presence of increasing concentrations of glucose and FA. Pharmacological tools will be used to inhibit or stimulate each step of neutral lipid synthesis, in order to identify the metabolic intermediate(s) generated along the esterification pathway (i.e., long-chain Acyl-CoA, diacyiglycerols, or triacylglycerols) responsible for the FA-induced impairment of beta-cell function. Specific Aim II: To assess whether the glucose-dependent deleterious effects of prolonged exposure to elevated FA on beta-cell function are glucose-specific, and whether the mechanisms of these effects are transcriptional, post-transcriptional, or translational. beta-cell exhaustion will be distinguished from bona fide toxicity in experiments where diazoxide will be used to inhibit insulin release. The glucose-specificity of PA effects will be investigated by using a non-glucose secretagogue to stimulate insulin secretion and insulin gene expression. The glucose-dependent effects of FA on proinsulin biosynthesis, insulin mRNA stability, and endogenous insulin gene transcription will be assessed. The effects of FA on insulin promoter activity will be characterized in HIT-Tl5 and betaHC-13 cells and also investigated in primary islets using the recombinant adenovirus system. Specific Aim III: To determine whether high-fat feeding in hyperglycemic Goto-Kakizaki (GK) rats impairs insulin secretion, insulin biosynthesis, and insulin gene expression, and whether these effects are prevented by normalization of blood glucose levels. GK or control rats will be fed a high-fat diet for 6 weeks, after which insulin secretion, proinsulin biosynthesis, and insulin gene expression will be assessed. Blood glucose levels will be normalized in GK rats by phloridzin administration, in an attempt to prevent the deleterious effects of high-fat diet on betacell function. These experiments will provide important insights into the pathophysiology of beta-cell dysfunction of type 2 diabetes, and have clear implications for the treatment of this disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
46
•
Blood Glucose
Project Title: NIDDM PRIMARY PREVENTION TRIAL (DPT-2) Principal Investigator & Institution: Haffner, Steven M.; Professor of Medicine; Medicine; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2002; Project Start 22-SEP-1994; Project End 31-MAY-2003 Summary: As part of a multi-center grant we will attempt to prevent the development of NIDDM in 200 subjects with impaired glucose tolerance. The overall study will involve 20 clinical centers and 4000 subjects. This proposal will take seven years, with a one year protocol development, five year clinical trial and one year evaluation period. The proposed intervention will be a factorial design with one factor being diet and exercise versus usual cre and the second factor being an insulin sensitizer (e.g. Metformin) versus placebo. The primary endpoint will be the development of NIDDM. Secondary endpoints include changes in lipids, lipoproteins, ankle/arm ratio, urinary albumin and carotid wall thickness. Subjects will be obtained by several methods including: a) community advertising through radio and television advertisements; b) selective screening based on blood glucose from the Brady Green clinic; and c) subjects from the San Antonio Heart Study. Subjects identified with newly discovered diabetes but with normal fasting glycemia (2-hr glucose greater than or equal to 200 mg/dl, but fasting glucose <140 mg/dl) will be entered into a parallel secondary prevention trial to prevent the development of fasting hyperglycemia. In addition to the endpoints for the subjects in the primary prevention trial, these subjects will have assessment for diabetic neuropathy and retinopathy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NITRIC OXIDE-RELEASING GLUCOSE BIOSENSORS Principal Investigator & Institution: Schoenfisch, Mark H.; Chemistry; University of North Carolina Chapel Hill Aob 104 Airport Drive Cb#1350 Chapel Hill, Nc 27599 Timing: Fiscal Year 2002; Project Start 25-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): The objective of the proposed research is to develop a new class of nitric oxide (NO)-releasing bioanalytical sensors and evaluate their utility for in vivo subcutaneous sensor applications. The concept of using local NO release to enhance the performance of in vivo subcutaneous sensors represents a novel approach to overcoming the difficulties that have thus far prevented the development of reliable in vivo biosensors. Current scientific knowledge regarding the role of NO in angiogenesis, phagocytosis, thrombosis, and wound healing suggests that controlled in situ NO release may effectively help reduce biofouling and increase blood flow to the sensor, thus minimizing physiological responses that tend to diminish the in vivo performance of subcutaneous sensors. Specifically, it is envisioned that slow release of NO locally at the implant site will both a) reduce bacterial adhesion and associated biofouling problems, and b) enhance overall wound healing and the formation of capillaries near the implant site such that analyte diffusion from blood to the sensor electrode is enhanced. The fundamental question to be answered by the proposed research is whether electrochemical bioanalytical sensors that continuously release NO can be prepared with improved biocompatibility without compromising the sensor's analytical response. Thus, we seek to determine if the chemistries required for sustained NO release can be made compatible with the chemistries required for selective and sensitive detection of glucose. In addition, we aim to employ micropatterning methods to create unique sensor architectures that support NO release while retaining superior analytical sensitivity. The versatility of the sol-gel process in terms of tuning NO release
Studies
47
properties by varying the amount of aminosilane, combined with the variety of pattern geometries that may be created using micropatterning techniques, will allow for the development of numerous types of heterogeneous NO-releasing surfaces with a broad range of possible applications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OBESE FEMALE RESTRAINED EATERS : TWO TREATMENT OPTIONS Principal Investigator & Institution: Stern, Judith M.; Professor; Nutrition; University of California Davis Sponsored Programs, 118 Everson Hall Davis, Ca 956165200 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: Obesity continues to be a major challenge for medical management. Traditional treatment aimed at improving health has focused on energy/dietary restriction along with lifestyle modification. This cannot be the optimal treatment for all obese people, as obesity has wide ranging etiology, not all of which is addressed by the above treatment. Restrained eaters are individuals who are chronically concerned about their weight ant attempt to control or reduce it by limiting their energy intake. We propose that restrained eaters have low potential for success via energy/dietary restriction, and thus may be better served by a novel treatment oriented toward reducing their restrained eating and improving other health habits. An increasing number of practioners are utilizing this "non-diet" approach with restrained eaters. There are insufficient data to establish whether it is preferable to a conventional behavioral energy restriction intervention. Thus, we will test 30-45, body mass indices (BMI) 30-45, will be stratified based on activity level, degree of dietary restraint, degrees of flexible and rigid control of eating, BMI, and age. Fifty percent will be assigned to a non-restrictive treatment program oriented toward reducing their restrained eating (encouraging eating in response to physiologic cues, i.e., hunger and satiety), and 50% will be assigned to a control group, a conventional behavioral energy restriction weight loss program. Both groups will meet weekly for six months, followed by a monthly after-care program lasting one year. We hypothesize that on a long-term basis (12 months, 18 months), improvements in self-esteem and depression will be greater in the non- diet group compared to the weight loss group. We will also monitor body image, eating disorder data with respect to: 1) metabolic fitness (blood pressure; lipoproteinstotal cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol; markers of insulin sensitivity-glucose, insulin; percent body fat and intraabdominal fat by dual-energy x-ray absorptiometry (DXA); 2) physical activity (amount of physical activity; resting heart rate; daily energy expenditure); and 3) eating behavior (quality of diet; degree of restrictive eating; plasma leptin). These pilot data will provide a basis for future studies. The team assembled is experienced in running clinical studies including the use of proposed questionnaires and all assays and techniques. A manual of procedures will be generated to assist others in replicating the intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: OPTIMIZATION & AUTOMATION OF PANCREATIC ISLET ISOLATION Principal Investigator & Institution: Stuiver, Ingrid; Microislet, Inc. 6540 Lusk Blvd, C250 San Diego, Ca 92121 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-DEC-2003
48
Blood Glucose
Summary: (provided by applicant): Islet allotransplatation has been demonstrated to greatly reduce or eliminate the requirement for exogenous insulin injection in patients with insulin-dependent diabetes mellitus. This experimental procedure offers diabetic patients hope for improved blood glucose regulation and, consequently, a reduced risk of long-term complications of the disease. In order to circumvent the problem of human donor tissue availability, the use of animal tissue, particularly that from the pig, has been studied in combination with a technology such as microencapsulation to "immunoisolate" the cells and prevent xenograft rejection. MicroIslets Inc. is developing an improved method for preparation of microencapsulated porcine islet cells for the treatment of Type I diabetes. MicroIslet has used technology licensed from Duke as a basis for generating improved methodology for the isolation, conditioning, storage and microencapsulation of islet cells. Here, we outline new methodology for porcine islet isolation whereby 400,000 islets will be harvested per pancreas. Preliminary data demonstrate that a singe intraperitoneal (ip) injection of encapsulated porcine islet cells prepared using this technology resulted in maintenance of normal blood glucose levels (100-150 mg/dl) in a previously diabetic baboon for 14 months, without the need for additional insulin injections or potentially harmful immunosuppressive drugs to prevent graft rejection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PACEI-DP: AN INTERVENTION FOR YOUTH AT RISK FOR DIABETES Principal Investigator & Institution: Patrick, Kevin M.; Adjunct Professor; Family and Preventive Medicine; University of California San Diego La Jolla, Ca 920930934 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Improved physical activity (PA) and dietary behaviors and reductions in overweight or obesity show great promise to reduce the risk of type 2 diabetes in adults. However, very few interventions have been reported that address this issue, and none that are useful for primary care providers or that address reducing diabetes risk in adolescents. We propose a randomized controlled trial to evaluate whether an integrated primary care and web-based intervention, PACEi-DP, can produce initial and sustained improvements in anthropometric, behavioral, metabolic, and physiological outcomes in adolescents who meet the ADA criteria for "high risk" for type 2 diabetes. PACEi-DP is a 1- year intervention involving: a) preprimary care visit web assessment and progress planning; b) clinician counseling; c) 12 months of web-based, phone and/or group-based follow-up. Pilot studies based upon selected elements of PACEi-DP demonstrate its promise in improving dietary & PA behaviors and in stabilizing BMI in overweight adolescents. We will recruit 93 adolescents, age 12 to 16 years, who meet the ADA criteria for high risk of Type 2 diabetes. Subjects will be recruited from 5 healthcare settings and the community and randomly assigned to one of three conditions: 1) usual medical care; 2) a web-based version of PACEi-DP where the follow-up component involves asynchronous webbased contact with subjects and their parent/guardian; or 3) a multi-modal PACEi-DP where the follow-up component adds phone and group contact. PACEi-DP will target 4 behaviors: 1) total energy expenditure from moderate and vigorous PA; 2) sedentary behavior and recreational media use; 3) Fruit/Vegetable/Fiber consumption (5 or more servings/day of fruits/vegetables and 3 or more servings/day of whole grains or legumes); and 4) total fat as percent of energy consumed. The intervention guides patients to select PA & diet target behaviors for which they develop action plans to discuss with the clinician. The clinician endorses or modifies the action plan and
Studies
49
encourages participation in the ongoing intervention. Web-tutorials, continuous web access, e-mail interaction, and (in Group 3) phone counseling and group meetings guide patients and parent/guardian to use cognitive & behavioral skills to change behaviors. PACEi-DP enables participants to receive tailored, stage-appropriate intervention on their diet & PA goals. The primary outcome will be the effect of PACEi-DP on BMI at 12 months. Secondary outcomes (at 6 and 12 mo.) will be: a) metabolic and physiological measures of insulin resistance (fasting insulin, fasting blood glucose, blood lipids, microalbuminuria, acanthosis nigricans, and blood pressure; b) anthropometric measures ( percent body fat by DEXA (at 12 months), waist/hip ratios; c) behavioral measures (moderate & vigorous PA; total energy expenditure; CSA; measures of sedentary behavior & recreational media use; servings of fruits, vegetables & fiber; and total fat as a percent of energy consumed. Exploratory measures will include psychosocial mediators of change; measures of parent/guardians' BMI and waist/hip ratios, and process, satisfaction & cost-effectiveness measures of each study arm. The PACEi-DP intervention is particularly innovative because its three components - previsit web assessment and behavior change planning, primary care provider counseling, and the ongoing web or web/phone/group intervention -are unified through a common behavioral theoretical framework. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PALM-TOP DIETARY MANAGER FOR CHILDREN WITH DIABETES Principal Investigator & Institution: Sirotinin, Sergey V.; President & Ceo; Dbaza, Inc. 5001 Baum Blvd, Ste 770 Pittsburgh, Pa 15213 Timing: Fiscal Year 2002; Project Start 30-SEP-1999; Project End 31-DEC-2003 Summary: (Scanned from the Applicant's Abstract): We are seeking SBIR Phase II support in order to produce and test the effectiveness of a technically refined, and commercially viable dietary self-management software suite for youngsters with Type I diabetes, a prevalent chronic disorder of childhood. The software suite called "Meals and Things" (MAT) consists of two modules: (a) a meal planning and recording software module that operates on a hand-held device; and (b) a supporting customizable management module that operates on a desktop PC (or commercial server). The final products will incorporate findings from a recent market test of the Phase I prototype. MAT seeks to help youths to adhere to their meal plans in order to facilitate better regulation of blood glucose and improve long-term medical outcomes. The final product will be examined with respect to: (a) its effectiveness to improve dietary selfmanagement; (b) its impact on blood glucose regulation (HbA1 levels); and (c) user's satisfaction. MAT will be tested in randomized trials with 50 recently diagnosed 8-13 year old children, using a pre-post-test design. The software suite will be targeted to youths with IDDM, parents, diabetes educators, and health care professionals. PROPOSED COMMERCIAL APPLICATIONS: The "Meal and Things" will serve as a valuable dietary self-management tool appropriate to school-age youths with Type I diabetes, their parents, diabetes educators, and health care professionals. The program, together with the Interactive CD-ROM "Kids and Diabetes" (also being developed by dbaza) will address components of diabetes self-care in a comprehensive fashion, with educational, conceptual, and visual continuity. It will appeal to health care providers, since it will reduce costs by providing more effective diabetes dietary education with no increase in staff; and to parents and youths, because it facilitates adherence to the medically recommended meal plan which then should impact positively on overall diabetes self-management and glycemic control. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
50
•
Blood Glucose
Project Title: 'PARENT-CHILD CO-REGULATION OF PEDIATRIC DIABETES' Principal Investigator & Institution: Gonder-Frederick, Linda A.; Associate Professor; Psychiatric Medicine; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2006 Summary: (provided by applicant): Successful diabetes management relies on a process of self-regulation in which treatment behavior is guided by feedback about changing blood glucose (BG) levels and decision-making. The processes involved in selfregulation have been studied extensively in adults with Type 1 Diabetes Mellitus (T1DM), leading to the development of sophisticated research tools that have significantly advanced our understanding and ability to predict clinical outcome. Additionally, this research has led to the development of a highly effective, empirically based, psychobehavioral intervention, Blood Glucose Awareness Training (BGAT), developed by our research team, that improves self-regulation and clinical outcome in adults with T1DM. Unfortunately, the processes involved in the self-regulation of pediatric diabetes have received virtually no empirical attention. The purpose of the proposed project is to correct this scientific neglect by adapting the conceptual and methodological tools used in adult studies to 1) investigate the process of diabetes regulation by school-aged children (6-11 yrs) with T1DM and their parents and 2) develop and test an intervention to enhance the skills critical to this process. This is an important population to target for this line of inquiry because: 1) children with T1DM and their parents appear to be far less accurate than adult patients in symptom and BG detection; 2) As a group, pediatric patients are more likely to suffer from negative clinical sequelae (e.g., severe hypoglycemia (SH) and DKA); and, 3) Early intervention could have greater public health care benefit by achieving more reductions in acute and long-term complications, health care utilization, and disability. Phases 1A and 1B of the proposed project will provide the first systematic and comprehensive study of symptom recognition, BG detection, decision-making, and subsequent clinical sequelae in schoolaged children with T1DM and their parents. A theoretical model of co-regulation of pediatric diabetes is proposed and tested, in which the behaviors of both parent and child influence the sequence of events that determine avoidance or occurrence of negative outcomes, such as extreme hypo- and hyperglycemia. Based on the findings of these studies and our current BGAT for adults, Phase 1 C will pilot test a translation of this intervention designed for parents of school-aged children with T1DM, BGAT for parents (BGAT-P). This intervention will take advantage of the critical role parents play as the primary teachers of children about diabetes management by including training activities for parents to do with their children designed to improve children's ability to recognize BG symptoms, detect extremes in BG, and make appropriate self-treatment decisions. Based on the findings from this pilot study, and feedback from parents, in Phase 2 BGAT-P will be further refined and tested in a controlled clinical trial to assess its short-term efficacy. Phase 3 is a 12-month follow-up study to determine whether the improvements found in Phase 2 are maintained over time and also to assess the impact of BGAT-P on future clinical negative events, including frequency of SH and DKA experienced by children. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PHARMACOGENETICS OF PRO12ALA PPAR GAMMA 2 IN DIABETES Principal Investigator & Institution: Shuldiner, Alan R.; Professor; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201
Studies
51
Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-AUG-2005 Summary: (Verbatim from Applicant's Abstract): Clinical studies indicate that there is great variability in the ability of thiazolidinediones, a class of insulin-sensitizing agents, to improve glycemic control in patients with type 2 diabetes. The receptor for thiazolidinediones is peroxisome proliferator activated receptor-gamma (PPARgama), a nuclear receptor that plays an important role in adipogenesis and insulin signaling. We recently identified a common genetic variant in the PPARgamma gene (Pro12Ala PPARgamma2). In vitro studies indicate that this single amino acid substitution has functional consequences. Furthermore, Pro12Ala PPARgamma2 is associated with increased body mass index (BMI) in two Caucasian populations, increased insulin sensitivity in African Americans and Pima Indians, and more rapid weight regain after weight loss in postmenopausal Caucasian women. We hypothesize that inter-individual variability in therapeutic efficacy to thiazolidinediones is due, at least in part, to genetic factors. Specifically, we hypothesize that diabetic subjects who carry the Pro12Ala PPARgamma2 variant will be more insulin sensitive and therefore less responsive to the insulin-sensitizing and glucose lowering effects of rosiglitazone therapy as compared to subjects without the variant. To test this hypothesis, we will perform a prospective rosiglitazone intervention in subjects with type 2 diabetes who either carry or lack the Pro12Ala PPARgamma2 variant. We will compare between the two groups responsivity to rosiglitazone therapy as measured by changes in glycemic control (hemoglobin A1c, fasting blood glucose), lipoprotein profile, insulin sensitivity (euglycemic hyperinsulinemic clamp), and fat metabolism (lipolysis by microdialysis and fat oxidation by indirect calorimetry. Furthermore, to detect novel genes and pathways that predict rosiglitazone responsivity and/or influence insulin sensitivity, we will compare between rosiglitazone responders and nonresponders mRNA expression patterns of several thousand genes in muscle and adipose tissue biopsies using cDNA microarray technology. These studies will define the clinical significance of the Pro12Ala PPARgamma2 variant, and the role of PPARgamma in adipocyte metabolism and insulin signaling in humans more generally. Testing for the Pro12Ala PPARgamma2 may differentiate between patients who will be responsive or unresponsive to thiazolidinedione therapy, which would allow physicians to more rationally prescribe medications based on underlying genetic mechanisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHYSICAL ACTIVITY, ENERGY BALANCE, AND COLON CANCER RISK Principal Investigator & Institution: Matthews, Charles E.; Assistant Professor; University of South Carolina at Columbia Byrnes Bldg., Room 501 Columbia, Sc 29208 Timing: Fiscal Year 2002; Project Start 29-SEP-2002; Project End 31-AUG-2007 Summary: There is consensus that low physical activity (PA) levels increase the risk of colon cancer in humans, particularly among individuals with elevated adiposity. However, the precise mechanism(s) of action for these associations have not been established. Although initial evidence indicates a role for inflammatory markers (e.g., prostaglandin-E2) among individuals with low PA or high levels of adiposity, simple descriptions of the patterns of cell proliferation and apoptosis, or markers of these processes, across PA levels are not available. Accordingly, the first aim of this proposal is to develop and refine hypotheses concerning the biologic mechanisms through which PA reduces risk for colon cancer by: (a) evaluating the independent and combined associations of physical activity/fitness, adiposity, and metabolic predictors (blood glucose, triglycerides) of colon cancer risk in the Aerobics Center Longitudinal Study
52
Blood Glucose
(Dallas, TX) using a nested-case control design (N=600), and (b) evaluating the independent and combined associations of PA and adiposity on biomarkers for colon cancer associated with inflammation (cyelooxygenase-2), cell proliferation (mib 1), and apoptosis (bax, bak, bcl2) in cross-sectional analyses of the Markers of Adenomatous Polyps II Study (N=200, Columbia, SC). Results from these analyses will be used to select up to 10 biomarkers for evaluation in a longitudinal pilot study. The second aim is to quantify the effect of changes in PA levels on selected biomarkers in a randomized trial (N=50, intervention vs. usual care) among adults not meeting current PA recommendations. Intervention participants will receive a 12-month home-base walking intervention based on Social Cognitive Theory that includes monthly phone contact with a health educator. Potential mediators and moderators of behavior change will be quantified (e.g., self-efficacy, social support). PA goals for the intervention group will be to walk briskly at least 5 times per week for 40-45 minute per day (1125 kcal/wk). Outcome biomarker measures will be obtained via rectal biopsy at baseline and 12months. In summary, the series of investigations outlined in this proposal will examine the independent and combined effects of PA and energy balance (adiposity) on colon cancer and adenomatous polyp outcomes, and relate these findings to parallel analyses on tissue biomarker outcomes describing the biologic mechanisms linking PA and energy balance to colon cancer risk. This work will extend our understanding of the biological mechanisms underlying these causal relationships. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PILOT STUDY--GENETICS OF DIABETIC NEPHROPATHY IN BABOON Principal Investigator & Institution: Rincon-Choles, Hernan; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: Diabetic nephropathy (DN), a microvascular complication of diabetes mellitus (DM), is the main cause of end stage kidney disease worldwide. There is a great need to find animal models of DM and DN that better resemble the physiopathological changes in humans. Both DM and DN are influenced by environmental factors and heredity. The SFBR has approximately 2400 baboons in a pedigreed colony, with a 10 cM linkage map available for 800 of these animals, and additional animals are being currently genotyped. Some baboons in this colony have developed clinical features of type-2 DM and 4 animals biopsied thus far have histological features similar to those found in humans with DN. Preliminary fasting blood glucose (FBG) screening of 478 baboons showed 44% with FBG equal to or > 126 mg/dl. Preliminary screening for microalbuminuria (MA) in 298 animals showed 33.5% of 149 control and 42% of 149 diabetic baboons had MA. One of the control and 3 of the diabetic baboons had proteinuria. A subset of 7 age- and weight- matched female baboons averaging 20 years of age underwent kidney biopsy, 4 diabetics and 3 controls. Diabetic animals had FBG > 126 mg/dl, hemoglobin A1C > 6%, abnormal intravenous glucose tolerance test and normal C-peptide levels. Kidney histology showed that diabetic animals had larger glomeruli, thickened glomerular basement membrane, mesangial matrix expansion and areas of mesangiolysis with early nodule formation. These histological changes closely resemble those of DN in humans, making the type-2 diabetic baboon a useful model of DN. We hypothesize that the characterization of the DN phenotype in genotyped baboons from the pedigree, confirmed by kidney biopsy, will allow us to run a genomewide linkage analysis to identify genes and chromosomal regions associated with the development and progression of DN. We will conduct a population-wide screening in
Studies
53
1000 animals to study the prevalence of DM and the pattern of microalbuminuria in the baboon. The intrarenal renin-angiotensin system (RAS) is activated in DN, as evidenced by the heightened hemodynamic response to blockade of the RAS in human DN. We will characterize the phenotype of DN in a subset of animals and investigate the kidney expression of components of the RAS and other cytokines and matrix proteins associated with DN. We will then perform a genome-wide search to find and localize quantitative trait loci that influence variation in albuminuria and disease progression. Our goal is to identify early markers of disease progression amenable to intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PILOT--EFFECTS OF MASSAGE THERAPY ON BLOOD GLUCOSE LEVEL Principal Investigator & Institution: Edwards, Bennett G.; Shaw University 118 E. South Street Raleigh, Nc 27601 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2007 Summary: Type II diabetes is a common problem among African-Americans and one with enormous medical and social impact. Stress may have a substantial impact on the level of blood gluose control. One approach to stress reduction is through nonmedicaition approaches such as massage therapy. The purpose for this study is to determine the effects of massage therapy on the Blood Glucose (BG) levels of patients with moderate forms of type II diabetes. "Moderate" will be designated as a person having BG levels 140 - 180 ml/dl (controlled) and elevated Hb A1c (7 - 8%). Ten subjects will be obtained from Project Direct that meet the fore mentioned criteria. Project Direct is a program sponsored by the Center for Disease Control to promote health education and treatment for African-Americans with diabetes. Patients 18 - 75 years old, on oral medication, will be recruited. Ten patients who volunteer and meet the criteria to participate in this study will become experimental subjects. Subjects will receive a full body massage for one hour 3 times per week for a total duraiton of 3 months. Stomach massage will be included with mild pressure application to the pancreas. Blood for Hb Alc will be obtained via venipuncture before the study and at the end of 12 weeks. Resting cortisol and and insulin levels will also be measured at the begining and end of the study. HR, BP, 02 saturation and pulse will be monitored before and after each exercise session. Weight will also be monitored. Patients' treating physicians will clear patients for participation. We will request patients and physicians to not alter medication type and dose for the duration of the study, unless absolutely necessary. The sample size will be too small to have statistical power, but we will be able to pilot enrollment procedures, assess measures to assure follow-up, and pilot the details of clinical research at Shaw University. A repeated measures ANOVA will be utilized to determine the effects of full body massage on Hb Alc. Resting insulin and cortisol levels, and vital signs will be measured before and after 12 weeks and a questionnaire measuring perceived stress will be administered (t-Tests) This study will provide valuable pilot information for a possible future randomized trial of massage therapy among patients with type II diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DELIVERY
PLACENTAL
VASCULAR
COMPROMISE
AND
PRETERM
Principal Investigator & Institution: Thorp, John M.; Professor; Obstetrics and Gynecology; University of North Carolina Chapel Hill Aob 104 Airport Drive Cb#1350 Chapel Hill, Nc 27599
54
Blood Glucose
Timing: Fiscal Year 2002; Project Start 01-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): There is substantial interest in determining the etiology of preterm delivery (PTD). Despite much effort, the cause remains elusive and effective prevention measures do not exist. Uteroplacental vascular compromise (UPVC) via inflammation, thrombosis, or atherosis is a biologically plausible cause of preterm delivery, albeit not adequately explored. We propose to test his hypothesis by conducting a prospective, epidemiologic study of UPVC and by integrating information about known risk factors for PTD. Placental histopathologic examination and morphometric analysis of the basal plate will be done to assess compromise of placental vessels. We will explore novel, possible antecedents of such compromise, dyslipidemia and insulin resistance, using nuclear magnetic resonance analysis of lipid subclasses and fasting insulin-glucose ratios. Given the inaccessibility of the uteroplacental vasculature in ongoing gestations at midpregnancy, we will utilize non-invasive measures of UPVC, Doppler velocimetry of the uterine artery, and maternal serum alpha fetoprotein to indirectly evaluate vascular function. In addition, we will carefully evaluate tobacco and cocaine use, nutrition, and changes in vaginal microflora within our cohort. The data will enable us to thoroughly assess whether UPVC constitutes a distinct etiologic pathway for PTD and help to identify modifiable risk factors. We will utilize cohort and case-cohort techniques, refined in our present research, to answer these questions. Blood, urine and vaginal fluid are collected twice between 15 and 20 weeks and between 24 and 29 weeks gestation. Hair will be collected after delivery. All subjects will complete two telephone interviews and two self administered questionnaires regarding various behaviors, dietary intake, physical activity, and psychosocial stressors. Placentas will be collected at the time of delivery and histopathologic analysis will be completed by an experienced perinatal pathologist for cases and a non-case subgroup. Nuclear magnetic resonance measurement of lipoprotein subclasses will be done to assess dyslipidemia. Insulin glucose ratios will be measured from fasting blood samples. We expect to enroll a cohort of 1800 women with 250 preterm deliveries and a randomly selected non-case subgroup (n=500). We will analyze the relationship between UPVC and PTD using logistic regression. Given 1) the size of the study, 2) thorough histopathologic assessment of the placenta, 3) extensive questionnaire data, 4) biologic markers of exposure to bacterial vaginosis, insulin resistance, dyslipidemia, and cocaine use, and 5) the careful assessment of potential confounding factors, this study promises to markedly advance our knowledge of the potential role of UPVC in the etiology of PTD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PLAINS INDIANS TRADITIONAL DIETS AND DIABETES CONTROL Principal Investigator & Institution: Specker, Bonny L.; Professor; Nutrition, Food Science and Hospitality; South Dakota State University Brookings, Sd 57007 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): At present, there are no specific dietary guidelines for the Northern Plains Indian with type 2 diabetes. Current medical nutrition therapy practices base the diabetic therapeutic guidelines on the Food Guide Pyramid that encourages a grain-based diet. Anecdotally, Northern Plains Indians have reported a better control of their type 2 diabetes when following a diet higher in protein. Genetic differences may contribute to decreased adaptation to higher carbohydrate loads among Northern Plains Indians compared to Northern European descendents. A diet patterned after the historical hunter-gatherer type diet, or even the early reservation diet (with
Studies
55
higher proportion of energy being supplied from protein), may lower the circulating insulin levels and provide better blood glucose control in Northern Plains Indians with type 2 diabetes. The hypothesis of this application is that Northern Plains Indians with non-insulin dependent, type 2 diabetes who receive an educational lesson that promotes a diet patterned according to the traditional consumption of macronutrients (25% calories from protein, 45-50% from carbohydrate, and 25-30% from fat) will have a better control of their diabetes as measured by their HbA1C, blood glucose, and circulating insulin concentrations compared to those educated to consume a grain-based diet that supplies a more typical mix of macronutrients (10-15% calories from protein, 50-55% from carbohydrate, and 30-35% from fat). A 26- week, dietary educational intervention given monthly will be conducted in the Northern Plains Indians from the Cheyenne River Reservation (Lakota Sioux). Adult Lakota volunteers with type 2 diabetes will be recruited and randomized to an experimental (Medicine Wheel Model) or control (Usual Care) group. The experimental group will receive dietary training using the Medicine Wheel Model for Native Nutrition, which promotes a diet patterned according to the traditional consumption of macronutrients. The control group will receive the usual care dietary training based on the Food Guide Pyramid. Primary outcome variables of HbA1C, fasting blood glucose, and circulating insulin concentrations and secondary outcome variables of blood lipid concentrations will be measured at the beginning and end of trial. Measurements of potential confounders of weight, height, usual dietary intake, activity levels, medication use, and incidence of infection will be taken at the beginning and end of the study period. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PLANT-BASED DIETRY INTERVENTION IN TYPE 2 DIABETES Principal Investigator & Institution: Barnard, Neal D.; Physicians Committee for Responsible Med Responsible Medicine Washington, Dc 20016 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Diabetes often leads to serious complications, including coronary heart disease, kidney disease, and blindness, among others. Previous studies have suggested that low-fat, plant-based diets can have a strongly favorable effect on the management of type 2 diabetes mellitus, as well as on the elevations of body weight and serum cholesterol that often accompany it, reducing the risk of complications, and raising the possibility of reducing or even eliminating medication use for many individuals. Evidence suggests that the dietary recommendations that are most effective in diabetes management may be similar to the low-fat, vegetarian diets that have demonstrated utility in reversing coronary artery blockages. However, no study to date has examined the effect of a low-fat, vegetarian diet as an intervention for diabetes in a substantial number of participants, and most studies using plant-based (near-vegetarian) diets have also included exercise as a major intervention component, making it impossible to separate the effects of physical activity from those of diet or to reach any definitive conclusion as to which type of dietary intervention is best. This study, which follows an encouraging preliminary trial reported in Preventive Medicine in 1999, will test the hypothesis that a low-fat, vegetarian diet yields significant improvements in key indices of diabetic control, including glycosylated hemoglobin, fasting serum glucose and insulin concentrations, microalbuminuria, and medication requirements, as well as in cardiovascular risk factors, such as body weight, serum lipids, and blood pressure, in a 22-week intervention controlled throughout for exercise, with a 1-year follow-up. Sixty-eight volunteers with type 2 diabetes will be randomly assigned to a low-fat, vegan (intervention) diet or a control diet deriving 15-20percent of
56
Blood Glucose
energy from protein and < 7percent of energy from saturated fats, with carbohydrate and monounsaturated fats together providing 60-70percent of energy intake, based on current American Diabetes Association guidelines. Participants in both groups will be asked to attend weekly meetings for nutrition and cooking instruction and group support, and will be asked not to alter their exercise patterns. Physical activity will be monitored by use of the Bouchard 3-Day Physical Activity Record. (Bouchard 1983) Diets will be assessed at baseline and 11, 22, and 74 weeks, using a 3-day dietary record. Fasting serum glucose will be monitored for the study duration and will be used to adjust medications according to a set protocol. Glycosylated hemoglobin, insulin concentrations, 24-hour urinary albumin, body weight, blood pressure, serum lipids, and related cardiovascular risk factors will be measured at baseline, 22 weeks, and 74 weeks. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESISTANCE
POLYCYSTIC
OVARY
SYNDROME:
ROLE
OF
INSULIN
Principal Investigator & Institution: Nestler, John E.; Professor and Chairman; Internal Medicine; Virginia Commonwealth University Richmond, Va 232980568 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (provided by applicant): This K24 Mid-Career Investigator in PatientOriented Research Award application is to support the continue development of Dr. John E. Nestler as a clinical investigator and research mentor. Dr. Nestler is Professor of Medicine at Virginia Commonwealth University's Medical College of Virginia, and has been a productive patient- oriented researcher whose research focus has been the pathophysiologic role of insulin resistance in the polycystic ovary syndrome (PCOS), a disorder that affects 6-10% of women of childbearing age. Dr. Nestler also has an established track record of mentorship of young clinical investigators. The broad longterm objective of Dr. Nestler's studies has been to conduct both mechanistic and translational studies exploring the role of insulin resistance in PCOS. The specific studies proposed in this application, which are currently funded by an NIH R0l grant and a U54 grant, are designed 1) to determine the effects of chronic insulin reduction on rates of spontaneous and clomiphene-induced ovulation in women with PCOS who were previously found to be refractory to clomiphene induction; 2) to determine whether reducing the serum insulin concentration beneficially influences gonadotropin secretory dynamics (i.e., decreases luteinizing hormone pulse amplitude and/or pulse frequency) in obese and/or lean women with PCOS; and 3) to explore whether insulin resistance causes an adverse cardiovascular risk profile in postmenopausal women with a history of PCOS during the premenopausal period. These studies will be conducted on the General Clinical Research Center using state-of-the-art methodologies, such as every 10 minute blood sampling for hormone pulse analysis by Cluster, Deconvolution Analysis and Approximate Entropy, and Reaven's steady-state plasma glucose (SSPG) technique for longitudinally monitoring insulin sensitivity. The K24 award will facilitate the completion of these studies, while also making it possible for Dr. Nestler to enhance his personal growth as a clinical investigator and to increase his mentoring activities. It will do so by providing Dr. Nestler with increased protected time, resulting from a decrease in administrative duties and clinical service responsibilities. As a result of the K24 award, Dr. Nestler will be able to devote 80% effort to research, further personal training in clinical research, and the training and mentorship of young investigators. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
57
Project Title: PRIMARY PREVENTION OF WEIGHT GAIN FOR WOMEN AGED 2545 Principal Investigator & Institution: Willett, Walter C.; Professor and Chairman; Nutrition; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 14-JAN-2002; Project End 31-DEC-2004 Summary: (provided by applicant) This research will be conducted primarily in Brazil as an extension of NIH grants # R0l CA 50385 and R0l HL60712-0l. Overweight (BMI (Body Mass Index) 25.0-29.9) and obesity (BMI greater than or equal to 30 kg/m2) now affect more than 40 percent of adult Brazilians. Women at reproductive age are particularly at risk of obesity and a 70 percent increase in the prevalence was observed in the last two decades in Brazil. Increasing fat intake does not appear to explain this trend, whereas a steady decline in the consumption of beans has been shown for the whole country. Many studies have demonstrated changes in blood glucose levels due to the intake of specific carbohydrate foods, as measured by glycemic index (GI). An exceptionally low blood glucose response was associated with beans and it has been suggested that the consumption of low-GI diets may: 1) decrease hunger/ increase satiation; 2) reduce lipogenesis. In a nonrandomized follow-up of children attending a program of obesity treatment, children assigned to a low GI diet had a decrease in BMI greater than the high GI group. There are no long term clinical trials of weight loss or prevention of weight gain comparing low with high GI diets. However, a dietary pattern identified through factor analysis in a survey in the city of Rio de Janeiro, Brazil, that represents mainly rice and bean intake was associated with lower risk of obesity. The purpose of this study is to compare in Brazilian women the effectiveness of encouraging them to eat two different dietary patterns (low vs. high GI), with equal macronutrient composition, on weight control over the course of 18 months. The low GI dietary pattern will be heavily based on the traditional rice and beans combination. The comparison group will be encouraged to eat a diet with the same amount of macronutrients, but closer to a Western diet. Both diets are realistic prescriptions of foods consumed by Brazilians.Specifically, this study will compare changes in weight (main outcome), food intake, blood chemistries and hunger/satiation in 206 adult women at reproductive age, with BMI of 23-27 kg/m2, randomized to either one of the diets after 4-week run-in period eating a high GI diet. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PRIMARY PREVENTION PROGRAM -DATA COORDINATING CENTER Principal Investigator & Institution: Fowler, Sarah E.; Research Professor; Statistics; George Washington University 2121 I St Nw Washington, Dc 20052 Timing: Fiscal Year 2002; Project Start 20-AUG-1994; Project End 31-MAY-2003 Summary: (Directly incorporated from the application) The Biostatistics Center of The George Washington University proposes to work in cooperative agreement with the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) to serve as the Data Coordinating Center (DCC) for a proposed multi-center clinical trial of the primary prevention of non-insulin dependent diabetes mellitus (NIDDM). Adiposity and inactivity have been established as critical factors in the etiology of glucose intolerance and are strongly associated with increased risk of glucose intolerance. We propose to determine the safety and efficacy of an intensive lifestyle intervention or prophylactic use of an oral hypoglycemic agent on the incidence of NIDDM among high
58
Blood Glucose
risk patients (obese, minority, family history of NIDDM, history of gestational diabetes mellitus) in a state of impaired glucose tolerance (IGT). The objective of the one year planning phase is to develop a protocol, operations manual and data collection forms to be implemented in a five year full-scale clinical trial. The trial will require large-scale screening and randomization of 4,000 high risk patients with a diagnosis of IGT over a one year period in 20 clinical centers. Eligible patients will be randomized to "conventional" dietary counseling or one of the comparison groups (intensive lifestyle intervention or an oral hypoglycemic agent). Randomized patients will be followed for a minimum of four years with quarterly follow-up visits. Conversion from a state of IGT to overt NIDDM will be determined by semi-annual 2-hour oral glucose tolerance tests (OGTTs) following a 75 g glucose load confirmed by a central laboratory. Covariates and secondary outcomes include carotid ultrasound imaging, electrocardiograms, serum lipids, albumin excretion rate, adiposity, insulin sensitivity, hemoglobin A1c, and fundus photographs. The specific aims of the DCC are to provide centralized support and biostatistical consultation in the development of the patient management protocols, operations manual, data collection forms and randomization procedures; implementation of a data processing system including data quality assessment; interim analysis of protocol performance, patient safety and treatment efficacy; and final analysis for publication of the results in collaboration with the clinical investigators. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RACE AND LONG-TERM DIABETES SELF-MANAGEMENT IN AN HMO Principal Investigator & Institution: Ross-Degnan, Dennis; Harvard Pilgrim Health Care, Inc. 93 Worcester St Wellesley, Ma 02481 Timing: Fiscal Year 2002; Project Start 15-JAN-2002; Project End 31-DEC-2004 Summary: (provided by applicant): This project will examine the complex relationships between race, diabetes self-management (including self-monitoring of blood glucose and diabetes drug therapy), glycemic control, and diabetes complications in a managed care setting over a nine-year period. African Americans with diabetes are less likely to be in glycemic control, a major risk factor for development of complications, including nephropathy, retinopathy, and peripheral vascular disease. Randomized controlled trials suggest that diabetes self-management including patient education, drug therapy, changes in diet, and regular exercise can improve glycemic control in the African American population. However, there is little epidemiological evidence regarding the role of race/ethnicity as a determinant of adherence to recommended diabetes selfmanagement practices, or regarding the relationship between self-management, glycemic control, and subsequent clinical outcomes. Further, previous studies of race and diabetes self-management have been limited by short study periods, inadequate sample size, and reliance on self-reported measures of self-monitoring of blood glucose. The clinical setting for this study is Harvard Vanguard Medical Associates (HVMA), a large multi-site, multi-specialty group affiliated with Harvard Pilgrim Health Care. HVMA consists of 14 health centers serving over 300,000 people in the Boston area. We will use an open cohort design to enroll all adult (l8 years) patients between 1991 and 1999 who have 24 months or more of uninterrupted enrollment in HVMA following ascertainment of non-gestational diabetes, defined by (1) hospital discharge diagnosis of diabetes mellitus, (2) outpatient diagnoses of diabetes mellitus, HbAlc lab test result 8.0, or use of a diabetes drug (insulin, sulfonylurea, or metformin). We estimate that the cohort will include approximately 1,800 adults identified as African American and 5,000 identified as Caucasian. Access to HVMA computerized medical records, hospital
Studies
59
emergency room and inpatient claims, lab, and pharmacy data will allow us to create reliable, objective measures of self-monitoring (home glucose monitor test strip use), drug therapy. glycemic control (HbAlc lab results), and diabetes complications (as measured in outpatient visits, emergency room visits, and hospitalizations). Stratifying by type of drug therapy (insulin/combined therapy vs. oral therapy), we will use descriptive analyses, generalized linear mixed models, and proportional hazards models to (1) identify racial differences in self-management practices and diabetes-related health outcomes over time; (2) assess whether African American race is an independent predictor of self-monitoring practice or adherence to drug regimen; and (3) whether there are racial/ethnic differences in the association between self-management and specific clinical endpoints, including glycemic control (HbAlc<8.0) and the incidence of diabetes-related complications over the nine-year study period. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF O-GLCNAC TRANSFERASE IN INSULIN GENE EXPRESSION Principal Investigator & Institution: Ozcan, Sabire; Molecular/Cellula/Biochemistry; University of Kentucky 109 Kinkead Hall Lexington, Ky 40506 Timing: Fiscal Year 2004; Project Start 15-JAN-2004; Project End 31-DEC-2005 Summary: (provided by applicant): Although several lines of evidence suggest that increased levels of O-GIcNAc modification interferes with normal glucose homeostasis, the exact functional consequences of this modification remain to determined. Recent data indicate that O-linked GIcNAc transferase (OGT1) in a complex with the corepressors Hdac1 and mSin3A mediates repression of gene expression in the HepG2 liver cell line. However, the target genes and the conditions under which this repressor complex is active in vivo are not known. Insulin gene expression in the pancreatic beta cells is induced by high blood glucose levels and is decreased when blood glucose levels are low. Using the deacetylase inhibitor trichostatin A, we have recently discovered that insulin gene expression is inhibited at low concentrations of glucose by the recruitment of deacetylases to the insulin promoter in the mouse insulinoma (MIN6) cell line. Furthermore, we found that OGT1 and Hdac1/2 are recruited to the insulin gene promoter and interact with each other only at low levels of glucose in the MIN6 beta cells. Based on these data, we hypothesize that OGT1 and Hdac1/2 are in a complex and repress insulin gene expression at low levels of glucose. We will test this hypothesis as described in the following three specific aims. 1) To analyze the role of OGT1 in repression of insulin gene expression in MIN6 beta cells. 2) To identify the transcription factor(s) that recruits the OGT1-Hdac1/2 repressor complex to the insulin gene promoter. 3) To identify genes with altered transcription in response to increased O-GIcNAc modification. Understanding the role of OGT1 in regulating insulin gene transcription will provide new insights into the mechanisms by which defects in OGIcNAc modification lead to symptoms associated with diabetes. In addition, the obtained data will be instrumental in the design of novel strategies for the treatment and prevention of type I and type II diabetes and the secondary complications associated with diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SELF-MONITORED MANAGEMENT
PHYSICAL
ACTIVITY
FOR
WEIGHT
Principal Investigator & Institution: Walker, Karen E.; Assistant Professor; Nursing; Temple University 406 Usb, 083-45 Philadelphia, Pa 19122
60
Blood Glucose
Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2006 Summary: (provided by applicant): This application for a Mentored Research Scientist Development Award (K01) is a re-submission by a new investigator. The goal of the award is to provide the investigator further training in the fields of obesity and community health nursing. As part of this training, the investigator will receive mentoring and pursue academic study in the following areas: 1) etiology and complications of obesity; 2) behavioral treatment of obesity; 3) community health nursing; 4) conduct of clinical trials; 5) exercise physiology; 6) biostatistics; and 7) nutrition. The proposal builds on a background in cardiovascular research, clinical study of weight loss maintenance, and community-based activities. Recent data show that 61% of US adults are overweight or obese. As a result, there is an epidemic of obesity-related health problems such as diabetes, coronary artery disease, and high blood pressure. Losses of only 5% to 10% of body weight significantly improve health, and individuals in programs that modify diet and lifestyle typically achieve weight losses of this magnitude. Unfortunately, the great majority of people cannot maintain the loss. Regular exercise is crucial to the maintenance of weight loss, but most individuals have problems with adherence due to a variety of barriers to exercise. Typical barriers are lack of time, lack of childcare, and lack of access to facilities. The goal of the proposed research is to improve the maintenance of weight loss by increasing physical activity in a low-income, primarily African American population that participates in a community-based behavioral weight loss program. All participants (n=152) will be treated with a 20-week weight reduction program followed by 52 weeks of maintenance. At the outset of the study, subjects will be randomized to one of two physical activity conditions. The research has two specific aims: The first is to compare at week 72 the maintenance of weight loss and physical activity adherence in individuals who are prescribed a standard structured exercise program of walking (Condition 1) versus a lifestyle activity intervention self-monitored via pedometer (Condition 2). Adherence will be determined by obtaining a common measure of physical activity across both conditions using accelerometers. The second aim is to compare short- (week 20) and long-term (week 72) differences between the two conditions in measures of physical (serum lipids, glucose/insulin ratio, interleukin-6, Creactive protein, resting blood pressure, cardiorespiratory fitness) and psychosocial health (mood, quality of life). This study has been selected to further develop the investigator's knowledge of the treatment of obesity using principles of community health nursing, and the training has been designed to facilitate the investigator's development as an independent clinical scientist studying innovative ways of reducing cardiovascular risks within urban communities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRENGTH TRAINING FOLLOWING GASTRIC BYPASS FOR OBESITY Principal Investigator & Institution: Geliebter, Allan; St. Luke's-Roosevelt Inst for Hlth Scis Health Sciences New York, Ny 100191102 Timing: Fiscal Year 2003; Project Start 01-MAR-2003; Project End 31-DEC-2004 Summary: (provided by applicant): As the incidence of obesity rises dramatically in the United States, more and more severely obese individuals are undergoing surgical treatment to reduce body weight and associated risk factors. Roux-en-Y gastric bypass (RYGB) is now the most common operation to treat morbid obesity in the US. However, little is known about the effects of RYGB on body composition and resting energy expenditure (REE). The main objectives of this study are to determine: 1) the
Studies
61
composition of weight loss following surgery, 2) whether protein supplementation and strength training can limit the expected reduction of lean mass and REE. The study candidates will be morbidly obese women with a body mass index (BMI) of 40-56 kg/m2, be 18 - 49 y.o. and premenopausal. Except for severe obesity, they will be relatively healthy with a history of diet failure. They will be sedentary except for walking. There will be 36 study participants who, after stratifying by race, will be randomly assigned to three treatment groups (n = 12): 1) standard postoperative nutritional counseling only, 2) protein supplementation and standard postoperative nutritional counseling, or 3) protein supplementation plus strength training and standard postoperative nutritional counseling. The protein supplementation will begin shortly after surgery and increase from 40 g/day to 80 g/d at 4 weeks. Strength training will begin 8 weeks postoperation, to allow for adequate wound healing, and will consist of twice weekly progressive resistance training for upper and lower body for a period of 12 weeks. A battery of test measurements following a 12 h overnight fast will be conducted prior to surgery and repeated postoperatively at 8 and 20 weeks. These tests will include measurement of REE and body composition using underwater weighing, air displacement (BODPOD), dual xray absorptiometry (DEXA), magnetic resonance imaging (MRI), isotope dilution (D20), sodium bromide, and regional anthropometrics. There also will be assessments of arm and leg strength. Additionally, there will be measures of fasting glucose and body weight related hormones insulin, leptin, cortisol, and the recently discovered ghrelin. The predictions are that during the dramatic weight loss after surgery, the loss of some lean tissue, which could adversely impact skeletal muscle and vital organs, will be reduced by enhanced protein intake and weight training. There also may be greater conservation of REE and bone density. Plasma glucose and hormones should all decrease, especially with exercise, except for ghrelin, which should increase. The findings should improve understanding of surgical weight loss in morbidly obese patients and have clinical applications in the postoperative care of such patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE GLYCOSYLATION GAP AND DIABETIC COMPLICATIONS Principal Investigator & Institution: Cohen, Robert M.; Associate Professor of Medicine; Internal Medicine; University of Cincinnati 2624 Clifton Ave Cincinnati, Oh 45221 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2006 Summary: (provided by applicant): Hemoglobin A1c (Hb1c) is the gold standard for assessing diabetes control yet some patients have HbA1c discordant from plasma glucose. We developed a measure of the discordance between Hb1c and a plasma test of glycemic control, the "Glycosylation Gap" (GG). The GG is highly reproducible, correlates with an important clinical outcome, diabetic nephropathy, and appears genetically linked. A parallel measure of variance between HbA1c and glucose monitoring (Hb glycosylation index), has been shown to predict retinopathy and nephropathy in the DCCT. These data suggest that variation in HbA1c, expressed as the GG, arises from biological mechanism(s) that contribute to diabetic complications in here-to-fore unrecognized ways. Since HbA1c is determined by red blood cell (RBC) glucose concentration, the rate of Hb glycosylation and RBC lifespan, this proposal examines the variability of these factors in diabetic and non-diabetic populations. We found substantial variation in RBC glucose relative to extracellular glucose. This in vitro erythrocyte membrane glucose gradient (EMGG) correlated with GG and by inference with a higher risk of complications. The fact that the RBC and the endothelial cell - the major cell type in which diabetic complications occur - share the same glucose
62
Blood Glucose
transporter, GLUT1, raises the question whether this finding is mediated by shared GLUT1 variation in the two tissues. These studies will seek to determine: (1) whether variation in GLUT1 function contributes to variation in HbA1c; (2) how variation in RBC lifespan or HbA1c formation rate contributes to HbA1c variability; (3) how long-term glycemic control affects the EMGG and the GG, and whether they represent reproducible phenotypes for genetic studies. These studies provide a comprehensive approach to understanding important sources of variation in HbA1c. The variation in EMGG could account for 11% of total variation in >30 million HbA1c measurements yearly in the United States. This proposal extends the consideration of complications risk from the glucose concentration in the plasma to the glucose concentration inside the cell. The proposal therefore has potentially important basic science, clinical and population implications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: USE OF NMR TO MEASURE TUMOR AND NORMAL TISSUE METAB DURING TUMOR ACIDIFICATION Principal Investigator & Institution: Glickson, Jerry D.; Research Professor; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2002; Project Start 01-FEB-2002; Project End 31-JAN-2003 Summary: This subcontract to Project 4 will examine metabolic and physiological aspects of acidification of human melanoma xenografts that are amenable to noninvasive measurement by magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI). These methods will be applied to animals supplied by Dr. Leeper's laboratory to test the hypothesis that NMR can non-invasively detect tumor specific changes in extracellular and intracellular pH (pHe and pHi, respectively) induced by hyperglycemia and by hyperglycemia plus inhibition of oxidative metabolism (with meta- iodobenzylguanidine, MiBG), and/or by hyperglycemia plus inhibition of the Na+/H+ cation exchanger (with Cariporide mesilate, HOE642) and the HCO3- /Cl-anion exchanger (with 4,4-diisothiocyanstilbene 2,2-disulphonic acid, DIDS). In addition, it is proposed that NMR can help delineate the underlying mechanism of acidification by hyperglycemia plus regulatory inhibition. To test this hypothesis, 31P MRS will be employed to measure the pHi and pHe in the tumor, in host muscle, and brain under conditions of normoglycemia, hyperglycemia plus MIBG and/or HOE642 plus DIDS. Inorganic phosphate (Pi) and 3-aminopropylphosphonate will serve as indicators of pHi and pHe, respectively. To test the hypothesis that tumor acidification under conditions of hyperglycemia and hyperglycemia plus respiratory inhibition is mediated by production of lactic acid (i.e., glycolysis), steady state lactate concentrations will be monitored on 1H MRS employing a selective multiple quantum coherence transfer pulse sequence developed by the subcontractor's laboratory to edit out the lactate resonance from interfering lipid resonances. Further insight into the mechanism of tumor acidification under conditions of hyperglycemia +/- respiratory inhibition will be obtained by measuring flux through the glycolytic pathway and through the TCA cycle from the kinetics of 13C-labeling of lactate and glutamate, respective, following infusion of [1-13C]glucose. The spatial distributions of 13C-labeled glucose and lactate in the tumor at isotope steady state (for glucose) will be imaged by 13C chemical shift imaging at constant concentrations of labeled glucose in the blood (19+/-) mM), and the vascular volume distribution will be imaged by dynamic 1H MRI using Gd-DTPAalbumin as a vascular marker. Images will be correlated with histology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
63
Project Title: VALIDATION OF LONG-TERM GLUCOSE SENSOR IN TISSUES Principal Investigator & Institution: Gough, David A.; Professor and Chair; Bioengineering; University of California San Diego La Jolla, Ca 920930934 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): There is an urgent need for a new glucose sensor that is: (1) highly reliable and continuous; (2) capable of automatic function, independent of user initiative, to warn of hypoglycemia; and (3) acceptable to users. We have an implantable electrochemical glucose sensor that can potentially meet this need. A prototype of this sensor has operated continuously as a central venous implant in dogs for over 100 days without the need for recalibration and now in humans for over one year. This achievement still represents the published world's record for implanted glucose sensor longevity. For reasons of safety, we are designing a tissue glucose sensor for long-term use in humans. The implant will include the sensor, electronics and telemetry, antenna, and battery. Glucose signals will be transmitted to an external receiver resembling a beeper that will display the actual glucose value and function as a hypoglycemia alarm. Our recent studies have focused on developing a complete understanding of the tissue sensor response to blood glucose. The working hypothesis is: "A useful analytical relationship exists between the signal of sensors implanted in tissue and blood glucose concentration." We have: defined sensor performance requirements, developed methods of sensor fabrication, implanted sensors in a welldefined hamster model, established novel confocal microscopy methods for nondestructive visualization of the tissue/sensor interface, and modeled sensor response. We will extend our studies by implanting sensors in pigs and carry out extensive analysis of sensor system dynamics, including development of a method for sensor recalibration, further documentation of implant biocompatibility, and establishment of system reliability. These studies will be carded out in addition to our continuing studies in hamsters and diabetic rats. These studies set the stage for trials in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: WEIGHT LOSS IN OBESE BREAST CANCER SURVIVORS Principal Investigator & Institution: Djuric, Zora; Associate Professor; Internal Medicine; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2002; Project Start 15-FEB-2001; Project End 31-JUL-2003 Summary: Obesity has been shown to be associated with a poor prognosis in breast cancer patients. Survival time is decreased and recurrence rates are increased with greater obesity. Whether or not weight loss can have favorable effects on prognosis in obese breast cancer survivors is not known, and that is the ultimate question we would like to ask. As a first step, effective methods for weight loss need to be established in this population. We started a pilot study with internal funds develop an individualized approach towards weight loss in obese breast cancer survivors, and preliminary data is encouraging. We would like to be able to extend this study for a full 18 months and analyze the blood samples that are being collected for markers of cancer risk. Forty eight obese cancer survivors have been enrolled. At baseline, a psychiatric evaluation was obtained for each women and questionnaires on diet, health, exercise and psychosocial factors were administered. Since we are asking women to make large lifestyle changes, we would like to extend the intervention for a full year (instead of 6 months) and add a 6-month follow-up point to examine maintenance of weight loss. A better understanding of the influence of behavioral factors on weight loss should help us design a successful larger study with recurrence as the endpoint. As a secondary aim,
64
Blood Glucose
we propose to analyze the blood samples collected for markers of cancer risk which are expected to be affected by weight loss: oxidative DNA damage, insulin-like growth factor 1 (IGF-1), and IGF-binding protein 3. The extent of changes in these markers will be compared with other plasma measures that are known to be affected by weight loss: leptin, glucose, lipids and triglyceride levels. This study should be useful to determine certain psychosocial are associated with extent of weight loss, and in turn whether weight loss is associated with changes in selected markers of breast cancer risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: YALE CENTER IN THE CHILDREN'S GLUCOSE SENSOR NETWORK Principal Investigator & Institution: Tamborlane, William V.; Professor of Pediatrics; Pediatrics; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: (prepared by applicant): Results of the Diabetes Control and Complications Trial indicate that most patients with type 1 diabetes (T1DM) should receive intensive treatment to lower the risk of microvascular and neuropathic complications. It has been shown that strict diabetes control can be achieved in youth with T1DM but at the expense of unacceptably high frequency of severe hypoglycemic events, especially in younger patients. Moreover, pilot studies using new continuous glucose sensoring systems in youth with T1DM indicate that many glucose swings from high to low values are asymptomatic and are not detected by self blood glucose monitoring (SBGM). Thus the investigators are submitting an application to be a center in the Type 1 Diabetes in Children Research Network to evaluate the utility of continuous glucose monitoring devices in improving diabetes control and preventing hypoglycemia in youth with T1DM. As a first step, the investigators are proposing to validate the accuracy of the MiniMed Continuous Glucose Monitoring System (CGMS) in children with and without T1DM against frequent blood glucose measurements in an inpatient Clinic and Research Center setting. Next, the CGMS will be used in a large, cross-sectional study to characterize and compare the frequency and severity of hypo and hyperglycemia by age (pre-school versus school age versus adolescents), type of insulin treatment (injections versus pump), and by HbA1c level (within target versus above target). Validation and cross-sectional studies will also provide the opportunity to test the effectiveness of current management guidelines regarding carbohydrate counting and the composition of bedtime snacks, as well as the impact of afternoon exercise on nocturnal hypoglycemia. The investigators are also proposing a randomized, prospective clinical trial to examine whether repeated use of the CGMS every six weeks for 24 weeks in conjunction with conventional SBGM is more effective than SBGM alone in improving diabetes control, lowering the risk for hypoglycemia, and reducing patient?s and parents? anxiety and fears of hypoglycemia. The introduction of new methods of continuous glucose sensoring promises to be the most important advance in therapy of T1DM in the past 20 years. The resources for clinical research and the expertise in the Network will also allow the investigators to assess the usefulness for children with T1DM of current and future glucose sensoring systems in a scientifically rigorous and timely manner. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
65
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “blood glucose” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for blood glucose in the PubMed Central database: •
An open prospective randomised trial to reduce the pain of blood glucose testing: ear versus thumb. by Carley SD, Libetta C, Flavin B, Butler J, Tong N, Sammy I.; 2000 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27419
•
Barriers to self-monitoring of blood glucose among adults with diabetes in an HMO: A cross sectional study. by Adams AS, Mah C, Soumerai SB, Zhang F, Barton MB, RossDegnan D.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153532
•
Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). by Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R.; 2000 May 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27380
•
Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. by Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL.; 1998 Feb 17; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=19188
•
Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. by Evans JM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD.; 1999 Jul 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28155
•
Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). by Gray A, Clarke P, Farmer A, Holman R.; 2002 Oct 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=129631
•
Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. by Dunder K, Lind L, Zethelius B, Berglund L, Lithell H.; 2003 Mar 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=152364
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
66
Blood Glucose
•
Neutralization of Glucagon by Antiserum as a Tool in Glucagon Physiology LACK OF DEPRESSION OF BASAL BLOOD GLUCOSE AFTER ANTISERUM TREATMENT IN RATS. by Holst JJ, Galbo H, Richter EA.; 1978 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=371752
•
Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. by Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L.; 1991 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296344
•
Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in mouse liver lowers blood glucose by suppressing hepatic glucose production. by Wu C, Okar DA, Newgard CB, Lange AJ.; 2001 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=198549
•
Renal Net Glucose Release In Vivo and Its Contribution to Blood Glucose in Rats. by Kida K, Nakajo S, Kamiya F, Toyama Y, Nishio T, Nakagawa H.; 1978 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=371822
•
The juice of fresh leaves of Catharanthus roseus Linn. reduces blood glucose in normal and alloxan diabetic rabbits. by Nammi S, Boini MK, Lodagala SD, Behara RB.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=194756
•
The Role of Aminogenic Glucagon Secretion in Blood Glucose Homeostasis. by Unger RH, Ohneda A, Aguilar-Parada E, Eisentraut AM.; 1969 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=322289
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with blood glucose, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “blood glucose” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for blood glucose (hyperlinks lead to article summaries):
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
Studies
67
•
A better mousetrap: what's new in blood glucose monitoring? Author(s): Cox M. Source: Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners. 2002 November-December; 16(6): 314-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12436103
•
A comparison of fructosamine and HbA1c for home self-monitoring blood glucose levels in type 2 diabetes. Author(s): Chen HS, Chen RL, Chang ZY, Li HD. Source: Zhonghua Yi Xue Za Zhi (Taipei). 2002 April; 65(4): 151-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12135193
•
A low glycemic diet significantly improves the 24-h blood glucose profile in people with type 2 diabetes, as assessed using the continuous glucose MiniMed monitor. Author(s): Brynes AE, Lee JL, Brighton RE, Leeds AR, Dornhorst A, Frost GS. Source: Diabetes Care. 2003 February; 26(2): 548-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12547905
•
A novel noninvasive blood glucose monitor. Author(s): Malchoff CD, Shoukri K, Landau JI, Buchert JM. Source: Diabetes Care. 2002 December; 25(12): 2268-75. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12453972
•
A reappraisal of the blood glucose homeostat which comprehensively explains the type 2 diabetes mellitus-syndrome X complex. Author(s): Koeslag JH, Saunders PT, Terblanche E. Source: The Journal of Physiology. 2003 June 1; 549(Pt 2): 333-46. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12717005
•
A study of forearm versus finger stick. Blood glucose monitoring. Author(s): Lee D, Weinert S, Miller E. Source: Diabetes Educ. 2001 June; Suppl: 6P. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12211930
•
Abnormal blood glucose concentrations on admission to a rural Kenyan district hospital: prevalence and outcome. Author(s): Osier FH, Berkley JA, Ross A, Sanderson F, Mohammed S, Newton CR. Source: Archives of Disease in Childhood. 2003 July; 88(7): 621-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12818911
68
Blood Glucose
•
Accessibility of blood glucose monitoring systems for blind and visually impaired people. Author(s): Uslan MM, Eghtesadi K, Burton D. Source: Diabetes Technology & Therapeutics. 2003; 5(3): 439-48. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12828828
•
Accuracy of glucose meters in measuring low blood glucose levels. Author(s): Choubtum L, Mahachoklertwattana P, Udomsubpayakul U, Preeyasombat C. Source: J Med Assoc Thai. 2002 November; 85 Suppl 4: S1104-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12549783
•
Accuracy of home blood glucose monitors using forearm blood samples: FreeStyle versus One Touch Ultra. Author(s): Demers J, Kane MP, Bakst G, Busch RS, Hamilton RA. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2003 June 1; 60(11): 1130-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12816023
•
Accuracy of self-monitoring of blood glucose: impact on diabetes management decisions during pregnancy. Author(s): Henry MJ, Major CA, Reinsch S. Source: Diabetes Educ. 2001 July-August; 27(4): 521-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12212340
•
Adaptive low-vision and blindness techniques for blood glucose monitoring. Author(s): Sokol-McKay D, Buskirk K, Whittaker P. Source: Diabetes Educ. 2003 July-August; 29(4): 614-8, 620, 622 Passim. No Abstract Available. Erratum In: Diabetes Educ. 2003 September-October; 29(5): 858. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=13677174
•
Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Author(s): Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JW, Heine RJ, Visser FC. Source: Archives of Internal Medicine. 2004 May 10; 164(9): 982-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15136307
•
Afternoon hypoglycaemia in Type 2 diabetes: lessons from blood glucose profiles. Author(s): Trovati M, Traversa M, Cavalot F. Source: Diabetes Nutr Metab. 2002 December; 15(6): 439-43. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12678465
Studies
69
•
Alternate site blood glucose testing: do patients prefer it? Author(s): Tieszen KL, New JP. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2003 April; 20(4): 325-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12675648
•
Alternative-site blood glucose measurement at the abdomen. Author(s): Van Der Valk PR, Van Der Schatte Olivier-Steding I, Wientjes KJ, Schoonen AJ, Hoogenberg K. Source: Diabetes Care. 2002 November; 25(11): 2114-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12401776
•
An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Author(s): Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H. Source: The American Journal of Clinical Nutrition. 2003 October; 78(4): 734-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14522731
•
An overview of human factors engineering at CDRH in the safety and effectiveness of blood glucose meters. Author(s): Kaye RD, Chenault VM. Source: Diabetes Technology & Therapeutics. 2002; 4(2): 247-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12079625
•
Anemia associated with new-onset diabetes: improvement with blood glucose control. Author(s): Pinero-Pilona A, Litonjua P, Devaraj S, Aviles-Santa L, Raskin P. Source: Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2002 July-August; 8(4): 27681. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12173914
•
Associations of blood glucose control with self-efficacy and rated anxiety/depression in type II diabetes mellitus patients. Author(s): Ikeda K, Aoki H, Saito K, Muramatsu Y, Suzuki T. Source: Psychological Reports. 2003 April; 92(2): 540-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12785638
•
Barriers to blood glucose monitoring in a multiethnic community. Author(s): Zgibor JC, Simmons D. Source: Diabetes Care. 2002 October; 25(10): 1772-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12351476
70
Blood Glucose
•
Bedside blood glucose monitoring in hospitals. Author(s): American Diabetes Association. Source: Diabetes Care. 2003 January; 26 Suppl 1: S119. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12502635
•
Bedside blood glucose monitoring in hospitals. Author(s): American Diabetes Association. Source: Diabetes Care. 2000 January; 23 Suppl 1: S84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12017689
•
Bimodality in blood glucose distribution: is it universal? Author(s): Lim TO, Bakri R, Morad Z, Hamid MA. Source: Diabetes Care. 2002 December; 25(12): 2212-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12453963
•
Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes. Author(s): Nosadini R, Tonolo G. Source: Journal of Nephrology. 2003 November-December; 16 Suppl 7: S42-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14733300
•
Blood glucose and the brain in diabetes: between a rock and a hard place? Author(s): Evans ML, Sherwin RS. Source: Curr Diab Rep. 2002 April; 2(2): 101-2. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12643129
•
Blood glucose concentrations are reduced in children born small for gestational age (SGA), and thyroid-stimulating hormone levels are increased in SGA with blunted postnatal catch-up growth. Author(s): Cianfarani S, Maiorana A, Geremia C, Scire G, Spadoni GL, Germani D. Source: The Journal of Clinical Endocrinology and Metabolism. 2003 June; 88(6): 2699705. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12788876
•
Blood glucose concentrations of arm and finger during dynamic glucose conditions. Author(s): Szuts EZ, Lock JP, Malomo KJ, Anagnostopoulos A. Source: Diabetes Technology & Therapeutics. 2002; 4(1): 3-11; Discussion 45-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12017417
Studies
71
•
Blood glucose dynamics and control of meal initiation: a pattern detection and recognition theory. Author(s): Campfield LA, Smith FJ. Source: Physiological Reviews. 2003 January; 83(1): 25-58. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12506126
•
Blood glucose estimations in adolescents with type 1 diabetes: predictors of accuracy and error. Author(s): Meltzer LJ, Johnson SB, Pappachan S, Silverstein J. Source: Journal of Pediatric Psychology. 2003 April-May; 28(3): 203-11. Erratum In: J Pediatr Psychol. 2003 July-August; 28(5): Following Page 373. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12654946
•
Blood glucose investigation--an experience. Author(s): Gurupadappa K. Source: Indian Journal of Medical Sciences. 2003 May; 57(5): 204-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14514252
•
Blood glucose is correlated with cerebrospinal fluid neurotransmitter metabolites. Author(s): Umhau JC, Petrulis SG, Diaz R, Rawlings R, George DT. Source: Neuroendocrinology. 2003 December; 78(6): 339-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14688447
•
Blood glucose management during critical illness. Author(s): Mizock BA. Source: Reviews in Endocrine & Metabolic Disorders. 2003 May; 4(2): 187-94. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12766547
•
Blood glucose measurement in acute medicine: inadequate detection and management. Author(s): Hennessy AR, Reynolds RM, Walker JD. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2002 August; 19(8): 698. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12147155
•
Blood glucose monitoring in gestational diabetes mellitus: 1- versus 2-h blood glucose determinations. Author(s): Leguizamon G, Krupitzki H, Glujovsky D, Olivera Ravasi M, Reece EA. Source: J Matern Fetal Neonatal Med. 2002 December;12(6):384-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12683648
72
Blood Glucose
•
Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease. Author(s): Oyibo SO, Pritchard GM, McLay L, James E, Laing I, Gokal R, Boulton AJ. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2002 August; 19(8): 693-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12147153
•
Blood glucose responses and incidence of hypoglycaemia in elite tennis under practice and tournament conditions. Author(s): Ferrauti A, Pluim BM, Busch T, Weber K. Source: J Sci Med Sport. 2003 March; 6(1): 28-39. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12801208
•
Blood glucose self-monitoring from abdominal skin: a precise and virtually pain-free method. Author(s): Holstein A, Thiessen E, Kaufmann N, Plaschke A, Egberts EH. Source: Acta Diabetologica. 2002 June; 39(2): 97-104. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12120920
•
Blood glucose testing in the classroom. What are the pros and cons for students and for school nurses? Author(s): Smaldone A, Dychkowski L. Source: School Nurse News. 2002 May; 19(3): 44-7. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12046172
•
Blood glucose threshold and the metabolic responses to incremental exercise tests with and without prior lactic acidosis induction. Author(s): Simoes HG, Campbell CS, Kushnick MR, Nakamura A, Katsanos CS, Baldissera V, Moffatt RJ. Source: European Journal of Applied Physiology. 2003 August; 89(6): 603-11. Epub 2003 May 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12759761
•
Can capillary whole blood glucose and venous plasma glucose measurements be used interchangeably in diagnosis of diabetes mellitus? Author(s): Stahl M, Brandslund I, Jorgensen LG, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N. Source: Scandinavian Journal of Clinical and Laboratory Investigation. 2002; 62(2): 15966. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12004932
Studies
73
•
Capillary blood glucose testing in older people: reliable and accurate. Author(s): Kabadi UK, Kabadi MU. Source: Journal of the American Geriatrics Society. 2003 January; 51(1): 136-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12534864
•
Carbohydrate and the regulation of blood glucose and metabolism. Author(s): Wolever TM. Source: Nutrition Reviews. 2003 May; 61(5 Pt 2): S40-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12828191
•
Carbohydrate ingestion, blood glucose and mood. Author(s): Benton D. Source: Neuroscience and Biobehavioral Reviews. 2002 May; 26(3): 293-308. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12034132
•
Changes in corneal and lens autofluorescence and blood glucose levels in diabetics: parameters of blood glucose control. Author(s): Mori F, Ishiko S, Abiko T, Kitaya N, Kato Y, Kanno H, Yoshida A. Source: Current Eye Research. 1997 June; 16(6): 534-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9192161
•
Changes in the count of pancreatic beta- and alpha-cells and blood glucose level in rats with alloxan-induced diabetes. Author(s): Aleeva GN, Kiyasov AP, Minnebaev MM, Burykin IM, Khafiz'yanova RKh. Source: Bulletin of Experimental Biology and Medicine. 2002 February; 133(2): 127-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12428279
•
Choosing a blood glucose meter. Author(s): Spollett GR. Source: Diabetes Self Manag. 2003 July-August; 20(4): 99-100, 102-6. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12908446
•
Clinical application of hair protein glycation in the assessment of blood glucose control and diabetic neuropathy. Author(s): Masuta S, Sakai M, Ohara T, Igaki N, Nakamichi T, Maeda Y, Hata F, Oimomi M, Baba S. Source: The Kobe Journal of Medical Sciences. 1989 February; 35(1): 1-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2507822
74
Blood Glucose
•
Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. Author(s): Bina DM, Anderson RL, Johnson ML, Bergenstal RM, Kendall DM. Source: Diabetes Care. 2003 April; 26(4): 981-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12663560
•
Closed-loop control of blood glucose levels in critically ill patients. Author(s): Chee F, Fernando T, van Heerden PV. Source: Anaesthesia and Intensive Care. 2002 June; 30(3): 295-307. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12075636
•
Colorectal cancer associated with BMI, physical activity, diabetes, and blood glucose. Author(s): Lund Nilsen TI, Vatten LJ. Source: Iarc Sci Publ. 2002; 156: 257-8. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12484182
•
Comparability of blood glucose concentrations measured in different sample systems for detecting glucose intolerance. Author(s): Haeckel R, Brinck U, Colic D, Janka HU, Puntmann I, Schneider J, Viebrock C. Source: Clinical Chemistry. 2002 June; 48(6 Pt 1): 936-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12029012
•
Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Author(s): Catargi B, Meyer L, Melki V, Renard E, Jeandidier N; for the EVADIAC Study Group. Source: Diabetes & Metabolism. 2002 April; 28(2): 133-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11976565
•
Comparison of glucose concentration in interstitial fluid, and capillary and venous blood during rapid changes in blood glucose levels. Author(s): Thennadil SN, Rennert JL, Wenzel BJ, Hazen KH, Ruchti TL, Block MB. Source: Diabetes Technology & Therapeutics. 2001 Fall; 3(3): 357-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11762514
Studies
75
•
Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany--results from the CODE-2 study. Author(s): Liebl A, Neiss A, Spannheimer A, Reitberger U, Wieseler B, Stammer H, Goertz A. Source: Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association. 2002 January; 110(1): 10-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11835119
•
Computer simulation and mathematical model of blood glucose behaviour. Author(s): Hebibovic M, Lacevic B, Velagic J, Alagic S, Kulenovic I. Source: Med Arh. 2004; 58(1 Suppl 2): 122-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15137226
•
Considerations on blood glucose management in Type 2 diabetes mellitus. Author(s): Home P, Chacra A, Chan J, Emslie-Smith A, Sorensen L, Crombrugge PV; Worldwide Initiative for Diabetes Education (WorldWIDE). Source: Diabetes/Metabolism Research and Reviews. 2002 July-August; 18(4): 273-85. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12203943
•
Continuous monitoring of blood glucose. Author(s): Robert JJ. Source: Hormone Research. 2002; 57 Suppl 1: 81-4. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11979031
•
Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Author(s): Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE. Source: Horm Metab Res Suppl. 1985; 15: 41-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3908280
•
Correlation between blood glucose concentration and glucose concentration in subcutaneous adipose tissue evaluated with microdialysis during intensive care. Author(s): Lourido J, Ederoth P, Sundvall N, Ungerstedt U, Nordstrom CH. Source: Scandinavian Journal of Clinical and Laboratory Investigation. 2002; 62(4): 28592. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12476927
•
Database programs for use with blood glucose meters. Author(s): Lehmann ED. Source: Diabetes Technology & Therapeutics. 1999 Fall; 1(3): 391-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11475281
76
Blood Glucose
•
Database software for use with blood glucose meters. Author(s): Lehmann ED. Source: Diabetes Technology & Therapeutics. 1999 Summer; 1(2): 229-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11475297
•
Day-to-day consistency in amount and source of carbohydrate associated with improved blood glucose control in type 1 diabetes. Author(s): Wolever TM, Hamad S, Chiasson JL, Josse RG, Leiter LA, Rodger NW, Ross SA, Ryan EA. Source: Journal of the American College of Nutrition. 1999 June; 18(3): 242-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10376780
•
Deteriorating ischaemic stroke. cytokines, soluble cytokine receptors, ferritin, systemic blood pressure, body temperature, blood glucose, diabetes, stroke severity, and CT infarction-volume as predictors of deteriorating ischaemic stroke. Author(s): Christensen H, Boysen G, Johannesen HH, Christensen E, Bendtzen K. Source: Journal of the Neurological Sciences. 2002 September 15; 201(1-2): 1-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12163186
•
Determining the best method for first-line assessment of neonatal blood glucose levels. Author(s): Thomas CL, Critchley L, Davies MW. Source: Journal of Paediatrics and Child Health. 2000 August; 36(4): 343-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10940168
•
Development of a quantitative weighted scoring instrument to evaluate bedside blood glucose testing programs. Author(s): Barr JT, Otto CN. Source: Clin Lab Manage Rev. 1998 March-April; 12(2): 70-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10178712
•
Development of a scale to measure adherence to self-monitoring of blood glucose with latent variable measurement. Author(s): Wagner JA, Schnoll RA, Gipson MT. Source: Diabetes Care. 1998 July; 21(7): 1046-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9653593
Studies
77
•
Development of noninvasive methods to monitor blood glucose levels in people with diabetes. Author(s): Marwick C. Source: Jama : the Journal of the American Medical Association. 1998 July 22-29; 280(4): 312-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9686536
•
Diabetes, blood glucose and preoperative evaluation. Author(s): Story DA, Aldridge J. Source: Anaesthesia and Intensive Care. 2000 February; 28(1): 110. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10701048
•
Diabetes, fasting blood glucose and age-related cataract: the Blue Mountains Eye Study. Author(s): Rowe NG, Mitchell PG, Cumming RG, Wans JJ. Source: Ophthalmic Epidemiology. 2000 June; 7(2): 103-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10934461
•
Diabetes: blood glucose monitoring. Author(s): Burden M. Source: Nurs Times. 2001 February 22-28; 97(8): 36-9. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11954219
•
Diagnosing diabetes: blood glucose and the role of the laboratory. Author(s): Higgins C. Source: British Journal of Nursing (Mark Allen Publishing). 2001 February 22-March 7; 10(4): 230-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12170647
•
Dietary therapy in type 2 diabetes oriented towards postprandial blood glucose improvement. Author(s): Slama G. Source: Diabetes/Metabolism Reviews. 1998 September; 14 Suppl 1: S19-24. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9816483
•
Direct measurement of whole blood glucose by a needle-type sensor. Author(s): Yamasaki Y, Ueda N, Nao K, Sekiya M, Kawamori R, Shichiri M, Kamada T. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 1989 March 15; 180(1): 93-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2743572
78
Blood Glucose
•
Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Author(s): Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL. Source: Proceedings of the National Academy of Sciences of the United States of America. 1998 February 17; 95(4): 1776-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9465093
•
Distribution of blood glucose in a national sample of Malaysian adults. Author(s): Lim TO, Ding LM, Zaki M, Suleiman AB, Kew ST, Maimunah AH, Rugayah B. Source: Med J Malaysia. 2000 March; 55(1): 65-77. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11072493
•
Distribution of blood glucose in a national sample of Malaysian adults. Author(s): Lim TO, Ding LM, Zaki M, Suleiman AB, Kew ST, Maimunah AH, Rugayah B. Source: Med J Malaysia. 2000 June; 55(2): 65-77. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10944904
•
Doctors and the assessment of blood glucose testing sticks: does colour blindness matter? Author(s): Campbell JL, Spalding JA, Mir FA, Birch J. Source: The British Journal of General Practice : the Journal of the Royal College of General Practitioners. 2000 May; 50(454): 393-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10897539
•
Does daily monitoring of blood glucose predict hemoglobin A1c levels? Author(s): Rose E, Ketchell D. Source: The Journal of Family Practice. 2003 June; 52(6): 485-90; Discussion 490. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12791231
•
Does high blood glucose mean more insulin? Type 1 diabetes management in children and adolescents. Author(s): Yee KC, Edwards KN. Source: Aust Fam Physician. 2003 September; 32(9): 727-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14524211
•
Effect of carbohydrate intake during warming-up on the regulation of blood glucose during exercise. Author(s): Brouns F, Rehrer NJ, Saris WH, Beckers E, Menheere P, ten Hoor F. Source: International Journal of Sports Medicine. 1989 May; 10 Suppl 1: S68-75. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2663744
Studies
79
•
Effect of exercise mode on blood glucose disposal during physiological hyperinsulinaemia in humans. Author(s): Tsintzas K, Simpson EJ, Seevaratnam N, Jones S. Source: European Journal of Applied Physiology. 2003 April; 89(2): 217-20. Epub 2003 February 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12665988
•
Effect of high altitude on blood glucose meter performance. Author(s): Fink KS, Christensen DB, Ellsworth A. Source: Diabetes Technology & Therapeutics. 2002; 4(5): 627-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12450444
•
Effect of intraoperative fluid on blood glucose level in neurosurgery. Author(s): Ittichaikulthol W, Lekprasert V, Pausawasdi S, Suchartwatnachai P. Source: J Med Assoc Thai. 1997 July; 80(7): 461-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9277076
•
Effect of modem transmission of blood glucose data on telephone consultation time, clinic work flow, and patient satisfaction for patients with gestational diabetes mellitus. Author(s): Kruger DF, White K, Galpern A, Mann K, Massirio A, McLellan M, Stevenson J. Source: Journal of the American Academy of Nurse Practitioners. 2003 August; 15(8): 371-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14509102
•
Effect of single-dose dexamethasone on blood glucose concentration in patients undergoing craniotomy. Author(s): Pasternak JJ, McGregor DG, Lanier WL. Source: Journal of Neurosurgical Anesthesiology. 2004 April; 16(2): 122-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15021280
•
Effects and correlates of blood glucose awareness training among patients with IDDM. Author(s): Cox DJ, Gonder-Frederick LA, Lee JH, Julian DM, Carter WR, Clarke WL. Source: Diabetes Care. 1989 May; 12(5): 313-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2721340
80
Blood Glucose
•
Effects of multiple subcutaneous doses of rhIGF-1 on total and free IGF-1 levels and blood glucose in humans. Author(s): Stong DB, Raskin R. Source: Annals of the New York Academy of Sciences. 1993 August 27; 692: 317-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8215041
•
Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids. Author(s): Iannello S, Camuto M, Cavaleri A, Milazzo P, Pisano MG, Bellomia D, Belfiore F. Source: Diabetes, Obesity & Metabolism. 2004 January; 6(1): 8-15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14686957
•
Efficacy of a new needleless insulin delivery system monitoring of blood glucose fluctuations and free insulin levels. Author(s): Katoulis EC, Drosinos EK, Dimitriadis GK, Hadjidakis DJ, Mavrokefalos PG, Raptis SA. Source: Int J Artif Organs. 1989 May; 12(5): 333-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2661445
•
Elevated albumin excretion and retinal changes in children with type 1 diabetes are related to long-term poor blood glucose control. Author(s): Norgaard K, Storm B, Graae M, Feldt-Rasmussen B. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1989 May-June; 6(4): 325-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2524337
•
Estimation of in vivo capillary or venous blood glucose concentration from analysis on stored venous blood or its plasma and use in quality control of near-patient glucose tests. Author(s): Felding P, Jensen I, Linnet K, Manford G. Source: Scandinavian Journal of Clinical and Laboratory Investigation. 2002; 62(3): 20110. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12088339
•
Evaluating once- and twice-daily self-monitored blood glucose testing strategies for stable insulin-treated patients with type 2 diabetes : the diabetes outcomes in veterans study. Author(s): Hoffman RM, Shah JH, Wendel CS, Duckworth WC, Adam KD, Bokhari SU, Dalton C, Murata GH; Diabetes Outcome in Veterans Study. Source: Diabetes Care. 2002 October; 25(10): 1744-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12351471
Studies
81
•
Evaluation of a new visual blood glucose reagent strip. Author(s): de Blieck G, Colagiuri S, Colagiuri R, Bransgrove A. Source: The Medical Journal of Australia. 1993 September 20; 159(6): 430. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8377707
•
Evaluation of blood glucose meters during hypoglycemia. Author(s): Velazquez FR. Source: Diabetes Care. 1997 July; 20(7): 1204-5; Author Reply 1206-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9203465
•
Evaluation of conventional blood glucose monitoring as an indicator of integrated glucose values using a continuous subcutaneous sensor. Author(s): Zavalkoff SR, Polychronakos C. Source: Diabetes Care. 2002 September; 25(9): 1603-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12196434
•
Evaluation of portable blood glucose meters. Problems and recommendations. Author(s): Slingerland RJ, Miedema K. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2003 September; 41(9): 1220-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14598872
•
Experience with an external quality assessment programme for point-of-care-testing (POCT) devices for the determination of blood glucose. Author(s): Wood WG, Hanke R, Meissner D, Reinauer H. Source: Clin Lab. 2003; 49(3-4): 151-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12705698
•
Expert PID control system for blood glucose control in critically ill patients. Author(s): Chee F, Fernando TL, Savkin AV, van Heeden V. Source: Ieee Transactions on Information Technology in Biomedicine : a Publication of the Ieee Engineering in Medicine and Biology Society. 2003 December; 7(4): 419-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15000368
•
Facilitating access to glucometer reagents increases blood glucose self-monitoring frequency and improves glycaemic control: a prospective study in insulin-treated diabetic patients. Author(s): Nyomba BL, Berard L, Murphy LJ. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2004 February; 21(2): 129-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14984447
82
Blood Glucose
•
Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Author(s): Vincze G, Barner JC, Lopez D. Source: Diabetes Educ. 2004 January-February; 30(1): 112-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14999899
•
Fasting blood glucose and risk of cardiovascular disease. Author(s): Balkau B, Jarrett RJ, Pyorala K, Eschwege E. Source: Diabetes Care. 1999 August; 22(8): 1385-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10480797
•
Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. Author(s): Larsson H, Ahren B, Lindgarde F, Berglund G. Source: Journal of Internal Medicine. 1995 June; 237(6): 537-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7782724
•
Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure. Author(s): Bjornholt JV, Erikssen G, Kjeldsen SE, Bodegard J, Thaulow E, Erikssen J. Source: Journal of Hypertension. 2003 July; 21(7): 1383-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12817188
•
Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Author(s): Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E. Source: Diabetes Care. 1999 January; 22(1): 45-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10333902
•
Feasibility and usefulness of dedicated software and e-mail for self-monitoring blood glucose in treating diabetes. Author(s): Perlemuter L, Yomtov B. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2002 August; 19(8): 701-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12147159
•
Feasibility of measuring blood glucose concentration by near-infrared Raman spectroscopy. Author(s): Berger AJ, Itzkan I, Feld MS. Source: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy. 1997 February; 53A(2): 287-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9097902
Studies
83
•
Fetal cyclic motor activity in diabetic pregnancies: sensitivity to maternal blood glucose. Author(s): Robertson SS, Dierker LJ. Source: Developmental Psychobiology. 2003 January; 42(1): 9-16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12471632
•
Fetal size at birth in relation to quality of blood glucose control in pregnancies complicated by pregestational diabetes mellitus. Author(s): Kimmerle R, Klockenbusch W. Source: British Journal of Obstetrics and Gynaecology. 1997 January; 104(1): 120-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8988714
•
Fetal size at birth in relation to quality of blood glucose control in pregnancies complicated by pregestational diabetes mellitus. Author(s): Persson B, Hanson U. Source: British Journal of Obstetrics and Gynaecology. 1996 May; 103(5): 427-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8624315
•
Final adult height and its relationship to blood glucose control and microvascular complications in IDDM. Author(s): Penfold J, Chase HP, Marshall G, Walravens CF, Walravens PA, Garg SK. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1995 February; 12(2): 129-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7743759
•
Finger infection resulting from self-monitoring of blood glucose and a new aid for reducing risk. Author(s): Suzuki Y, Atsumi Y, Matsuoka K. Source: Diabetes Care. 1998 August; 21(8): 1373-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9702457
•
Forearm blood glucose testing in diabetes mellitus. Author(s): Greenhalgh S, Bradshaw S, Hall CM, Price DA. Source: Archives of Disease in Childhood. 2004 June; 89(6): 516-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15155393
•
FreeStyle: a small-volume electrochemical glucose sensor for home blood glucose testing. Author(s): Feldman B, McGarraugh G, Heller A, Bohannon N, Skyler J, DeLeeuw E, Clarke D. Source: Diabetes Technology & Therapeutics. 2000 Summer; 2(2): 221-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11469262
84
Blood Glucose
•
Frequency characterization of blood glucose dynamics. Author(s): Gough DA, Kreutz-Delgado K, Bremer TM. Source: Annals of Biomedical Engineering. 2003 January; 31(1): 91-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12572659
•
Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. Author(s): Evans JM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD. Source: Bmj (Clinical Research Ed.). 1999 July 10; 319(7202): 83-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10398627
•
Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Author(s): Blonde L, Ginsberg BH, Horn S, Hirsch IB, James B, Mulcahy K, Nettles A, Smout R, Wright H. Source: Diabetes Care. 2002 January; 25(1): 245-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11772926
•
Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Author(s): Harris MI; National Health and Nutrition Examination Survey (NHANES III). Source: Diabetes Care. 2001 June; 24(6): 979-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11375356
•
Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. Author(s): Cox DJ, Kovatchev BP, Julian DM, Gonder-Frederick LA, Polonsky WH, Schlundt DG, Clarke WL. Source: The Journal of Clinical Endocrinology and Metabolism. 1994 December; 79(6): 1659-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7989471
•
Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration. Author(s): Holzapfel A, Festa A, Stacher-Janotta G, Bergmann H, Shnawa N, Brannath W, Schernthaner G, Stacher G. Source: Diabetologia. 1999 December; 42(12): 1410-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10651258
Studies
85
•
Gastric myoelectrical activity, gastric emptying, and correlations with symptoms and fasting blood glucose levels in diabetic patients. Author(s): Soykan I, Lin Z, Sarosiek I, McCallum RW. Source: The American Journal of the Medical Sciences. 1999 April; 317(4): 226-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10210357
•
Gestational diabetes mellitus: metabolic and blood glucose parameters in singleton versus twin pregnancies. Author(s): Schwartz DB, Daoud Y, Zazula P, Goyert G, Bronsteen R, Wright D, Copes J. Source: American Journal of Obstetrics and Gynecology. 1999 October; 181(4): 912-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10521752
•
GHb (HbA(1c)) is more sensitive than fasting blood glucose as a screening test for diabetes. Author(s): Papoz L, Favier F, Clabe A, Sanchez A, Le Moullec N. Source: Diabetes Care. 2000 August; 23(8): 1206-7; Author Reply 1208. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10937531
•
Gingival crevicular blood for assessment of blood glucose in diabetic patients. Author(s): Parker RC, Rapley JW, Isley W, Spencer P, Killoy WJ. Source: J Periodontol. 1993 July; 64(7): 666-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8366416
•
Giving the fingers a rest: alternative site testing eases blood glucose monitoring. Author(s): Seley J. Source: The American Journal of Nursing. 2003 March; 103(3): 73, 75, 77. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12626946
•
Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Author(s): Harrower A. Source: Metabolism: Clinical and Experimental. 2000 October; 49(10 Suppl 2): 7-11. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11078469
•
Glipizide: preprandial multi-dose combination therapy capable of maintaining normal blood glucose throughout the day. Author(s): Bernstein RK. Source: Diabetes Care. 1985 May-June; 8(3): 306-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=4006665
86
Blood Glucose
•
Glomerular charge selectivity and the influence of improved blood glucose control in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Author(s): Bangstad HJ, Kofoed-Enevoldsen A, Dahl-Jorgensen K, Hanssen KF. Source: Diabetologia. 1992 December; 35(12): 1165-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1478369
•
Glucometers: accuracy and precision, Part II. Selection of a blood glucose monitor for standard hospital use. Author(s): Considine JM, Law T. Source: Journal of Pediatric Nursing. 1993 June; 8(3): 193-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8340886
•
Glucose content in human skin: relationship with blood glucose levels. Author(s): Jensen BM, Bjerring P, Christiansen JS, Orskov H. Source: Scandinavian Journal of Clinical and Laboratory Investigation. 1995 August; 55(5): 427-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8545601
•
Glucose monitoring at the thenar: evaluation of upper dermal blood glucose kinetics during rapid systemic blood glucose changes. Author(s): Jungheim K, Koschinsky T. Source: Hormone and Metabolic Research. Hormon- Und Stoffwechselforschung. Hormones Et Metabolisme. 2002 June; 34(6): 325-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12173073
•
Glycated haemoglobin values: problems in assessing blood glucose control in diabetes mellitus. Author(s): Kilpatrick ES, Rumley AG, Dominiczak MH, Small M. Source: Bmj (Clinical Research Ed.). 1994 October 15; 309(6960): 983-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7950717
•
Glycated haemoglobin, diabetes, and mortality in men. Maybe disturbance in physiological mechanisms regulating blood glucose is risk factor for cardiovascular death. Author(s): Jarrett RJ. Source: Bmj (Clinical Research Ed.). 2001 April 21; 322(7292): 996; Author Reply 996-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11339225
•
Glycation of hair protein in the assessment of long-term control of blood glucose. Author(s): Oimomi M, Masuda S, Igaki N, Nakamichi T, Hata F, Matsumoto S, Baba S. Source: Jpn J Med. 1988 August; 27(3): 277-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3143025
Studies
87
•
Glycosylated haemoglobin and blood glucose levels in Libyan diabetic patients. Author(s): Rao GM, Morghom LO, Abukhris AA, Mansori SS, Alphgih FA, Ragale LY. Source: Trop Geogr Med. 1986 December; 38(4): 391-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3810843
•
Good blood glucose control characterizes patients without retinopathy after long diabetes duration. Author(s): Kullberg CE, Arnqvist HJ. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1995 April; 12(4): 314-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7600746
•
Granuloma annulare secondary to self-monitoring of blood glucose. Author(s): Renfrow L, Beisswenger PJ, Austin B. Source: Diabetes Care. 1985 January-February; 8(1): 101. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3971839
•
Graphical display of capillary blood glucose data using Chernoff faces. Author(s): Phillipou G. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1992 April; 9(3): 293-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1576817
•
Haematocrit and the Boehringer advantage blood glucose meter. Author(s): Wiener K. Source: Annals of Clinical Biochemistry. 1998 March; 35 ( Pt 2): 325-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9547911
•
Has blood glucose level measured on admission to hospital in a patient with acute pancreatitis any prognostic value? Author(s): Lankisch PG, Blum T, Bruns A, Droge M, Brinkmann G, Struckmann K, Nauck M, Maisonneuve P, Lowenfels AB. Source: Pancreatology : Official Journal of the International Association of Pancreatology (Iap). [et Al.]. 2001; 1(3): 224-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12120199
•
Helping patients with diabetes select a blood glucose monitor. Author(s): Kulkarni K. Source: Journal of the American Pharmaceutical Association (Washington,D.C. : 1996). 2002 July-August; 42(4): 658-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12150366
88
Blood Glucose
•
Helping your patient choose the right blood glucose meter. Author(s): Mensing C. Source: Nursing Management (Harrow, London, England : 1994). 2003 October; Suppl: 22-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14694863
•
HemoCue blood glucose analyser and haematocrit. Author(s): Jones GR. Source: Annals of Clinical Biochemistry. 1993 September; 30 ( Pt 5): 510-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8250515
•
Hemoglobin Glycosylation Index is not related with blood glucose. Author(s): Merino-Torres JF, Fajardo-Montanana C, Ferrer-Garcia JC, Pinon-Selles F. Source: Journal of Diabetes and Its Complications. 2003 September-October; 17(5): 24953. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12954152
•
Hemoglobin variant HbG-coushatta (beta-22 Glu --> Ala) found by dissociation of blood glucose from values of HbA1C measured by HPLC. Author(s): Ogawa K, Bando T, Ogawa M, Miyazaki A, Nakanishi T, Shimizu A. Source: Intern Med. 2003 September; 42(9): 781-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14518662
•
Hepatitis C in a ward for cystic fibrosis and diabetic patients: possible transmission by spring-loaded finger-stick devices for self-monitoring of capillary blood glucose. Author(s): Desenclos JC, Bourdiol-Razes M, Rolin B, Garandeau P, Ducos J, Brechot C, Thiers V. Source: Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America. 2001 November; 22(11): 701-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11842991
•
High viscosity hydroxypropylmethylcellulose reduces postprandial blood glucose concentrations in NIDDM patients. Author(s): Reppas C, Adair CH, Barnett JL, Berardi RR, DuRoss D, Swidan SZ, Thill PF, Tobey SW, Dressman JB. Source: Diabetes Research and Clinical Practice. 1993 October-November; 22(1): 61-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8137718
Studies
89
•
High-fat versus high-carbohydrate enteral formulae: effect on blood glucose, Cpeptide, and ketones in patients with type 2 diabetes treated with insulin or sulfonylurea. Author(s): Sanz-Paris A, Calvo L, Guallard A, Salazar I, Albero R. Source: Nutrition (Burbank, Los Angeles County, Calif.). 1998 November-December; 14(11-12): 840-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9834926
•
Home blood glucose monitoring. Author(s): Foster SA, Goode JV, Small RE. Source: The Annals of Pharmacotherapy. 1999 March; 33(3): 355-63. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10200862
•
Home blood glucose monitoring. Author(s): Hounsome B. Source: Prof Nurse. 1998 August; 13(11): 765-8, 770. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9782992
•
Home monitoring of blood glucose (HMBG) in Type-2 diabetes mellitus in a developing country. Author(s): Kibriya MG, Ali L, Banik NG, Khan AK. Source: Diabetes Research and Clinical Practice. 1999 December; 46(3): 253-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10624792
•
Home monitoring of blood glucose concentration by owners of diabetic dogs. Author(s): Casella M, Wess G, Hassig M, Reusch CE. Source: The Journal of Small Animal Practice. 2003 July; 44(7): 298-305. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12866927
•
How well do patients with type 1 diabetes measure their blood glucose in daily life. Author(s): Heinemann L, Overmann H, Muhlhauser I. Source: Diabetes Care. 1998 March; 21(3): 461-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9540034
•
Human amnion-isolated cells normalize blood glucose in streptozotocin-induced diabetic mice. Author(s): Wei JP, Zhang TS, Kawa S, Aizawa T, Ota M, Akaike T, Kato K, Konishi I, Nikaido T. Source: Cell Transplantation. 2003; 12(5): 545-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12953929
90
Blood Glucose
•
Human oral mucosa studies with varying blood glucose concentration by noninvasive ATR-FT-IR-spectroscopy. Author(s): Heise HM, Marbach R. Source: Cell Mol Biol (Noisy-Le-Grand). 1998 September; 44(6): 899-912. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9763193
•
Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Author(s): Spyer G, Hattersley AT, MacDonald IA, Amiel S, MacLeod KM. Source: Lancet. 2000 December 9; 356(9246): 1970-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11130525
•
Hypoglycemic action of Cucurbita ficifolia on Type 2 diabetic patients with moderately high blood glucose levels. Author(s): Acosta-Patino JL, Jimenez-Balderas E, Juarez-Oropeza MA, Diaz-Zagoya JC. Source: Journal of Ethnopharmacology. 2001 September; 77(1): 99-101. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11483384
•
Hypophosphataemia in the metabolic syndrome. Gender differences in body weight and blood glucose. Author(s): Haglin L, Lindblad A, Bygren LO. Source: European Journal of Clinical Nutrition. 2001 June; 55(6): 493-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11423926
•
Impact of body mass index on fasting blood glucose concentration among Helicobater pylori carriers. Author(s): Kyriazanos ID, Sfiniadakis I, Dimakos P, Gizaris V, Datsakis K, Dafnopoulou A. Source: Digestive Diseases (Basel, Switzerland). 2003; 21(3): 262-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14571101
•
Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). Author(s): Gray A, Clarke P, Farmer A, Holman R; United Kingdom Prospective Diabetes Study (UKPDS) Group. Source: Bmj (Clinical Research Ed.). 2002 October 19; 325(7369): 860. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12386035
•
Importance of using and understanding self-monitoring of blood glucose (SMBG) data in assessing ambient and long-term glycaemic control. Author(s): Nomura DM. Source: J Indian Med Assoc. 2002 July; 100(7): 448, 450-1. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12674169
Studies
91
•
Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. Author(s): Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Source: Bmj (Clinical Research Ed.). 2003 March 29; 326(7391): 681. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12663403
•
Influence of diazepam on blood glucose levels in nondiabetic and non-insulindependent diabetic subjects under dental treatment with local anesthesia. Author(s): Schaira VR, Ranali J, Saad MJ, de Oliveira PC, Ambrosano GM, Volpato MC. Source: Anesthesia Progress. 2004; 51(1): 14-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15106685
•
Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metforminglibenclamide therapy (Glucovance) in type 2 diabetes. Author(s): Garber A, Marre M, Blonde L, Allavoine T, Howlett H, Lehert P, Cornes M. Source: Diabetes, Obesity & Metabolism. 2003 May; 5(3): 171-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12681024
•
Informal diabetes education: impact on self-management and blood glucose control. Author(s): Gillard ML, Nwankwo R, Fitzgerald JT, Oh M, Musch DC, Johnson MW, Anderson R. Source: Diabetes Educ. 2004 January-February; 30(1): 136-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14999901
•
Injection of the insulin receptor alpha subunit increases blood glucose levels in mice. Author(s): Kanezaki Y, Matsushima R, Obata T, Nakaya Y, Matsumoto T, Ebina Y. Source: Biochemical and Biophysical Research Communications. 2003 September 26; 309(3): 572-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12963028
•
Inpatient blood glucose testing. Issues NPs should consider. Author(s): Nichols JH. Source: Adv Nurse Pract. 2003 August; 11(8): 67-8, 88. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=13677087
92
Blood Glucose
•
Intensified blood glucose monitoring improves glycemic control in stable, insulintreated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Author(s): Murata GH, Shah JH, Hoffman RM, Wendel CS, Adam KD, Solvas PA, Bokhari SU, Duckworth WC; Diabetes Outcomes in Veterans Study (DOVES). Source: Diabetes Care. 2003 June; 26(6): 1759-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12766106
•
Interpretation of home blood glucose monitoring. Author(s): Goldberg LD. Source: Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2003 July-August; 9(4): 329. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14569981
•
Intragam can interfere with blood glucose monitoring. Author(s): Kannan S, Rowland CH, Hockings GI, Tauchmann PM. Source: The Medical Journal of Australia. 2004 March 1; 180(5): 251-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14984349
•
Intrapulmonary administration of natural honey solution, hyperosmolar dextrose or hypoosmolar distill water to normal individuals and to patients with type-2 diabetes mellitus or hypertension: their effects on blood glucose level, plasma insulin and Cpeptide, blood pressure and peaked expiratory flow rate. Author(s): Al-Waili N. Source: European Journal of Medical Research. 2003 July 31; 8(7): 295-303. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12911866
•
Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Author(s): Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B. Source: Critical Care Medicine. 2004 March; 32(3): 848-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15090972
•
Inverse association between the effect of carbohydrates on blood glucose and subsequent short-term food intake in young men. Author(s): Anderson GH, Catherine NL, Woodend DM, Wolever TM. Source: The American Journal of Clinical Nutrition. 2002 November; 76(5): 1023-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12399274
Studies
93
•
Investigation on the accuracy of the blood glucose monitoring device Prestige IQ. Author(s): Larbig M, Forst T, Mondok A, Forst S, Pfutzner A. Source: Diabetes Nutr Metab. 2003 August; 16(4): 257-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14768776
•
Involving patients can work in home blood glucose testing. Author(s): Kerr D. Source: Bmj (Clinical Research Ed.). 2003 January 11; 326(7380): 103. Erratum In: Bmj. 2003 February 8; 326(7384): 321. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12521981
•
Is fasting blood glucose a reliable parameter for screening for diabetes in hypertension? Author(s): Bur A, Herkner H, Woisetschlager C, Vlcek M, Derhaschnig U, Hirschl MM. Source: American Journal of Hypertension : Journal of the American Society of Hypertension. 2003 April; 16(4): 297-301. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12670746
•
Is protein or sugar better for low blood glucose? Author(s): Spanheimer RG. Source: Postgraduate Medicine. 2003 October; 114(4): 8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14587202
•
Knowledge, attitudes, technical competence, and blood glucose control of Type 1 diabetic patients during and after an education programme. Author(s): Lennon GM, Taylor KG, Debney L, Bailey CJ. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1990 November; 7(9): 825-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2148137
•
Lack of compliance with home blood glucose monitoring predicts hospitalization in diabetes. Author(s): Burge MR. Source: Diabetes Care. 2001 August; 24(8): 1502-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11473098
•
Lantus reduces blood glucose levels, less hypoglycemia in treatment of type 2 diabetes. Author(s): Walczak IM. Source: Diabetes Technology & Therapeutics. 2002; 4(5): 735-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12458566
94
Blood Glucose
•
Laughter lowered the increase in postprandial blood glucose. Author(s): Hayashi K, Hayashi T, Iwanaga S, Kawai K, Ishii H, Shoji S, Murakami K. Source: Diabetes Care. 2003 May; 26(5): 1651-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12716853
•
Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Author(s): Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Source: Diabetes Care. 2001 November; 24(11): 1858-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11679447
•
Long-term abstinent alcoholics have a blunted blood glucose response to 2-deoxy-dglucose. Author(s): Lloyd G. Source: Alcohol and Alcoholism (Oxford, Oxfordshire). 2003 May-June; 38(3): 287; Author Reply 287. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12711667
•
Long-term abstinent alcoholics have a blunted blood glucose response to 2-Deoxy-dglucose. Author(s): Umhau JC, Petrulis SG, Diaz R, Riggs PA, Biddison JR, George DT. Source: Alcohol and Alcoholism (Oxford, Oxfordshire). 2002 November-December; 37(6): 586-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12414552
•
Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. Author(s): Giacco R, Parillo M, Rivellese AA, Lasorella G, Giacco A, D'Episcopo L, Riccardi G. Source: Diabetes Care. 2000 October; 23(10): 1461-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11023137
•
Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group. Author(s): Thulin T, Lehtonen A, Dahlof C, Nilsson-Ehle P, Engqvist L, Lagerstedt C, Berglund E. Source: Int J Clin Pharmacol Ther. 1999 January; 37(1): 28-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10027480
Studies
95
•
Low blood glucose and olanzapine. Author(s): Budman CL, Gayer AI. Source: The American Journal of Psychiatry. 2001 March; 158(3): 500-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11230004
•
Low blood glucose levels and other complications during growth hormone supplementation in sepsis. Author(s): Faintuch J, Leme RB, Cruz ME, Lima AM, Giannella Neto D, GamaRodrigues JJ. Source: Revista Do Hospital Das Clinicas. 1999 July-August; 54(4): 135-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10779822
•
Lowering of blood glucose in athymic nude mice and rats, grafted with human lung cancers. Author(s): Fortmeyer HP, Hick J, Blum U. Source: In Vivo. 1989 May-June; 3(3): 143-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2519847
•
Maternal blood glucose and the baby. The origins of the hyperglycaemia and pregnancy outcome study The Scott-Heron Lecture at the Royal Victoria Hospital--17 January 2001. Author(s): Hadden DR. Source: Ulster Med J. 2001 November; 70(2): 119-35. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11795762
•
Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Author(s): Schwedes U, Siebolds M, Mertes G; SMBG Study Group. Source: Diabetes Care. 2002 November; 25(11): 1928-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12401734
•
Measuring and managing hyperglycemia in pregnancy: from glycosuria to continuous blood glucose monitoring. Author(s): Mazze RS. Source: Semin Perinatol. 2002 June; 26(3): 171-80. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12099306
•
Menopausal hot flash frequency changes in response to experimental manipulation of blood glucose. Author(s): Dormire SL, Reame NK. Source: Nursing Research. 2003 September-October; 52(5): 338-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14501548
96
Blood Glucose
•
Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Author(s): Kovatchev BP, Cox DJ, Gonder-Frederick L, Clarke WL. Source: Diabetes Technology & Therapeutics. 2002; 4(3): 295-303. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12165168
•
Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Author(s): Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, Silink M, Donaghue K. Source: Metabolism: Clinical and Experimental. 2001 June; 50(6): 657-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11398141
•
Monitoring blood glucose changes in cutaneous tissue by temperature-modulated localized reflectance measurements. Author(s): Yeh SJ, Hanna CF, Khalil OS. Source: Clinical Chemistry. 2003 June; 49(6 Pt 1): 924-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12765989
•
Mood changes associated with blood glucose fluctuations in insulin-dependent diabetes mellitus. Author(s): Gonder-Frederick LA, Cox DJ, Bobbitt SA, Pennebaker JW. Source: Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association. 1989; 8(1): 45-59. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2707223
•
Most infectious complications in parenterally fed trauma patients are not due to elevated blood glucose levels. Author(s): Kudsk KA, Laulederkind A, Hanna MK. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2001 July-August; 25(4): 174-9. Erratum In: Jpen J Parenter Enteral Nutr 2001 September-October; 25(5): 289. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11434646
•
Myocardial infarction and prevalence of diabetes mellitus. Is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes? Author(s): Tenerz A, Lonnberg I, Berne C, Nilsson G, Leppert J. Source: European Heart Journal. 2001 July; 22(13): 1102-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11428850
•
n-3 fatty acids and blood glucose control in diabetes mellitus. Author(s): Vessby B. Source: Journal of Internal Medicine. Supplement. 1989; 225(731): 207-10. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2650692
Studies
97
•
Natural progress of blood glucose in full-term low-grade low-birthweight infants. Author(s): Ishikawa N. Source: Pediatrics International : Official Journal of the Japan Pediatric Society. 2002 December; 44(6): 583-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12421252
•
Near-patient testing of blood glucose using the Bayer Rapidlab 860 analyser in a regional neonatal unit. Author(s): Peet AC, Kennedy DM, Hocking MD, Ewer AK. Source: Annals of Clinical Biochemistry. 2002 September; 39(Pt 5): 502-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12227857
•
Neurosis induced by home monitoring of blood glucose concentrations. Author(s): Beer SF, Lawson C, Watkins PJ. Source: Bmj (Clinical Research Ed.). 1989 February 11; 298(6670): 362. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2493934
•
New ADA criteria in the Korean population: fasting blood glucose is not enough for diagnosis of mild diabetes especially in the elderly. Author(s): Choi YH, Ahn YB, Yoon KH, Kang MI, Cha BY, Lee KW, Son HY, Kang SK. Source: Korean J Intern Med. 2000 December; 15(3): 211-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11242809
•
Nifedipine and blood glucose in normal human volunteers. Author(s): Purohit AK, Raval JD, Shah GF, Gandhi TP, Gibert RN. Source: J Assoc Physicians India. 1989 February; 37(2): 148-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2808280
•
Noninvasive blood glucose measurements by near-infrared transmission spectroscopy across human tongues. Author(s): Burmeister JJ, Arnold MA, Small GW. Source: Diabetes Technology & Therapeutics. 2000 Spring; 2(1): 5-16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11467321
•
Non-invasive blood glucose monitoring by means of near infrared spectroscopy: investigation of long-term accuracy and stability. Author(s): Samann A, Fischbacher CH, Jagemann KU, Danzer K, Schuler J, Papenkordt L, Muller UA. Source: Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association. 2000; 108(6): 406-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11026754
98
Blood Glucose
•
Noninvasive blood glucose monitoring with optical coherence tomography: a pilot study in human subjects. Author(s): Larin KV, Eledrisi MS, Motamedi M, Esenaliev RO. Source: Diabetes Care. 2002 December; 25(12): 2263-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12453971
•
Noninvasive laser measurement of blood glucose in the eye: a bright idea or an optical illusion? Author(s): Arnold MA, Klonoff DA. Source: Diabetes Technology & Therapeutics. 1999 Summer; 1(2): 117-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11475282
•
Occurrence of low blood glucose concentrations during the afternoon in type 2 (noninsulin-dependent) diabetic patients on oral hypoglycaemic agents: importance of blood glucose monitoring. Author(s): Trovati M, Burzacca S, Mularoni E, Massucco P, Cavalot F, Mattiello L, Anfossi G. Source: Diabetologia. 1991 September; 34(9): 662-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1955099
•
Office-based blood glucose meters in screening for gestational diabetes. Author(s): Masse J. Source: American Journal of Obstetrics and Gynecology. 1996 May; 174(5): 1667-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9065158
•
On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Author(s): Holst JJ, Toft-Nielsen MB, Orskov C, Nauck M, Willms B. Source: Annals of the New York Academy of Sciences. 1996 December 26; 805: 729-36. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8993469
•
On-line chemiluminescence assay using FIA and fiber optics for urinary and blood glucose. Author(s): Cattaneo MV, Luong JH. Source: Enzyme and Microbial Technology. 1993 May; 15(5): 424-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7763630
•
Opioid antagonism alters blood glucose homeostasis during exercise in humans. Author(s): Hickey MS, Trappe SW, Blostein AC, Edwards BA, Goodpaster B, Craig BW. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 1994 June; 76(6): 2452-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7928870
Studies
99
•
Optimal blood glucose control during 18 years preserves peripheral nerve function in patients with 30 years' duration of type 1 diabetes. Author(s): Larsen JR, Sjoholm H, Hanssen KF, Sandvik L, Berg TJ, Dahl-Jorgensen K. Source: Diabetes Care. 2003 August; 26(8): 2400-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12882869
•
Optimal insulin infusion resulting from a mathematical model of blood glucose dynamics. Author(s): Fisher ME, Teo KL. Source: Ieee Transactions on Bio-Medical Engineering. 1989 April; 36(4): 479-86. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2714828
•
Optimizing blood glucose control in type 2 diabetes: an approach based on fasting blood glucose measurements. Author(s): Holman RR, Turner RC. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1988 September; 5(6): 582-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2974783
•
Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type I (insulin-dependent) diabetic patients. Author(s): Madsbad S, Sauerbrey N, Moller-Jensen B, Krarup T, Kuhl C. Source: Acta Med Scand. 1987; 222(1): 71-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3630779
•
Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Author(s): Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Source: Hypertension. 2002 March 1; 39(3): 777-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11897762
•
Performance evaluation of the Precision PCx point-of-care blood glucose analyzer using discriminant ratio methodology. Author(s): Deyi VY, Philippe M, Alexandre KC, De Nayer P, Hermans MP. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2002 October; 40(10): 1052-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12476948
•
Performance of Precision G blood glucose analyzer with a new test strip G2b on neonatal samples. Author(s): Meric B, Kilicaslan N, Kerman K, Ozkan D, Kurun U, Aksu N, Ozsoz M. Source: Clinical Chemistry. 2002 January; 48(1): 179-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11751555
100
Blood Glucose
•
Physiological differences between interstitial glucose and blood glucose measured in human subjects. Author(s): Kulcu E, Tamada JA, Reach G, Potts RO, Lesho MJ. Source: Diabetes Care. 2003 August; 26(8): 2405-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12882870
•
Point-of-care testing of blood glucose in the neonatal unit using the AVL Omni 9 analyser. Author(s): Newman JD, Pecache NS, Barfield CP, Balazs ND. Source: Annals of Clinical Biochemistry. 2002 September; 39(Pt 5): 509-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12227858
•
Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Author(s): Bonora E, Muggeo M. Source: Diabetologia. 2001 December; 44(12): 2107-14. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11793012
•
Postprandial blood glucose. Keeping increases in check for cardiovascular health. Author(s): Watts SA. Source: Adv Nurse Pract. 2001 August; 9(8): 46-8. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12420465
•
Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Author(s): Manderson JG, Patterson CC, Hadden DR, Traub AI, Ennis C, McCance DR. Source: American Journal of Obstetrics and Gynecology. 2003 August; 189(2): 507-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14520226
•
Problems of comparing blood glucose molality and molarity determined with an Omni, an EML 105 and an Ebio analyser. Author(s): Haeckel R, Hanecke P. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2003 July; 41(7): 950-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12940524
•
Prognostic value of blood glucose in Hodgkin's disease. Author(s): Bisagni A, de Gramont A, Brissaud P, Krulik M, Hubert D, Sirinelli A, Debray J. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1985 January; 3(1): 128-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3965630
Studies
101
•
Programmable meters. The handy blood glucose meter meets the 21st century. Author(s): Gordon D. Source: Diabetes Forecast. 2002 May; 55(5): 65-8. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14964161
•
Quality assessment of blood glucose testing in general practitioners' offices improves quality. Author(s): Stahl M, Brandslund I, Iversen S, Filtenborg JA. Source: Clinical Chemistry. 1997 October; 43(10): 1926-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9342014
•
Quality assurance for blood glucose monitoring in health-care facilities. Author(s): Walker EA, Paduano DJ, Shamoon H. Source: Diabetes Care. 1991 November; 14(11): 1043-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1797485
•
Quality assurance for blood glucose monitoring. The balance of feasibility and standards. Author(s): Walker EA. Source: Nurs Clin North Am. 1993 March; 28(1): 61-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8451217
•
Quality control in patient self-monitoring of blood glucose. Author(s): Greyson J. Source: Diabetes Care. 1993 September; 16(9): 1306-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8404439
•
Quality control of "one touch" II blood glucose meters used by nurses in clinical departments. Author(s): van 't Sant P, Hovenier JT, Kreutzer HJ. Source: Eur J Clin Chem Clin Biochem. 1994 September; 32(9): 723-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7865630
•
Quality control of blood glucose meters is a must! (Contribution of the hemocue glucose analyser) Author(s): Meyer C, Schletzer-Mari A, Arcanger B, Leroux R, Lecomte F, Coconnier E, Lucas F. Source: Diabetes & Metabolism. 1998 November; 24(5): 455-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9881245
102
Blood Glucose
•
Quality control of intensified insulin therapy: HbA1 versus blood glucose. Author(s): Bischof F, Meyerhoff C, Pfeiffer EF. Source: Hormone and Metabolic Research. Hormon- Und Stoffwechselforschung. Hormones Et Metabolisme. 1994 December; 26(12): 574-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7705761
•
Quality of life, perceived difficulties in adherence to a diabetes regimen, and blood glucose control. Author(s): Hanestad BR, Albrektsen G. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1991 October; 8(8): 759-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1838068
•
Quality-control materials for use with monitors of blood glucose. Author(s): Stejskal J, Wendland MA. Source: Clinical Chemistry. 1988 January; 34(1): 212. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3338175
•
Quality-control materials for use with monitors of blood glucose: "Refloflux II" (Boehringer Mannheim) and "Sugar-Chex" (Streck Laboratories) controls. Author(s): Rawal N, Henderson AR. Source: Clinical Chemistry. 1987 July; 33(7): 1294-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3594892
•
Rapid changes in postprandial blood glucose produce concentration differences at finger, forearm, and thigh sampling sites. Author(s): Ellison JM, Stegmann JM, Colner SL, Michael RH, Sharma MK, Ervin KR, Horwitz DL. Source: Diabetes Care. 2002 June; 25(6): 961-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12032099
•
Rate of fall of blood glucose and physiological responses of counterregulatory hormones, clinical symptoms and cognitive function to hypoglycaemia in Type I diabetes mellitus in the postprandial state. Author(s): Fanelli CG, Pampanelli S, Porcellati F, Bartocci L, Scionti L, Rossetti P, Bolli GB. Source: Diabetologia. 2003 January; 46(1): 53-64. Epub 2002 November 09. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12637983
Studies
103
•
Reduction in self-monitoring of blood glucose in persons with type 2 diabetes results in cost savings and no change in glycemic control. Author(s): Meier JL, Swislocki AL, Lopez JR, Noth RH, Bartlebaugh P, Siegel D. Source: Am J Manag Care. 2002 June; 8(6): 557-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12068962
•
Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: interest of continuous glucose monitoring. Author(s): Kessler L, Passemard R, Oberholzer J, Benhamou PY, Bucher P, Toso C, Meyer P, Penfornis A, Badet L, Wolf P, Colin C, Morel P, Pinget M; GRAGIL Group. Source: Diabetes Care. 2002 December; 25(12): 2256-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12453970
•
Regulation of blood glucose level in diabetes mellitus using palatable diet composition. Author(s): Katiyar VK. Source: Australas Phys Eng Sci Med. 2003 September; 26(3): 132-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14626853
•
Relationship between blood glucose control, pathogenesis and progression of diabetic nephropathy. Author(s): Nosadini R, Tonolo G. Source: Journal of the American Society of Nephrology : Jasn. 2004 January; 15 Suppl 1: S1-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14684663
•
Repeated random blood glucose measurements as universal screening test for gestational diabetes mellitus. Author(s): Ostlund I, Hanson U. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2004 January; 83(1): 46-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14678085
•
Research use of the AIDA www.2aida.org diabetes software simulation program: a review--part 2. Generating simulated blood glucose data for prototype validation. Author(s): Lehmann ED. Source: Diabetes Technology & Therapeutics. 2003; 5(4): 641-51. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14511419
•
Reservations on the use of error grid analysis for the validation of blood glucose assays. Author(s): Gough DA, Botvinick EL. Source: Diabetes Care. 1997 June; 20(6): 1034-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9167120
104
Blood Glucose
•
Rorschach variables related to blood glucose control in insulin-dependent diabetes patients. Author(s): Sultan S, Jebrane A, Heurtier-Hartemann A. Source: Journal of Personality Assessment. 2002 August; 79(1): 122-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12227663
•
Selecting an accurate point-of-care testing system: clinical and technical issues and implications in neonatal blood glucose monitoring. Author(s): Sirkin A, Jalloh T, Lee L. Source: Journal for Specialists in Pediatric Nursing : Jspn. 2002 July-September; 7(3): 10412. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12236242
•
Self monitoring of blood glucose in blind diabetic patients. Author(s): Windecker R, Heinemann L, Sawicki PT. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1997 August; 14(8): 703-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9272599
•
Self monitoring of blood glucose. Author(s): Banerjee S, Mandal S, Daga S. Source: J Indian Med Assoc. 2002 July; 100(7): 418-9. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12674164
•
Self monitoring of glucose by people with diabetes. Patients with non-insulin dependent diabetes should monitor urine urine rather than blood glucose. Author(s): Chantelau E, Nowicki S. Source: Bmj (Clinical Research Ed.). 1997 July 19; 315(7101): 185. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9251556
•
Self-monitored blood glucose in pregnant women without gestational diabetes mellitus. Author(s): Montaner P, Dominguez R, Corcoy R. Source: Diabetes Care. 2002 November; 25(11): 2104-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12401765
•
Self-monitored blood glucose: a common pitfall. Author(s): Raine CH 3rd. Source: Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2003 March-April; 9(2): 1379. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12917076
Studies
105
•
Self-monitoring of blood glucose in gestational diabetes. Author(s): Homko CJ, Reece EA. Source: J Matern Fetal Neonatal Med. 2002 December;12(6):389-95. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12683649
•
Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Author(s): Guerci B, Drouin P, Grange V, Bougneres P, Fontaine P, Kerlan V, Passa P, Thivolet Ch, Vialettes B, Charbonnel B; ASIA Group. Source: Diabetes & Metabolism. 2003 December; 29(6): 587-94. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14707887
•
Self-testing of blood glucose: biosensors and beyond. Author(s): Newman JD. Source: Medical Device Technology. 2002 May; 13(4): 12-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12066331
•
Specificity of noninvasive blood glucose sensing using optical coherence tomography technique: a pilot study. Author(s): Larin KV, Motamedi M, Ashitkov TV, Esenaliev RO. Source: Physics in Medicine and Biology. 2003 May 21; 48(10): 1371-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12812453
•
The effect of blood glucose regulation on retinal nerve fiber layer thickness in diabetic patients. Author(s): Lonneville YH, Ozdek SC, Onol M, Yetkin I, Gurelik G, Hasanreisoglu B. Source: Ophthalmologica. Journal International D'ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde. 2003 September-October; 217(5): 347-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12913325
•
The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Author(s): Rosak C, Haupt E, Walter T, Werner J. Source: Diabetes Nutr Metab. 2002 June; 15(3): 143-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12173728
106
Blood Glucose
•
The effect of walking before and after breakfast on blood glucose levels in patients with type 1 diabetes treated with intensive insulin therapy. Author(s): Yamanouchi K, Abe R, Takeda A, Atsumi Y, Shichiri M, Sato Y. Source: Diabetes Research and Clinical Practice. 2002 October; 58(1): 11-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12161052
•
The FDA reevaluates alternative site testing for blood glucose. Author(s): Ginsberg BH. Source: Diabetes Technology & Therapeutics. 2002; 4(3): 347-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12165174
•
The random blood glucose level, a risk factor for mortality after acute myocardial infarction, in non-diabetic patients. Author(s): Mane AS, McHugh P, Conneely J, McCarthy C. Source: Ir Med J. 2003 July-August; 96(7): 214-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14518587
•
The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Author(s): Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2002 October; 19(10): 870-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12358878
•
The relationship between periodontal disease and blood glucose level among type II diabetic patients. Author(s): Almas K, Al-Qahtani M, Al-Yami M, Khan N. Source: The Journal of Contemporary Dental Practice [electronic Resource]. 2001 November 15; 2(4): 18-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12167917
•
The role of blood glucose availability and fatigue in the development of cognitive impairment during combat training. Author(s): Owen G, Turley H, Casey A. Source: Aviation, Space, and Environmental Medicine. 2004 March; 75(3): 240-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15018292
•
Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Author(s): Boyne MS, Silver DM, Kaplan J, Saudek CD. Source: Diabetes. 2003 November; 52(11): 2790-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14578298
Studies
107
•
Understanding the processes behind the regulation of blood glucose. Author(s): James P, McFadden R. Source: Nurs Times. 2004 April 20-26; 100(16): 56-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15132068
•
Urine glucose testing: another look at its relevance when blood glucose monitoring is unaffordable. Author(s): Feleke Y, Abdulkadir J. Source: Ethiop Med J. 1998 April; 36(2): 93-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10214451
•
Use of a blood glucose meter for radiochromic film analysis in blood irradiation. Author(s): Cheung T, Butson MJ, Yu PK. Source: Physics in Medicine and Biology. 2002 October 7; 47(19): N259-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12408483
•
Use of an automated device for alternative site blood glucose monitoring. Author(s): Fineberg SE, Bergenstal RM, Bernstein RM, Laffel LM, Schwartz SL. Source: Diabetes Care. 2001 July; 24(7): 1217-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11423505
•
Use of an enzyme thermistor for semi-continuous blood glucose measurements. Author(s): Carlsson T, Adamson U, Lins PE, Danielsson B. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 1996 July 30; 251(2): 187-200. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8862473
•
Use of the HemoCue blood glucose analyzer in research studies. Author(s): Rassam AG, Mcleod J, Burge MR, Schade DS. Source: Diabetes Care. 1998 August; 21(8): 1369-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9702453
•
Usefulness of the hemocue blood glucose photometer in hypoglycaemic conditions. Author(s): M'Bemba J, Chevalier A, Bruzzo F, Slama G, Selam JL. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1997 August; 14(8): 711. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9272604
108
Blood Glucose
•
User's guide for self-monitoring of capillary blood glucose levels. Author(s): Rasaiah B. Source: Cmaj : Canadian Medical Association Journal = Journal De L'association Medicale Canadienne. 1989 January 1; 140(1): 25-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2909269
•
Using A1C to gauge blood glucose control. Author(s): Griffin C. Source: Nursing. 2003 December; 33(12): 72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14708544
•
Using statistical quality control techniques to monitor blood glucose levels. Author(s): Oniki TA, Clemmer TP, Arthur LK, Linford LH. Source: Proc Annu Symp Comput Appl Med Care. 1995; : 586-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8563353
•
Vacuum-assisted lancing of the forearm: an effective and less painful approach to blood glucose monitoring. Author(s): Cunningham DD, Henning TP, Shain EB, Young DF, Elstrom TA, Taylor EJ, Schroder SM, Gatcomb PM, Tamborlane WV. Source: Diabetes Technology & Therapeutics. 2000 Winter; 2(4): 541-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11469617
•
Validation of home blood glucose meters with respect to clinical and analytical approaches. Author(s): Brunner GA, Ellmerer M, Sendlhofer G, Wutte A, Trajanoski Z, Schaupp L, Quehenberger F, Wach P, Krejs GJ, Pieber TR. Source: Diabetes Care. 1998 April; 21(4): 585-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9571347
•
Validity of home blood glucose reporting by geriatric patients. Author(s): Herndon CM, Dole EJ, Rhyne RL, Fike DS. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2001 February 15; 58(4): 320-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11225168
•
Validity of random blood glucose as a predictor of the quality of glycaemic control by glycated haemoglobin in out-patient diabetic patients at Kenyatta National Hospital. Author(s): Otieno FC, Ng'ang'a L, Kariuki M. Source: East Afr Med J. 2002 September; 79(9): 491-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12625691
Studies
109
•
Value of postoperative blood glucose in predicting complications and length of stay after coronary artery bypass grafting. Author(s): Fish LH, Weaver TW, Moore AL, Steel LG. Source: The American Journal of Cardiology. 2003 July 1; 92(1): 74-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12842253
•
Variability of blood glucose levels in patients with type 1 diabetes mellitus on intensified insulin regimens. Author(s): Moberg EA, Lins PE, Adamson UK. Source: Diabete Metab. 1994 November-December; 20(6): 546-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7713278
•
Variation in the calpain-10 gene affects blood glucose levels in the British population. Author(s): Lynn S, Evans JC, White C, Frayling TM, Hattersley AT, Turnbull DM, Horikawa Y, Cox NJ, Bell GI, Walker M. Source: Diabetes. 2002 January; 51(1): 247-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11756349
•
Very low density lipoprotein subfraction abnormalities in IDDM patients: any effect of blood glucose control? Author(s): Patti L, Di Marino L, Maffettone A, Romano G, Annuzzi G, Riccardi G, Rivellese AA. Source: Diabetologia. 1995 December; 38(12): 1419-24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8786015
•
Visual function, blood pressure and blood glucose in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Author(s): Rottembourg J, Bellio P, Maiga K, Remaoun M, Rousselie F, Legrain M. Source: Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985; 21: 330-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3991520
•
Visual interpretation of blood glucose test strips. Author(s): Laux L. Source: Diabetes Educ. 1994 January-February; 20(1): 41-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8137703
•
Walking for exercise - immediate effect on blood glucose levels in type 2 diabetes. Author(s): Fritz T, Rosenqvist U. Source: Scandinavian Journal of Primary Health Care. 2001 March; 19(1): 31-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11303544
110
Blood Glucose
•
Weak magnetic fields antagonize the effects of melatonin on blood glucose levels in Parkinson's disease. Author(s): Sandyk R. Source: The International Journal of Neuroscience. 1993 January; 68(1-2): 85-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8063518
•
What do statistics really tell us about the quality of the data from self-monitoring of blood glucose? Author(s): Dedrick RF, Davis WK. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1989 April; 6(3): 267-73. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2523790
•
What is "normalization" of blood glucose? Author(s): Cheraskin E. Source: Southern Medical Journal. 1996 February; 89(2): 256-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8578367
•
What is blood glucose: can it be measured? Author(s): Burrin JM, Alberti KG. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1990 MarchApril; 7(3): 199-206. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2139389
•
What is the normal range of blood glucose concentrations in healthy term newborns? Author(s): Nicholl R. Source: Archives of Disease in Childhood. 2003 March; 88(3): 238-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12598390
•
What is the real contribution of fasting plasma glucose and postprandial glucose in predicting HbA(1c) and overall blood glucose control? Author(s): Caputo S, Pitocco D, Ruotolo V, Ghirlanda G. Source: Diabetes Care. 2001 November; 24(11): 2011. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11679485
•
White coat hyperglycaemia: disparity between diabetes clinic and home blood glucose concentrations. Author(s): Campbell LV, Ashwell SM, Borkman M, Chisholm DJ. Source: Bmj (Clinical Research Ed.). 1992 November 14; 305(6863): 1194-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1467722
Studies
111
•
Whole blood glucose: what are we actually measuring? Author(s): Wiener K. Source: Annals of Clinical Biochemistry. 1995 January; 32 ( Pt 1): 1-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7762948
•
Whole-body glucose metabolism in obese patients with type 2 diabetes mellitus: the impact of hypertension and strict blood glucose control. Author(s): Vestergaard H, Parving HH, Hansen L, Pedersen O. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1995 February; 12(2): 156-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7743763
•
Xenografts of human fetal pancreas regulate blood glucose to human levels. Author(s): Tuch BE. Source: Transplantation Proceedings. 1992 June; 24(3): 977-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1604694
113
CHAPTER 2. NUTRITION AND BLOOD GLUCOSE Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and blood glucose.
Finding Nutrition Studies on Blood Glucose The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “blood glucose” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
114
Blood Glucose
The following is a typical result when searching for recently indexed consumer information on blood glucose: •
Low blood glucose reactions: a review of the basics. Source: Heckman, M.S. Diabetes-forecast. Alexandria, Va. : American Diabetes Association Inc. August 1995. volume 48 (8) page 28-29. 0095-8301
•
The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Author(s): Department of Clinical Pharmacology and Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy. Source: Franciosi, M Pellegrini, F De Berardis, G Belfiglio, M Cavaliere, D Di Nardo, B Greenfield, S Kaplan, S H Sacco, M Tognoni, G Valentini, M Nicolucci, A Diabetes-Care. 2001 November; 24(11): 1870-7 0149-5992
The following information is typical of that found when using the “Full IBIDS Database” to search for “blood glucose” (or a synonym): •
Effects of electroacupuncture at weiwanxiashu and zusanli points on blood glucose and plasma pancreatic glucagon contents in diabetic rabbits. Author(s): College of Basic Medicine, Chengdu University of TCM, Chengdu 610075. Source: Zeng, Z Li, Y J-Tradit-Chin-Med. 2002 June; 22(2): 134-6 0254-6272
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Nutrition
115
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to blood glucose; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Pyridoxine Source: Integrative Medicine Communications; www.drkoop.com Vitamin B6 (Pyridoxine) Source: Integrative Medicine Communications; www.drkoop.com
•
Minerals Biotin Source: Healthnotes, Inc.; www.healthnotes.com Chromium Source: Prima Communications, Inc.www.personalhealthzone.com Selenium Source: Integrative Medicine Communications; www.drkoop.com Vanadium Source: Prima Communications, Inc.www.personalhealthzone.com
•
Food and Diet Burdock Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,235,00.html
116
Blood Glucose
Carbo-Loading Diet Source: Healthnotes, Inc.; www.healthnotes.com Weight Loss and Obesity Source: Healthnotes, Inc.; www.healthnotes.com
117
CHAPTER 3. ALTERNATIVE MEDICINE AND BLOOD GLUCOSE Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to blood glucose. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to blood glucose and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “blood glucose” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to blood glucose: •
Antidiabetic effect of diasulin, a herbal drug, on blood glucose, plasma insulin and hepatic enzymes of glucose metabolism in hyperglycaemic rats. Author(s): Pari L, Saravanan R. Source: Diabetes, Obesity & Metabolism. 2004 July; 6(4): 286-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15171753
•
Aqueous extract of Ocimum canum decreases levels of fasting blood glucose and free radicals and increases antiatherogenic lipid levels in mice. Author(s): Nyarko AK, Asare-Anane H, Ofosuhene M, Addy ME, Teye K, Addo P. Source: Vascular Pharmacology. 2002 December; 39(6): 273-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14567064
118
Blood Glucose
•
Daily variations of blood glucose, acid-base state and PCO2 in rats: effect of light exposure. Author(s): Challet E, Malan A, Turek FW, Van Reeth O. Source: Neuroscience Letters. 2004 January 23; 355(1-2): 131-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14729252
•
Decreased insulitis and blood glucose levels after injection of GAD-transduced lymphocytes into NOD mice. Author(s): Li F, Filippova M, Fagoaga O, Nehlsen-Cannarella S, Escher A. Source: Molecular Therapy : the Journal of the American Society of Gene Therapy. 2002 December; 6(6): 701-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12498766
•
Effect of Artemisia santonicum L. on blood glucose in normal and alloxan-induced diabetic rabbits. Author(s): Korkmaz H, Gurdal A. Source: Phytotherapy Research : Ptr. 2002 November; 16(7): 675-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12410552
•
Effect of Casearia esculenta root extract on blood glucose and plasma antioxidant status in streptozotocin diabetic rats. Author(s): Prakasam A, Sethupathy S, Pugalendi KV. Source: Polish Journal of Pharmacology. 2003 January-February; 55(1): 43-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12856825
•
Effect of ficus relegiosa on blood glucose and total lipid levels of normal and alloxan diabetic rabbits. Author(s): Wadood N, Wadood A, Nisar M. Source: J Ayub Med Coll Abbottabad. 2003 October-December; 15(4): 40-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15067832
•
Effect of Gymnema montanum on blood glucose, plasma insulin, and carbohydrate metabolic enzymes in alloxan-induced diabetic rats. Author(s): Ananthan R, Latha M, Pari L, Ramkumar KM, Baskar CG, Bai VN. Source: Journal of Medicinal Food. 2003 Spring; 6(1): 43-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12804019
•
Effect of Hibiscus rosa sinensis Linn. ethanol flower extract on blood glucose and lipid profile in streptozotocin induced diabetes in rats. Author(s): Sachdewa A, Khemani LD. Source: Journal of Ethnopharmacology. 2003 November; 89(1): 61-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14522433
Alternative Medicine 119
•
Effect of oral magnesium supplementation on the lipid profile and blood glucose of patients with type 2 diabetes mellitus. Author(s): Lal J, Vasudev K, Kela AK, Jain SK. Source: J Assoc Physicians India. 2003 January; 51: 37-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12693452
•
Effect of specimen collection and storage on blood glucose and lactate concentrations in healthy, hyperthyroid and diabetic cats. Author(s): Christopher MM, O'Neill S. Source: Vet Clin Pathol. 2000; 29(1): 22-28. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12070820
•
Effects of American ginseng berry extract on blood glucose levels in ob/ob mice. Author(s): Xie JT, Aung HH, Wu JA, Attel AS, Yuan CS. Source: The American Journal of Chinese Medicine. 2002; 30(2-3): 187-94. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12230007
•
Effects of electroacupuncture at weiwanxiashu and zusanli points on blood glucose and plasma pancreatic glucagon contents in diabetic rabbits. Author(s): Zeng Z, Li Y. Source: J Tradit Chin Med. 2002 June; 22(2): 134-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12125491
•
Effects of Petroselinum crispum extract on pancreatic B cells and blood glucose of streptozotocin-induced diabetic rats. Author(s): Yanardag R, Bolkent S, Tabakoglu-Oguz A, Ozsoy-Sacan O. Source: Biological & Pharmaceutical Bulletin. 2003 August; 26(8): 1206-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12913280
•
Extract of Ocimum canum lowers blood glucose and facilitates insulin release by isolated pancreatic beta-islet cells. Author(s): Nyarko AK, Asare-Anane H, Ofosuhene M, Addy ME. Source: Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2002 May; 9(4): 346-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12120816
•
Increased intestinal permeability as a cause of fluctuating postprandial blood glucose levels in Type 1 diabetic patients. Author(s): Damci T, Nuhoglu I, Devranoglu G, Osar Z, Demir M, Ilkova H. Source: European Journal of Clinical Investigation. 2003 May; 33(5): 397-401. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12713453
120
Blood Glucose
•
Inhibitory effect of aqueous extract from the gall of Rhus chinensis on alphaglucosidase activity and postprandial blood glucose. Author(s): Shim YJ, Doo HK, Ahn SY, Kim YS, Seong JK, Park IS, Min BH. Source: Journal of Ethnopharmacology. 2003 April; 85(2-3): 283-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12639753
•
The effect of guar gum addition to a semisolid meal on appetite related to blood glucose, in dieting men. Author(s): Kovacs EM, Westerterp-Plantenga MS, Saris WH, Melanson KJ, Goossens I, Geurten P, Brouns F. Source: European Journal of Clinical Nutrition. 2002 August; 56(8): 771-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12122554
•
The juice of fresh leaves of Catharanthus roseus Linn. reduces blood glucose in normal and alloxan diabetic rabbits. Author(s): Nammi S, Boini MK, Lodagala SD, Behara RB. Source: Bmc Complementary and Alternative Medicine [electronic Resource]. 2003 September 02; 3(1): 4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12950994
•
Two herbal preparations, Cordyceps Cs4 and Cogent db: do they act on blood glucose, insulin sensitivity, and diabetes as “viscous dietary fibers?”. Author(s): Hockaday TD. Source: Journal of Alternative and Complementary Medicine (New York, N.Y.). 2002 August; 8(4): 403-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12230899
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
Alternative Medicine 121
•
HealthGate: http://www.tnp.com/
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to blood glucose; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Diabetes Source: Healthnotes, Inc.; www.healthnotes.com Diabetes Source: Prima Communications, Inc.www.personalhealthzone.com Diabetes Mellitus Source: Integrative Medicine Communications; www.drkoop.com High Cholesterol Source: Healthnotes, Inc.; www.healthnotes.com High Triglycerides Source: Healthnotes, Inc.; www.healthnotes.com Hypoglycemia Source: Healthnotes, Inc.; www.healthnotes.com Insulin Resistance Syndrome Source: Healthnotes, Inc.; www.healthnotes.com PMS Source: Integrative Medicine Communications; www.drkoop.com Premenstrual Syndrome Source: Integrative Medicine Communications; www.drkoop.com
•
Alternative Therapy Massage Source: Integrative Medicine Communications; www.drkoop.com
•
Herbs and Supplements Beta-Glucan Source: Healthnotes, Inc.; www.healthnotes.com
122
Blood Glucose
Boswellia Alternative names: Frankincense; Boswellia serrata Roxb. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Crataegus Alternative names: Hawthorn; Crataegus oxyacantha L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Dandelion Alternative names: Taraxacum officinale Source: Integrative Medicine Communications; www.drkoop.com Docosahexaenoic Acid Source: Healthnotes, Inc.; www.healthnotes.com EDTA Source: Integrative Medicine Communications; www.drkoop.com Ethylenediaminetetraacetic Acid (EDTA) Source: Integrative Medicine Communications; www.drkoop.com Fenugreek Alternative names: Trigonella foenum-graecum Source: Healthnotes, Inc.; www.healthnotes.com Fenugreek Source: Prima Communications, Inc.www.personalhealthzone.com Fructo-Oligosaccharides (FOS) and Other Oligosaccharides Source: Healthnotes, Inc.; www.healthnotes.com Ginkgo Biloba Source: Healthnotes, Inc.; www.healthnotes.com Glimepiride Source: Healthnotes, Inc.; www.healthnotes.com Glipizide Source: Healthnotes, Inc.; www.healthnotes.com Glucomannan Source: Healthnotes, Inc.; www.healthnotes.com Glucosamine Source: Healthnotes, Inc.; www.healthnotes.com Glycyrrhiza Alternative names: Licorice; Glycyrrhiza glabra L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
Alternative Medicine 123
Gymnema Alternative names: Gurmar; Gymnema sylvestre Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Gymnema Alternative names: Gymnema sylvestre Source: Healthnotes, Inc.; www.healthnotes.com Gymnema Source: Prima Communications, Inc.www.personalhealthzone.com Horehound Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10036,00.html Insulin Source: Healthnotes, Inc.; www.healthnotes.com Insulin Alternative names: Humalog, Humulin, Iletin, Novolin, Velosulin Source: Prima Communications, Inc.www.personalhealthzone.com IP-6 Source: Healthnotes, Inc.; www.healthnotes.com Juniperus Alternative names: Juniper; Juniperus sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Luffa Alternative names: Luffa sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Momordica Alternative names: Bitter Gourd, Karela; Momordica charantia Linn. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Musa Banana Alternative names: Plantain, Banana; Musa sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Ocimum Alternative names: Basil, Albahaca; Ocimum basilicum Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Oral Hypoglycemics Source: Prima Communications, Inc.www.personalhealthzone.com Origanum Alternative names: Oregano; Origanum vulgare Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
124
Blood Glucose
Panax Alternative names: Ginseng; Panax ginseng Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Plantago Psyllium Alternative names: Psyllium, Ispaghula; Plantago psyllium/ovata Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Psyllium Alternative names: Plantago ovata, Plantago ispaghula Source: Healthnotes, Inc.; www.healthnotes.com Repaglinide Source: Healthnotes, Inc.; www.healthnotes.com Silybum Alternative names: Milk Thistle; Silybum marianum (L.) Gaertn. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Smilax Alternative names: Sarsaparilla; Smilax glabra Roxb. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Syzygium Clove Alternative names: Clove, Jamun; Syzygium sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Taraxacum Officinale Source: Integrative Medicine Communications; www.drkoop.com Trigonella Alternative names: Fenugreek; Trigonella foenum graecum L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Zingiber Alternative names: Ginger; Zingiber officinale Roscoe Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Zizyphus Alternative names: Jujube; Ziziphus sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
125
CHAPTER 4. DISSERTATIONS ON BLOOD GLUCOSE Overview In this chapter, we will give you a bibliography on recent dissertations relating to blood glucose. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “blood glucose” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on blood glucose, we have not necessarily excluded non-medical dissertations in this bibliography.
Dissertations on Blood Glucose ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to blood glucose. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
A SELF-CONTROL BEHAVIOR TECHNIQUES COURSE TO INCREASE ADHERENCE TO THE GOAL FOR FREQUENCY OF SELF-MONITORING OF BLOOD GLUCOSE (DIABETES MELLITUS) by JONES, PHYLLIS MARIE, PHD from University of Pittsburgh, 1989, 387 pages http://wwwlib.umi.com/dissertations/fullcit/8921397
•
INFLUENCE OF SELF-MONITORING AND VISUAL DISCRIMINATION TRAINING ON CHILDREN'S ACCURACY IN BLOOD GLUCOSE MONITORING (DIABETES, TEACHING STRATEGIES, ERROR ANALYSIS) by KRAUSE, EVELYN RITTER, PHD from University of Denver, 1984, 202 pages http://wwwlib.umi.com/dissertations/fullcit/8500213
•
Ingestion of caffeinated coffee impairs blood glucose homeostasis in response to either high or low glycemic index cereals in non-obese males by Kacker, Sita; MSc from University of Guelph (Canada), 2003, 126 pages http://wwwlib.umi.com/dissertations/fullcit/MQ85065
126
Blood Glucose
•
Mediation and modulation of blood glucose responses to stress by adrenal hormones and brain norepinephrine implications for behavioral responses to stress by Bialik, Robert J; PhD from Carleton University (Canada), 1987 http://wwwlib.umi.com/dissertations/fullcit/NL39349
•
THE EFFECT OF A DIABETES EDUCATION PROGRAM ON SOCIAL SUPPORT, DIABETES KNOWLEDGE LEVEL, BLOOD GLUCOSE LEVEL, AND WEIGHT AMONG NONINSULIN-DEPENDENT DIABETICS by RODRIGUEZ, MAURILIA FLORES, PHD from Texas Woman's University, 1991, 208 pages http://wwwlib.umi.com/dissertations/fullcit/9219649
•
THE EFFECT OF BREAKFAST ON THE MOTOR PERFORMANCE AND BLOOD GLUCOSE LEVEL OF UNIVERSITY WOMEN by YARBROUGH, EDNA ISABEL, EDD from University of Arkansas, 1973, 94 pages http://wwwlib.umi.com/dissertations/fullcit/7327392
•
The effect of insulin, blood glucose levels and diazepam following transient forebrain ischemia in the rat by Voll, Christopher Laurence; PhD from University of Calgary (Canada), 1989 http://wwwlib.umi.com/dissertations/fullcit/NL54346
•
THE EFFECT OF MENSTRUAL CYCLE ON FASTING BLOOD GLUCOSE PATTERNS OF INSULIN DEPENDENT WOMEN WITH DIABETES MELLITUS by KANDT, DENISE CHARMANE, EDD from University of Arkansas, 1992, 159 pages http://wwwlib.umi.com/dissertations/fullcit/9334094
•
THE EFFECT OF STRESS INOCULATION TRAINING PROCEDURES ON THE CONTROL OF BLOOD GLUCOSE AND STRESS LEVELS IN INDIVIDUALS WITH DIABETES MELLITUS by AMORY, KEVIN VINCENT, PHD from The University of Iowa, 1987, 103 pages http://wwwlib.umi.com/dissertations/fullcit/8729432
•
THE EFFECT OF THE INGESTION OF GLUCOSE AND FRUCTOSE ON BLOOD GLUCOSE CONCENTRATION OF RESTING AND EXERCISING UNIVERSITY STUDENTS by HASSON, SCOTT MATHER, EDD from University of Northern Colorado, 1982, 111 pages http://wwwlib.umi.com/dissertations/fullcit/8301154
•
THE EFFECTS OF TIME OF TESTING AND ELEVATED BLOOD GLUCOSE ON COGNITIVE PERFORMANCE (GLUCOSE) by HILL, MARK RANDOLPH, PHD from The University of North Dakota, 1992, 120 pages http://wwwlib.umi.com/dissertations/fullcit/9312404
•
THE RELATIONSHIP BETWEEN BLOOD GLUCOSE LEVEL AND READING COMPREHENSION IN DIABETIC CHILDREN by GRUBB, JAMES ALLEN, EDD from The University of Tennessee, 1990, 41 pages http://wwwlib.umi.com/dissertations/fullcit/9121718
•
THE ROLE OF BLOOD GLUCOSE IN BINGE EATING BEHAVIOR (EATING DISORDERS) by TOTTEN, DEBORAH PALCZEWSKI, PHD from University of Virginia, 1990, 241 pages http://wwwlib.umi.com/dissertations/fullcit/9023486
Dissertations 127
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
129
CHAPTER 5. PATENTS ON BLOOD GLUCOSE Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.8 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “blood glucose” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on blood glucose, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Blood Glucose By performing a patent search focusing on blood glucose, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an 8Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
130
Blood Glucose
example of the type of information that you can expect to obtain from a patent search on blood glucose: •
Analyte measurement device and method of use Inventor(s): Bennett; Gregory (Milpitas, CA), Bird; Dennis (San Jose, CA), Haviland; Alan (Morgan Hill, CA), Hufford; William (Milpitas, CA) Assignee(s): Lifescan, Inc. (Milpitas, CA) Patent Number: 6,576,416 Date filed: June 19, 2001 Abstract: Devices, systems, methods and kits are provided for use in determining the concentration of chemical and biochemical components in aqueous fluids. The subject devices include test strips which define a longitudinal axis and include a distal edge configured for insertion into a measurement instrument and having an alignment notch formed in the distal edge for engagement with an alignment member of the measurement instrument. The alignment notch has opposing edges wherein at least a portion of the opposing edges is in substantially parallel relation to the longitudinal axis. In using the subject devices, the devices are inserted into a measurement instrument having an alignment pin. When operatively engaged with the alignment pin, the notch serves to maintain the device in a substantially motionless position. The invention is useful in a variety of applications, particularly in the determination of blood glucose concentrations. Excerpt(s): The present invention is related to the field of medical diagnostic devices for determining the concentration of chemical and biochemical components (analytes) in aqueous fluids. Particularly, the present invention is directed to measuring the concentration of an analyte in, or a property of, a biological fluid such as blood and more particularly glucose in blood. The quantification or assay of chemical and/or biochemical constituents within biological fluids, such as blood, urine, and saliva, and within biological fluid fractions or derivatives such as blood serum and blood plasma, is of ever increasing importance for medical diagnosis and treatment, as well as the quantification of exposure to therapeutic drugs, intoxicants, hazardous chemicals, and the like. One such common application is the measurement of blood glucose levels in diabetics. Widely accepted assays involve measuring a change in a physical characteristic of the fluid being tested or an element of such fluid when exposed to a particular energy source. These physical characteristics are typically an electrical, magnetic, fluidic, or optical property of the fluid or a component thereof. For example, with a colorimetric assay system, an optical property may be monitored wherein a change in light absorption of the fluid can be related to an analyte concentration in, or a property of, the fluid. Web site: http://www.delphion.com/details?pn=US06576416__
Patents 131
•
Apparatus and method for adjunct (add-on) neuromodulation with an external stimulator
treatment
of
diabetes
by
Inventor(s): Boveja; Birinder R. (P.O. Box 210095, Milwaukee, WI 53221) Assignee(s): none reported Patent Number: 6,615,081 Date filed: April 19, 2001 Abstract: A system and method of neuromodulation adjunct (add-on) therapy for Diabetes and blood glucose regulation, comprises an implantable lead-receiver and an external stimulator. Neuromodulation is performed using a pulsed electrical stimulation. The external stimulator contains a power source, controlling circuitry, a primary coil, and predetermined programs. The primary coil of the external stimulator inductively transfers electrical signals to the lead-receiver, which is also in electrical contact with a vagus nerve. The external stimulator emits electrical pulses to stimulate the vagus nerve according to a predetermined program. The patient acts as his/her own feedback loop. In a second mode of operation, an operator may manually override the predetermined sequence of stimulation, based on meal schedule. The external stimulator may also be equipped with a telecommunications module to control the predetermined programs remotely. Excerpt(s): This invention relates generally to medical device therapy for diabetes, more specifically to a medical device system for adjunct therapy of diabetes by neuromodulation of a selected nerve or nerve bundle utilizing an implanted leadreceiver and an external stimulator. Diabetes is a significant health problem affecting millions of Americans. It is the leading risk factor in coronary heart disease and stroke, leading cause of blindness, end-stage renal disease, and a major contributor to lower extremity amputations. Diabetes mellitus is a heterogeneous group of diseases, all of which ultimately lead to hyperglycemia (an elevation of glucose in the blood) and excretion of glucose in the urine as hyperglycemia increases. Diabetes mellitus is also characterized by the inability to reabsorb water, which results in increased urine production (polyuria), excessive thirst (polydipsia), and excessive eating (polyphagia). Nerves have trophic influences on tissues, and the secretion of insulin is stimulated by vagal nerve fibers. Decreased glucose tolerance following vagotomy (interruption of the imulses carried by the vagus nerve) has been reported in human subjects, and sympathetic stimulation via the splanchnic nerve inhibits insulin release. The central nervous system also plays a role in regulating insulin secretion, and the outflow probably occurs via the hypothalamus and the autonomic nervous system. Web site: http://www.delphion.com/details?pn=US06615081__ •
Automatic skin puncturing system Inventor(s): Kelly; Helen V. (1650 Sunset Strip, Sunrise, FL 33313) Assignee(s): none reported Patent Number: 6,530,892 Date filed: March 7, 2001 Abstract: An automatic skin puncturing system that was operable with one hand for allowing individuals with the use of only a single hand to take the blood samples needed to monitor their blood glucose levels. The automatic skin puncturing system
132
Blood Glucose
includes a housing assembly, a power connecting jack, a battery holder, an indexable, motor driven turntable, an index switch, a reed switch, a lancet lifting assembly, a disposable lancet carousel cartridge, and an electronic, micro-processor controlled circuit. Excerpt(s): The present invention relates to medical accessories and more particularly to an automatic skin puncturing system that is operable with one hand to allow an individual paralyzed on one side to take a blood sample from a finger tip for use in blood glucose level monitoring. Many individuals suffer strokes and other paralyzing afflictions that render them paralyzed on one side of their bodies. Such paralysis limits the activities that can be performed by these individuals. In most cases, individuals with the use of only one half of their bodies cannot perform the physicals steps necessary to use a lancet to take a blood sample from their finger tip. Such a limitation can be life threatening for individuals who must monitor their blood glucose level on a regular basis in order to prevent diabetic comas, and other serious consequence of out of limit blood glucose levels. It wold be desirable, therefore, to have an automatic skin puncturing system that was operable with one hand for allowing individuals with the use of only a single hand to take the blood samples needed to monitor their blood glucose levels. It is thus an object of the invention to provide an automatic skin puncturing system that is operable with one hand to allow an individual paralyzed on one side to take a blood sample from a finger tip for use in blood glucose level monitoring. Web site: http://www.delphion.com/details?pn=US06530892__ •
Blood analyte monitoring through subcutaneous measurement Inventor(s): Bonnecaze; Roger T. (Austin, TX), Freeland; Angela C. (Austin, TX) Assignee(s): TheraSense, Inc. (Alameda, CA) Patent Number: 6,579,690 Date filed: July 24, 2000 Abstract: One embodiment of the invention is a method for obtaining an estimate of an analyte concentration in a first fluid. First, measurements of an analyte concentration in a second fluid are obtained using a sensing device. An analyte concentration estimate in the first fluid is determined from these measurements by minimizing the relation: f[b]=x.sup.2 [b]+.lambda.PSI.[b], where b is a vector representing analyte concentration in the first body fluid, X.sup.2 [b] is a function representing a fit between the estimates and the measurements,.lambda. is a weighting function, and.PSI.[b] is a function indicating smoothness of the analyte concentration estimates in the first fluid. Another embodiment includes a sensing device for obtaining the measurements of an analyte concentration in the first fluid and a processor configured and arranged to determine the analyte concentration in the first body fluid according to this method. This method and device can be used, for example, to determine blood glucose concentration from measurements of the glucose concentration in subcutaneous tissue. These measurements may be made using in vitro or in vivo samples. In some instances, a subcutaneously implanted sensing device, such as electrochemical sensor, is used to make the measurements. Excerpt(s): The present invention is, in general, directed to devices and methods for the monitoring of the concentration of an analyte, such as glucose, using a subcutaneous sensor. More particularly, the present invention relates to devices and methods for the
Patents 133
monitoring of an analyte using a subcutaneous electrochemical sensor to provide information to a patient about the level of the analyte in blood. The monitoring of the level of analytes, such as glucose, lactate or oxygen, in certain individuals is vitally important to their health. High or low levels of these analytes may have detrimental effects. For example, the monitoring of glucose is particularly important to individuals with diabetes, as they must determine when insulin is needed to reduce glucose levels in their bodies or when additional glucose is needed to raise the level of glucose. A variety of methods have been used to measure analyte concentrations. For example, colorimetric, electrochemical, and optical methods have been developed for the determination of blood glucose concentration. Implanted electrochemical sensors may be used to periodically or continuously monitor glucose (or other analyte) concentration. Although sensors accurately measure the glucose concentration when inserted directly into the bloodstream, infection may occur at this implantation site. Web site: http://www.delphion.com/details?pn=US06579690__ •
Chromium picolinate compositions and uses thereof Inventor(s): Chakrin; Lawrence W. (Chatham, NY), de la Harpe; Jon (New York, NY), Komorowski; James R. (Stratford, CT), Price; Fredric D. (Bedford, NY), Skluth; Lauren K. (Goldens Bridge, NY) Assignee(s): Ambi Inc. (Purchase, NY) Patent Number: 6,713,469 Date filed: July 25, 2002 Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in combination with at least one of a cyclooxygenase inhibitor, an acid, a mucolytic and a salicin-containing herb. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass. Excerpt(s): The present invention relates to compositions comprising chromic tripicolinate or chromic polynicotinate in combination with at least one of a cyclooxygenase inhibitor, acid, mucolytic and salicin-containing herb, and uses of these compositions in lowering blood glucose levels, increasing lean body mass and lowering blood serum lipid levels. Chromium is a nutritionally essential trace element. The essentiality of chromium in the diet was established in 1959 by Schwartz, as cited in Present Knowledge in Nutrition, page 571, fifth edition (1984, the Nutrition Foundation, Washington, D.C.). Chromium depletion is characterized by the disturbance of glucose, lipid and protein metabolism and by a shortened lifespan. Chromium is essential for optimal insulin activity in all known insulin-dependent systems (Boyle et al., Southern Med. J. 70:1449-1453, 1977). Insufficient dietary chromium has been linked to both maturity-onset diabetes and to cardiovascular disease. The principle energy sources for the body are glucose and fatty acids. Chromium depletion results in biologically ineffective insulin and compromised glucose metabolism. Under these conditions, the body must rely primarily on lipid metabolism to meet its energy requirements, resulting in the production of excessive amounts of acetyl-CoA and ketone bodies. Some of the documented acetyl-CoA is converted to increased cholesterol biosynthesis, resulting in hypercholesterolemia. Diabetes mellitus is characterized in large part by glycosuria, hypercholesterolemia, and often ketoacidosis. The accelerated atherosclerotic process seen in diabetics is associated with hypercholesterolemia (Boyle et al., supra.).
134
Blood Glucose
Web site: http://www.delphion.com/details?pn=US06713469__ •
Combination therapy for type II diabetes or Syndrome X Inventor(s): Gwynne; John Thomas (Doylestown, PA), Randazzo; Bruce Paul (Rydal, PA), Vitou; Philippe John Robert (Paris, FR) Assignee(s): Wyeth (Madison, NJ) Patent Number: 6,734,197 Date filed: June 6, 2002 Abstract: This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents. Excerpt(s): This invention relates to pharmaceutical combinations of PTPase inhibiting compounds, a biguanide agent and, optionally, a sulfonylurea agent. Particularly, this invention concerns methods of treating or inhibiting type II diabetes or Syndrome X and related conditions in a mammal in need of such treatment utilizing combinations of these classes of pharmacological agents. The prevalence of insulin resistance in glucose intolerant subjects has long been recognized. Reaven et al (American Journal of Medicine 1976, 60, 80) used a continuous infusion of glucose and insulin (insulin/glucose clamp technique) and oral glucose tolerance tests to demonstrate that insulin resistance existed in a diverse group of nonobese, nonketotic subjects. These subjects ranged from borderline glucose tolerant to overt, fasting hyperglycemia. The diabetic groups in these studies included both insulin dependent (IDDM) and noninsulin dependent (NIDDM) subjects. Coincident with sustained insulin resistance is the more easily determined hyperinsulinemia, which can be measured by accurate determination of circulating plasma insulin concentration in the plasma of subjects. Hyperinsulinemia can be present as a result of insulin resistance, such as is in obese and/or diabetic (NIDDM) subjects and/or glucose intolerant subjects, or in IDDM subjects, as a consequence of over injection of insulin compared with normal physiological release of the hormone by the endocrine pancreas. Web site: http://www.delphion.com/details?pn=US06734197__
•
Composition and method for maintaining blood glucose level Inventor(s): Dhawan; Sanju (Chandigarh, IN), Singla; Anil Kumar (Chandigarh, IN) Assignee(s): Council of Scientific & Industrial Research (New Delhi, IN) Patent Number: 6,703,045 Date filed: August 21, 2001 Abstract: A composition useful for reducing serum glucose levels by an oral controlled release system and a method for treating diabetes in a human being by controlling the blood glucose level (BGL) and reducing the complications associated with diabetic
Patents 135
hyperglycemia and also the long term management of Non-Insulin Dependent Diabetes Mellitus (NIDDM) by avoiding the problems associated with the tight control of BGL, i.e., hypoglycemia tolerance and seizures. The composition is directed to a solid, hydrophilic matrix controlled release oral dosage form where the dosage form contains a therapeutically effective amount of antidiabetic drug in the matrix ensuring complete bioavailability of the drug from the matrix of the tablet. The formulation undergoes substantially or approaches zero order release of active drug and the concentration of the excepients and the water swellable polymers is chosen in such a way that the erosion or dissolution rate of the polymer is equal to the swelling rate of the polymer to get a constant release. Also, the concentration is chosen in such a way that the tablet will be fully dissolved at the same time the last of the drug is released and in addition a bioadhesive polymer may also be added to increase the residence time of the dosage form in the g.i.t. and at high concentration of the polymer, beta cyclodextrin may also be added to improve the release kinetics. Excerpt(s): (1) American Diabetes Association. Diabetes 1996 Vital Statistics. Rockville, Md.: American Diabetes Association, 1996. (2) Harris, M. I., Cowie, C. C., Stern, M. P. eds. Diabetes in America, 2nd. ed. National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468, 1995. (3) Clark, C. M., Vinicor, F. Introduction: Risks and benefits of intensive management in non-insulin-dependent diabetes mellitus. The Fifth Regensrief Conference. Ann Intern Med, 124(1, pt 2), 81-85, 1996. Web site: http://www.delphion.com/details?pn=US06703045__ •
Compounds to treat diabetes and associated conditions Inventor(s): Dey; Debendranath (Fremont, CA), Lakner; Frederick J. (Hayward, CA), Medicherla; Satyanarayana (Sunnyvale, CA), Nag; Bishwajit (Fremont, CA), Neogi; Partha (Fremont, CA) Assignee(s): Calyx Therapeutics Inc. (Hayward, CA) Patent Number: 6,525,093 Date filed: November 8, 1999 Abstract: Compounds are provided that lower blood glucose concentrations, lower serum triglyceride concentrations, lower systolic blood pressure, and increase glucose uptake by adipose tissue, but do not affect the expression of PPAR-.gamma. by adipose tissue. Excerpt(s): The present application is directed to novel antidiabetic compounds. The causes of Type I and Type II diabetes are still unknown, although both genetic and environmental factors seem to be involved. Type I diabetes (or insulin-dependent diabetes) is an autonomic immune disease in which the responsible autoantigen is still unknown. Patients with Type I diabetes need to take insulin intravenously to survive. Type II diabetes (formerly referred to as non-insulin dependent diabetes) is a metabolic disorder resulting from the body's inability either to make a sufficient amount of insulin or to properly use the insulin that is produced. Insulin secretion and insulin resistance are considered the major metabolic defects, but the precise genetic factors involved remain unknown. As is apparent from the above table, there are disadvantages to each of the currently available agents for use in the treatment of diabetes. Accordingly, there is a continuing interest in the identification and development of new agents, particularly orally administered, water-soluble agents that can be used for the treatment of diabetes.
136
Blood Glucose
Web site: http://www.delphion.com/details?pn=US06525093__ •
Device and method for enhancing transdermal flux of agents being sampled Inventor(s): Cormier; Michel J. N. (278 Andsbury Ave., Mountain View, CA 94043), Theeuwes; Felix (27350 Altamont Rd., Los Altos Hills, CA 94022) Assignee(s): none reported Patent Number: 6,537,264 Date filed: December 16, 1999 Abstract: A minimally invasive transdermal agent sampling device (2, 10) comprises a sheet (6) having a plurality of openings (8) and a plurality of microblades (4) for piercing the skin (20). A suction device (10) applies a negative pressure through the openings (8) to the microslits in the skin (20) for enhanced efflux of interstitial fluid. The device (2, 10) can be used for transdermal sampling of body analytes such as glucose for measuring/estimating blood glucose concentration. Excerpt(s): The present invention relates to transdermal agent sampling. More particularly, this invention relates to the transdermal sampling of agents, such as glucose, body electrolytes and substances of abuse, such as but not limited to alcohol and illicit drugs. The present invention uses skin-piercing microblades to enhance the transdermal flux of the agents during transdermal sampling. Obtaining a droplet of blood for the purpose of sampling a constituent (e.g., glucose) is commonly achieved by piercing the skin using a lancet or other blade-like element. Many such skin piercing devices are spring-driven so that the piercing is accomplished automatically by a pen or similar spring-loaded device. See for example, Suzuki et al. U.S. Pat. No. 5,368,047. Many blood sampling devices also apply suction to the wound following piercing by the lancet. The suction assists in obtaining a blood sample of appropriate size for testing blood components such as glucose. See for example, Suzuki et al. U.S. Pat. No. 5,368,047; Swierczek U.S. Pat. No. 5,054,499; Ishibashi U.S. Pat. No. 5,320,607; Haber et al., U.S. Pat. No. 5,231,993; and Swierczek U.S. Pat. No. 5,201,324. Web site: http://www.delphion.com/details?pn=US06537264__
•
Device and method for obtaining interstitial fluid from a patient for diagnostic tests Inventor(s): Henning; Timothy P. (Vernon Hills, IL), Lowery; Michael G. (Wildwood, IL) Assignee(s): Abbott Laboratories (Abbott Park, IL) Patent Number: 6,537,243 Date filed: October 12, 2000 Abstract: A device for obtaining a sample of interstitial fluid from a patient for use in monitoring the level of blood glucose in the patient. The device comprises a hollow tube having a wall surrounding a cavity, wherein the wall of the tube contains a multiplicity of pores. Excerpt(s): This invention relates to a device and a method for obtaining interstitial fluid from the body of a patient for use in a diagnostic test. More particularly, this invention relates to a device and a method for obtaining interstitial fluid from the body of a patient at a rapid rate of collection. Interstitial fluid is the substantially clear, substantially colorless fluid found in the human body that occupies the space between
Patents 137
the cells of the human body. Several methods have been used to obtain interstitial fluid from the body of a patient for diagnostic tests. Diagnostic tests that can be run with samples of interstitial fluid include, but are not limited to, glucose, creatinine, BUN, uric acid, magnesium, chloride, potassium, lactate, sodium, oxygen, carbon dioxide, triglyceride, and cholesterol. It is much more difficult to obtain a sample of interstitial fluid from the body of a patient than it is to obtain a sample of blood from the body of a patient. Blood is pumped under pressure through blood vessels by the heart. Consequently, a cut in a blood vessel will naturally lead to blood flowing out of the cut because the blood is flowing under pressure. Interstitial fluid, which is not pumped through vessels in the body, is under a slight negative pressure. Moreover, the amount of interstitial fluid that can be obtained from a patient is small because this fluid only occupies the space between the cells of the human body. Currently available methods for obtaining large amounts of interstitial fluid are unsatisfactory, because these methods are accompanied by undesirable side effects. Web site: http://www.delphion.com/details?pn=US06537243__ •
Device for isolating regions of living tissue Inventor(s): Agostino; Mark D. (Alameda, CA), Braig; James R. (Piedmont, CA), Cortella; Julian (Alameda, CA), Goldberger; Daniel S. (Boulder, CO), Rule; Peter (Los Altos Hills, CA) Assignee(s): OptiScan Biomedical Corporation (Alameda, CA) Patent Number: 6,631,282 Date filed: October 2, 2001 Abstract: A device and method are provided for use with a non-invasive optical measurement system, such as a thermal gradient spectrometer for improved determination of analyte concentrations within living tissue. In a preferred embodiment, a site selector is secured to a patient's forearm thereby isolating a measurement site on the patient's skin for determination of blood glucose levels. The site selector attaches to a thermal mass window of the spectrometer and thus forms an interface between the patient's skin and the thermal mass window. When the spectrometer must be temporarily removed from the patient's skin, such as to allow the patient mobility, the site selector is left secured to the forearm so as to maintain a consistent measurement site on the skin. When the spectrometer is later reattached to the patient, the site selector will again form an interface between the gradient spectrometer and the same location of skin as before. Excerpt(s): This invention relates generally to determining analyte concentrations within living tissue. More particularly, this invention relates to a device for isolating regions of living tissue for consistent transfer of thermal spectra to and from the tissue. Millions of diabetics are forced to draw blood on a daily basis to determine their blood glucose levels. A search for a non-invasive methodology to accurately determine blood glucose levels has been substantially expanded in order to alleviate the discomfort of these individuals. A significant advance in the state of the art of non-invasive blood glucose analysis has been realized by an apparatus taught in U.S. Pat. No. 6,198,949, titled SOLID-STATE NON-INVASIVE INFRARED ABSORPTION SPECTROMETER FOR THE GENERATION AND CAPTURE OF THERMAL GRADIENT SPECTRA FROM LIVING TISSUE, issued Mar. 6, 2001, and by methodology taught in U.S. Pat. No. 6,161,028, titled METHOD FOR DETERMINING ANALYTE CONCENTRATION USING PERIODIC TEMPERATURE MODULATION AND PHASE DETECTION,
138
Blood Glucose
issued Dec. 12, 2000, both of which are hereby incorporated in their entirety by reference. U.S. Pat. No. 6,198,949 discloses a spectrometer for non-invasive transfer of thermal gradient spectra to and from living tissue. The spectrometer includes an infrared transmissive thermal mass, referred to as a thermal mass window, for inducing a transient temperature gradient in the tissue by means of conductive heat transfer with the tissue, and a cooling system in operative combination with the thermal mass for the cooling thereof. Also provided is an infrared sensor for detecting infrared emissions from the tissue as the transient temperature gradient progresses into the tissue, and for providing output signals proportional to the detected infrared emissions. A data capture system is provided for sampling the output signals received from the infrared sensor as the transient temperature gradient progresses into to the tissue. The transient thermal gradients arising due to the intermittent heating and cooling of the patient's skin generate thermal spectra which yield very good measurements of the patient's blood glucose levels. Web site: http://www.delphion.com/details?pn=US06631282__ •
Device for signal processing for measurement of physiological analytes Inventor(s): Berner; Bret (El Granada, CA), Dunn; Timothy C. (Menlo Park, CA), Farinas; Kathleen C. (San Carlos, CA), Garrison; Michael D. (Seattle, WA), Kurnik; Ronald T. (Foster City, CA), Lesho; Matthew J. (San Mateo, CA), Potts; Russell O. (San Francisco, CA), Tamada; Janet A. (Mountain View, CA), Tierney; Michael J. (San Jose, CA) Assignee(s): Cygnus, Inc. (Redwood City, CA) Patent Number: 6,595,919 Date filed: February 27, 2001 Abstract: A method is provided for continually or continuously measuring the concentration of target chemical analytes present in a biological system, and processing analyte-specific signals to obtain a measurement value that is closely correlated with the concentration of the target chemical analyte in the biological system. One important application of the invention involves a method for signal processing in a system for monitoring blood glucose values. Excerpt(s): The invention relates generally to methods for continually or continuously measuring the concentration of target chemical analytes present in a biological system. More particularly, the invention relates to methods for processing signals obtained during measurement of physiological analytes. One important application of the invention involves a method for monitoring blood glucose concentrations. A number of diagnostic tests are routinely performed on humans to evaluate the amount or existence of substances present in blood or other body fluids. These diagnostic tests typically rely on physiological fluid samples removed from a subject, either using a syringe or by pricking the skin. One particular diagnostic test entails self-monitoring of blood glucose levels by diabetics. Diabetes is a major health concern, and treatment of the more severe form of the condition, Type I (insulin-dependent) diabetes, requires one or more insulin injections per day. Insulin controls utilization of glucose or sugar in the blood and prevents hyperglycemia which, if left uncorrected, can lead to ketosis. On the other hand, improper administration of insulin therapy can result in hypoglycemic episodes, which can cause coma and death. Hyperglycemia in diabetics has been correlated with several long-term effects of diabetes, such as heart disease, atherosclerosis, blindness, stroke, hypertension and kidney failure.
Patents 139
Web site: http://www.delphion.com/details?pn=US06595919__ •
Diphenylethylene compounds Inventor(s): Dey; Debendranath (Fremont, CA), Medicherla; Satyanarayana (Cupertino, CA), Nag; Bishwajit (Fremont, CA) Assignee(s): Calyx Therapeutics, Inc. (Hayward, CA) Patent Number: 6,624,197 Date filed: August 17, 2000 Abstract: Novel diphenylethylene and styrenes are provided which are administered orally to decrease blood glucose levels in rats. The glucose tolerance in insulin resistant rats is also shown, as well as lowering of triglyceride levels in serum insulin resistant, hyperinsulinemic and hypertriglycedemic rats. The compounds are orally effective antidiabetic agents that potentially may reduce abnormality of glucose and lipid metabolism in diabetes. Excerpt(s): The field of the invention is novel diphenylethylene compounds and their use for treatment of diabetes. Extracts of the leaves, flowers, and gum of the tree Pterocarpus marsupium Roxb. (Leguminosae), also known as the Indian Kino Tree, have been used traditionally for the treatment of diarrhea, toothaches, fever and urinary and skin infections. Extracts of the bark have been long regarded as useful for the therapy of diabetes. Hypoglycemic activity of a naturally occurring pterostilbene, trans1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene, isolated from the heartwood of pterocarpus marsupium as been reported by Manickam et al., J. Nat. Prod., 1997, 60:609610. However, this pterostilbene is water insoluble and has not been shown to be efficacious in the treatment of diabetes, particularly in instances where insulin is present but inactive. The cause of diabetes is yet unknown, although both genetics and environment appear to be factors. Insulin dependent (Type I) and non-insulin dependent (Type II) are the types of diabetes. Type I is an autonomic immune disease in which the responsible autoantigen is still unknown. Patients of Type I need to take insulin intravenously to survive. However, Type II diabetes, the more common form of the disease, is a metabolic disorder resulting from the body's inability to make a sufficient amount of insulin or to properly use the insulin that is produced within the body. Insulin secretion and insulin resistance are considered the major defects, however, the precise genetic factors involved in the mechanism remain unknown. Web site: http://www.delphion.com/details?pn=US06624197__
•
Disposable lancet combined with a reagent carrying strip and a system for extracting and analyzing blood in the body utilizing such a disposable lancet Inventor(s): Klitmose; Lars Peter (Gentofte, DK) Assignee(s): Novo Nordisk A/S (Bagsvaerd, DK) Patent Number: 6,620,112 Date filed: March 14, 2001 Abstract: A disposable lancet combined with a reagent carrying strip which carries a reagent that indicates the concentration of a blood component in a blood sample placed in contact with the strip. The reagent carrying strip is connected to the lancet, e.g. by
140
Blood Glucose
molding. One end of the lancet is sharpened for piercing the skin. The strip is sheet-like and has a first side and a second side, which sides are both accessible for the user, such that the reagent carrying strip can be inserted into a blood glucose meter. A weakened tear line is provided at a connection between the lancet and an edge of the reagent carrying strip so that the reagent carrying strip may be easily disconnected from the lancet. Excerpt(s): The invention relates to a disposable lancet combined with a reagent carrying-strip. The lancet has a sharp distal end for piercing the skin of a user, and a reagent carrying strip, which reacts to a blood sample. The invention furthermore relates to a system for extracting and analysing blood in a body utilizing a disposable lancet in combination with a reagent carrying strip. Patients with certain illnesses like diabetes must verify several times a day the sugar content of their blood. This is often done by placing a drop of blood on to a reagent carrying strip, which causes the reactive reagent on the strip to react with the blood. Usually the reagent carrying strip carries an enzyme that reacts with the blood component to be measured. The result of the test is read by a blood g lucose meter before or/and after applying blood. Most such blood glucose meters on the market today either read the change of colour due to the chemical reaction, or read the current produced from the chemical reaction between reagent or blood glucose. Web site: http://www.delphion.com/details?pn=US06620112__ •
Glucose measurement utilizing non-invasive assessment methods Inventor(s): Berman; Herbert L. (Los Altos Hills, CA), Blair; Robert N. (San Jose, CA), Roe; Jeffrey N. (San Ramon, CA) Assignee(s): MedOptix, Inc. (Cupertino, CA) Patent Number: 6,522,903 Date filed: October 19, 2000 Abstract: This involves non-invasive glucose measurement processes for determining blood glucose level in the human body. After achieving a static level of glucose at a surface of the skin over some period of time, the glucose may then be measured by a variety of different processes. A sample of the glucose may also first be extracted from the skin and this sample may then be measured. Clearly, these processes are especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. These procedures may be used for other analyte materials that are found in appropriate regions of the outer skin. Excerpt(s): This invention involves non-invasive glucose measurement and a process for determining blood glucose levels in the human body. Preferably, the process is used on a fingertip or other part of the body, typically a skin surface of the body. The American Diabetes Association reports that nearly 6% of the population in the United States, a group of 16 million people, has diabetes. The Association further reports that diabetes is the seventh leading cause of death in the United States, contributing to nearly 200,000 deaths per year. Diabetes is a chronic disease having no cure. The complications of the disease include blindness, kidney disease, nerve disease, and heart disease, perhaps with stroke. Diabetes is said to be the leading cause of new cases of blindness in individuals in the range of ages between 20 and 74; from 12,000-24,000 people per year lose their sight because of diabetes. Diabetes is the leading cause of end-stage renal disease, accounting for nearly 40% of new cases. Nearly 60-70% of people with diabetes
Patents 141
have mild to severe forms of diabetic nerve damage which, in severe forms, can lead to lower limb amputations. People with diabetes are 2-4 times more likely to have heart disease and to suffer strokes. Diabetes is a disease in which the body does not produce or properly use insulin, a hormone needed to convert sugar, starches, and the like into energy. Although the cause of diabetes is not completely understood, genetics, environmental factors, and viral causes have been partially identified. Web site: http://www.delphion.com/details?pn=US06522903__ •
Implantable blood glucose sensor system Inventor(s): Eglise; David (Snowdrop Villas, 53 Alma Road, Windsor, Berkshire SL4 3HH, GB) Assignee(s): none reported Patent Number: 6,579,498 Date filed: October 11, 2000 Abstract: An implanted sensing device (1) for monitoring an analyte (e.g. blood-glucose) includes a non-toxic macromolecular material (2) encapsulated within an envelope (3) of bio-compatible semi-permeable membrane. A sensor (4) responds to change of a physical property (e.g. viscosity) of the material (2) when the analyte contacts the material (2), to signal the change to a measurement circuit (5) that together with the sensor (4) and a transponder (6) are included within the envelope (3). The transponder (6) is interrogated externally of the implanted sensor (1) by an interrogation unit (7) to transmit measurement data for processing and storage. The interrogation signal is utilized within the device (1) to power the circuit (5) and transponder (6) and conveys data to the device for re-calibration or resetting of signal-datum values to compensate for aging or drift. Excerpt(s): This invention relates to sensing devices and systems, and is particularly concerned with sensing devices and systems for use in monitoring the presence or activity of specific chemical analytes. According to one aspect of the present invention a sensing device for use in monitoring the presence or activity of a specific chemical analyte, comprises an enclosure having a membrane-wall that is semi-permeable to said chemical analyte, macromolecular material contained within the enclosure, said material exhibiting physical change in response to contact with said chemical analyte, a sensor contained within the enclosure to respond to said physical change, and means for transmitting a signal from said sensing device dependent on the response of said sensor. The sensing device according to the invention is especially applicable for monitoring the presence or level of activity of a specific bio-chemical, drug or other analyte in vivo, within the body of a human or animal patient. In this context the sensing device may be provided for implant subcutaneously or otherwise within the patient so that the particular analyte can be sensed as it permeates the semi-permeable wall of the device. Web site: http://www.delphion.com/details?pn=US06579498__
142
•
Blood Glucose
Insoluble compositions for controlling blood glucose Inventor(s): Brader; Mark Laurence (Indianapolis, IN) Assignee(s): Eli Lilly and Company (Indianapolis, IN) Patent Number: 6,531,448 Date filed: December 21, 1998 Abstract: The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations. Excerpt(s): This invention is in the field of human medicine. More particularly, this invention is in the field of pharmaceutical treatment of the diseases of diabetes and hyperglycemia. It has long been a goal of insulin therapy to mimic the pattern of endogenous insulin secretion in normal individuals. The daily physiological demand for insulin fluctuates and can be separated into two phases: (a) the absorptive phase requiring a pulse of insulin to dispose of the meal-related blood glucose surge, and (b) the post-absorptive phase requiring a sustained delivery of insulin to regulate hepatic glucose output for maintaining optimal fasting blood glucose. Accordingly, effective therapy for people with diabetes generally involves the combined use of two types of exogenous insulin formulations: a rapid acting meal time insulin provided by bolus injections and a long-acting, so-called, basal insulin, administered by injection once or twice daily to control blood glucose levels between meals. An ideal basal insulin will provide an extended and "flat" time action--that is, it will control blood glucose levels for at least 12 hours, and preferably for 24 hours or more, without significant risk of hypoglycemia. Furthermore, an ideal basal insulin should be mixable with a soluble meal-time insulin, and should not cause irritation or reaction at the site of administration. Finally, basal insulin preparations that are suspension formulations should be able to be readily, and uniformly resuspended by the patient prior to administration. Web site: http://www.delphion.com/details?pn=US06531448__
•
Insulin-dose calculator disk Inventor(s): Glaser; Nichole (937 Eucalyptus St., Davis, CA 95616) Assignee(s): none reported Patent Number: 6,543,682 Date filed: May 3, 2000 Abstract: This is a manual circular calculator for determining an appropriate insulin injection dosage to be taken with a meal. Preferably, the calculator has a pair of circular
Patents 143
members which rotate around a single common center to allow calculation of the dosage. The front member includes a viewing panel showing an array of insulin injection dosage values that are printed on the rear circular member. The front member includes a series of measured blood glucose levels along a radius adjacent the viewing panel. The rear member typically has visible ingested carbohydrate values positioned along the outer perimeter of the member and, as noted above, a number of insulin injection dosage value arrays which become visible as one member is turned relative to the other. It is common that a physician would have a kit of these inventive devices, so that the appropriate one could be chosen depending on the insulin sensitivity, age, and size of the patient. In using the inventive calculator, a patient measures his or her blood glucose level and determines the weight of carbohydrates to be ingested at a particular meal. The carbohydrate ingestion is found on the outer perimeter of the back member of the device, the front member of the inventive device is turned so that an array of insulin values is visible, and the appropriate blood glucose level is read along the radius of the front circular member. The corresponding insulin injection dosage is seen in the window. Excerpt(s): This invention is a manual circular calculator for determining an appropriate insulin injection dosage to be taken with a meal. Preferably, the calculator has a pair of circular members which rotate around a single common center to allow calculation of the dosage. The front member includes a viewing panel showing an array of insulin injection dosage values which are printed on the rear circular member. The front member includes a series of measured blood glucose levels along a radius adjacent the viewing panel. The rear member typically has visible ingested carbohydrate values positioned along the outer perimeter of the member and, as noted above, a number of insulin injection dosage value arrays which become visible as one member is turned relative to the other. It is common that a physician would have a kit of these inventive devices, so that the appropriate one could be chosen depending on the insulin sensitivity, age, and size of the patient. In using the inventive calculator, a patient measures his or her blood glucose level and determines the weight of carbohydrates to be ingested at a particular meal. The carbohydrate ingestion is found on the outer periameter of the back member of the device, the front member of the inventive device is turned so that an array of insulin values is visible, and the appropriate blood glucose level is read along the radius of the front circular member. The corresponding insulin injection dosage is seen in the window. The American Diabetes Association reports that nearly six percent (6%) of the population in the United States, a group of about 16 million people, has diabetes. A significant number of these people do not know they have the disease. The Association further reports that diabetes is the seventh leading cause of death in the United States, contributing to nearly two hundred thousand deaths per year. Diabetes is a chronic disease having no known cure. The complications of the disease include blindness, kidney disease, nerve disease, and heart disease, perhaps with stroke. Diabetes is said to be the leading cause of new cases of blindness in individuals between the ages of twenty and seventy-four. Perhaps twelve to twenty-four thousand people per year lose their sight because of diabetes. Diabetes is the leading cause of end-stage renal disease, accounting for nearly forty percent of new cases. Nearly sixty to seventy percent of those with diabetes have mild to severe forms of diabetic nerve damage which, in severe forms, can lead to lower limb amputations. People with diabetes are two-to-four times more likely to have heart disease and to suffer strokes. Web site: http://www.delphion.com/details?pn=US06543682__
144
•
Blood Glucose
Limiting weight gain of cats by feeding carbohydrate source that excludes rice Inventor(s): Sunvold; Gregory D. (Eaton, OH) Assignee(s): The Procter & Gamble Company (Cincinnati, OH) Patent Number: 6,630,159 Date filed: March 27, 2001 Abstract: A process is provided for limiting weight gain in cats. The process includes feeding the cat a pet food composition that includes a source of protein, a source of fat, and a source of carbohydrates from a grain source that excludes rice. Use of preferred low glycemic index grain sources that comprise a blend of corn and sorghum; a blend of corn, sorghum, and barley; or a blend of corn, sorghum, and oats, has the effect of decreasing the postprandial blood glucose and insulin response of the cat as compared to when feeding a rice-based diet. The result is that the animal becomes satiated and voluntarily decreases its intake of food, causing less weight gain. This effect is even more marked when the composition is fed to male cats. Excerpt(s): This invention relates to a process of administering a pet food composition to prevent obesity in companion animals, such as cats and dogs. More particularly, the invention relates to a process for limiting weight gain in cats. The invention is further directed to a process for decreasing the postprandial blood glucose and insulin response in cats to promote satiety and a voluntary decrease in food intake. Obesity is a significant health concern in companion animals. Veterinary care professionals have reported that approximately 20-40% of the pets in their care are overweight. These animals bear a greater risk for health problems associated with the respiratory, cardiovascular, and skeletal systems. More particularly, obese feline patients have demonstrated greater susceptibility to diseases such as diabetes mellitus, osteoarthritis, ligament injuries, perineal dermatitis, cardiomyopathy, and hepatic lipidosis. Accordingly, new technologies meeting the health needs of obese feline patients are in high demand by pet owners and veterinarians alike. The causes of feline obesity include sedentary lifestyle and confinement indoors, as well as improper nutrition, genetic predisposition, and hormonal disorders such as thyroid and pituitary gland dysfunction. Moreover, spayed and neutered cats often exhibit a decrease in their physical activity and metabolism and therefore, have a greater tendency to gain weight. Web site: http://www.delphion.com/details?pn=US06630159__
•
Liquid formulation of metformin Inventor(s): Chandran; Ravi (Bolton Landing, NY), Gogia; Ashish (New Delhi, IN) Assignee(s): Ranbaxy Signature LLC (Princeton, NJ) Patent Number: 6,559,187 Date filed: August 7, 2001 Abstract: The present invention is directed to a liquid formulation of metformin or its pharmaceutically acceptable salts thereof. The liquid pharmaceutical composition comprises a therapeutically effective amount of metformin or its pharmaceutically acceptable salt, in a liquid carrier, which may also include a sweetener that does not increase the blood glucose level of a subject after ingestion thereof. In one embodiment, it may also include alkyl hydroxyethylcellulose, and/or a polyhydroxy alcohol. In
Patents 145
another embodiment, the carrier may contain a sweetener, mineral acid, and bicarbonate salt maintained at a pH of 4.0 to 9.0. It is useful for treating hyperglycemia and diabetes. Excerpt(s): The present invention relates to a liquid formulation of metformin and salts thereof and to the use thereof in treating hyperglycemia and/or diabetes. Diabetes Mellitus is the most common of the serious metabolic diseases affecting humans. It has been estimated that there are over 200 million people that have diabetes in the world. Metabolically, diabetes is characterized by an inappropriate elevation of blood glucose levels. In Type I Diabetes Mellitus, this is due to an absence of insulin in the individual. In Type II Diabetes Mellitus, although there is circulating insulin, its signal is not efficiently transduced via the insulin receptor, giving rise to insulin resistance, where the body responds less and less well to a given amount of insulin. Insulin is a peptide hormone which is produced by the Langerhorn islets in the pancreas. Insulin triggers increased glucose utilization, protein synthesis, and the formation and storage of neutral lipids. The present invention focuses on Type II Diabetes Mellitus, or non-insulindependent diabetes. Web site: http://www.delphion.com/details?pn=US06559187__ •
Method and apparatus for non-invasive analysis of blood glucose Inventor(s): Fuller; Milton E. (Reno, NV) Assignee(s): Pindi Products, Inc. (Reno, NV) Patent Number: 6,723,048 Date filed: June 24, 2002 Abstract: An apparatus for non-invasive detection and quantitation of analytes in a sample, such as blood glucose, employs a novel amplifier that uses high-gauss permanent magnets to permit an Rf signal to be transmitted through the sample. The concentration of the analyte can be determined from the magnitude of the reduction in the amplitude of the Rf signal at a characteristic frequency. Excerpt(s): The present invention relates to an apparatus for noninvasive testing and monitoring of biological molecules such as glucose. Diabetes mellitus is a medical condition in which the body does not adequately produce the quantity or quality of insulin needed to maintain normal levels of glucose in the circulating blood. The two most common types of diabetes are type I, also known as Insulin Dependent Diabetes Mellitus (IDDM), which accounts for 5-10% of all cases, and type II or Non-Insulin Dependent Diabetes Mellitus (NIDDM), which accounts for 90-95% of all cases. IDDM occurs in childhood, and those suffering from the disease require insulin doses throughout their lives. NIDDM generally occurs in adults and, although insulin may be required, the disease may be controllable with oral medication, weight loss, a nutritious diet and a regular exercise program. Diabetes affects about 16 million people in the U.S. and over 100 million people worldwide. Diabetes can lead to severe health complications associated with the accumulated affects of poor blood glucose control, including blindness, kidney failure, heart failure, and peripheral neuropathy associated with limb pain, poor circulation, gangrene and subsequent amputation (Davidson, Diabetes Mellitus--Diagnosis and Treatment, 3rd Edition, Churchill Livingstone, N.Y., 1991). As a result, frequent self-monitoring of blood glucose is crucial for effective treatment and for reducing diabetes-associated morbidity and mortality. Web site: http://www.delphion.com/details?pn=US06723048__
146
•
Blood Glucose
Method for controlling the membrane structure of a starch granule Inventor(s): Chawan; Dhyaneshwar B. (Liverpool, NY) Assignee(s): Heartland Health Solutions, LLC (Brentwood, TN) Patent Number: 6,720,312 Date filed: March 16, 2001 Excerpt(s): The invention relates to a method for treating patients with type 2 diabetes using a food composition able to control the release of glucose into the patient's blood. This is achieved by the introduction into the food composition of an additive, such as propylene glycol alginate, which reduces the cooking losses and enhances the starch cell wall membrane to thereby slow the enzymatic hydrolysis of the gelatinized starch by insulin. The result is a steady state release of glucose and a net reduction in the release of blood glucose (glycemic index) relative to release of glucose observed in a diabetes patient having consumed a food composition without propylene glycol alginate. In diabetic people either there is insufficient insulin (type 1) or insulin resistance (type 2 non-insulin dependent). In the U.S. alone, 10.3 million were recently reported as type 2 diabetes, mostly adults. Data in the literature suggest highly processed foods and foods high in carbohydrates are some of the causes for the onset of type 2 diabetes. Type 2 diabetes is the most common form of diabetes. When people eat, their bodies turn the food into glucose (sugar) to use as fuel. In healthy people, insulin helps the glucose get into the cells. In people with type 2 diabetes, glucose builds up in the blood beyond a normal or healthy level. In the absence of low insulin levels (as in diabetic patients) the blood glucose level rises above the safe levels. Web site: http://www.delphion.com/details?pn=US06720312__
•
Method for creating spectral instrument variation tolerance in calibration algorithms Inventor(s): Cadell; Theodore E. (Conestogo, CA), Pawluczyk; Romuald (Conestogo, CA), Scecina; Thomas (Medfield, MA) Assignee(s): CME Telemetrix Inc. (Waterloo, CA) Patent Number: 6,615,151 Date filed: August 28, 2001 Abstract: The present invention relates to a method of building instrument variation tolerance into calibration algorithms for spectroscopic devices for chemical composition analysis with spectroscopic methods. The method of the present invention is particularly suitable for blood glucose, cholesterol and other chemical components prediction based on near-infrared spectrophotometry measurements. A method includes developing a calibration algorithm on a first instrument; applying the calibration algorithm to a second instrument; calibrating the second instrument and adjusting the calibration algorithm to account for differences between the first instrument and the second instrument; and repeating the step of applying (above) in respect of (n) further instruments to provide a calibration algorithm which may then be used on other instruments. Methods are also provided that develop calibration algorithms by adding instrument variations, based on mathematical manipulation, of the spectral data collected on calibration instruments. Excerpt(s): The present invention relates to the fields of spectroscopy, spectrophotometry, and chemometrics. In particular, the present invention relates to a
Patents 147
method of building instrument variation tolerance into calibration algorithms for spectroscopic devices for chemical composition analysis with spectroscopic methods. The method of the present invention is particularly suitable for blood glucose, cholesterol and other chemical components prediction based on near-infrared spectrophotometry measurements. Spectroscopy is a well established method, which has extremely wide applications for chemical analysis of plasma, gases, liquids and solids practically in all field of modern science and technology as well in everyday life including food production, food processing, healthcare and medicine. The role of spectroscopy is to identify and to perform quantitative analysis of chemical composition of various bodies and substances or to recognize and measure concentration one or more selected chemical components (analytes) in the bodies and substances. One of such applications is a non-invasive measurement of different substances like glucose, cholesterol water, fat, protein, hemoglobin, melanin and other in human body, therefore a non-invasive glucose concentration measurement has been selected here as an illustrative example only and cannot be considered as an exclusive area of patent application. Biotechnological analysis and examination are often based on the measurement of various chemical analytes in the composition of a biological matrix such as blood, interstitial fluid, or living tissue. Such measurements may be used to evaluate a patient's state of health and to determine what, if any, treatment is necessary. For example, the frequent monitoring of blood glucose levels in diabetic persons with glucometers is often necessary to allow such persons to manage the diabetes mellitus disease, by taking insulin injections or oral drugs to lower blood glucose when required. Intensive treatment based on frequent blood glucose measurements can significantly reduce the incidence of blindness, kidney loss, and other complications associated with diabetes. Web site: http://www.delphion.com/details?pn=US06615151__ •
Method for treating, controlling, and preventing Diabetes Mellitus Inventor(s): Farouqi; Hafez Taji (Amman, JO), Murad; Osama Mansour (Amman, JO), Seir; Husni Abu (Amman, JO) Assignee(s): Diabex, Inc. (Wake Forest, NC) Patent Number: 6,555,126 Date filed: January 2, 2001 Abstract: This invention pertains to a method that can control, treat, and prevent Diabetes Mellitus. The method includes means of administering a potent product, including mainly the active ingredient Linalool, in any one of several forms, alone or with other additives and catalysts, such as vitamin E to enable the body to handle and control, then correct the complications of Diabetes Mellitus. A modest percentage of users suffering from this disease can be cured completely while the majority of others improve remarkably and experience lower blood glucose and reduce the glycated hemoglobin HbAlc readings to what are medically acceptable and healthy levels. Others, who are vulnerable to the disease due to hereditary factors, or other reasons, can help prevent it. The method works in several ways, including activation of the pancreas and re-establishing the ability of body cells to utilize and handle better and well, the glucose in the blood, and regulate the level of natural insulin in the body. The method employs Linalool in any one of its forms that can be found naturally or synthetically. Excerpt(s): This invention relates to a method that can be used to treat, control, cure, and prevent Diabetes Mellitus, of all types, through the administration of Linalool, alone, in
148
Blood Glucose
any form, and possibly with other hypoglycemic additives in several forms, and by various means. The method does not cause any harmful or unpleasant side effects. Diabetes Mellitus is a feared and complex disorder. It has been a most distressing disease that can develop to a seriously life threatening condition. For ages, society was resigned to accepting various methods and medications that became a standard with no real hope for a cure, or drastic eradication of the disease. In fact, many of the drugs used cause serious side effects. A most important indicator of the ability of the body to deal with the complications of diabetes is the glycated hemoglobin HbAlc, that gives an integrated reading of the level of blood glucose. While all other known methods and medications help lower the glucose level at limited periods of the day or night time, the HbAlC remains higher than the normal 4.3 to 6.7 range regardless of the insulin dosage and other medicines. No full cure is expected or hoped for by the present regimens. The described method herein is new and unique, and actually reduces the HbAlc reading to the normal levels and for all patients. This method has actually cured some patients of both types I and II diabetes to such a degree that they stopped taking any medication while leading normal lives. Web site: http://www.delphion.com/details?pn=US06555126__ •
Methods for lowering viscosity of glucomannan compositions, uses and compositions Inventor(s): Ryan; Valerie J. (Boston, MA), Yuan; Chienkuo Ronnie (Chelmsford, MA), Crosby; Guy A. (Weston, MA) Assignee(s): Opta Food Ingredients, Inc. (Bedford, MA) Patent Number: 6,733,769 Date filed: May 6, 1999 Abstract: Methods of producing low viscosity glucomannan compositions by mixing a viscosity lowering compound with glucomannan under conditions suitable to form a low viscosity glucomannan composition are disclosed. The ability to modulate (increase or decrease) viscosity by combining glucomannan with compounds of differing molecular weights is described. Also, methods for lowering blood glucose and cholesterol in mammals by administering an effective therapeutic amount of maltodextrin-glucomannan complex are described. Additionally, methods for converting a food or beverage product from an initial low viscosity substance to a high viscosity end-product are also described herein. Excerpt(s): Starch and hydrocolloid mixtures are often employed to modify and control the texture of food products. It has been well established that the addition of hydrocolloids increases the viscosity of starch. Konjac flour interacts synergistically with hydrocolloids such as.kappa.-carrageenan, as well as other hydrocolloids in modifying the texture of food products. Yoshimura, M., et al., J. Agric. Food Chem., 44:2970 (1996). Konjac flour is produced from the tuber of the plant Amorphopallus konjac. Konjac flour contains a high molecular weight glucomannan polysaccharide consisting of mannose and glucose in a molecular ratio of approximately 3:2 respectively, with beta1,4-linkages. The molecular weight is greater than 300,000 daltons. Hydroxyl groups are present throughout the molecule providing some hydrophilicity, thereby imparting water solubility. Acetyl groups are important in controlling the gelling mechanism, but not critical in water solubility. Konjac flour has several properties that can be readily used in food formulations. When konjac flour is mixed with water, the small sacs containing the flour swell as they absorb the water. The viscosity of the dispersion begins to increase as the sacs swell with water and release the konjac flour. Konjac has a
Patents 149
high capacity for water absorption. Tye, R. J., Food Technology, 45(3):82-92 (March 1991). Therefore, the addition of konjac flour may alter the viscosity of the preparation. Konjac flour may be used with starch, with or without other gums or stabilizers present. Generally, as the concentration of konjac increases in the presence of many starches there is a concomitant increase in the viscosity of the dispersion mixture. Konjac flour functionally interacts with most starches to give a considerable increase in viscosity that is maintained during cooking and cooling. Tye (March 1991). Web site: http://www.delphion.com/details?pn=US06733769__ •
Near infrared blood glucose monitoring system Inventor(s): Bynum; Kevin P. (Yonkers, NY), Ciurczak; Emil W. (Goldens Bridge, NY), Mark; Howard (Suffern, NY) Assignee(s): Euro-Celtique, S.A. (Luxembourg, LU) Patent Number: 6,675,030 Date filed: August 17, 2001 Abstract: An individualized modeling equation for predicting a patient's blood glucose values is generated as a function of non-invasive spectral scans of a body part and an analysis of blood samples from the patient, and is stored on a central computer. The central computer predicts a blood glucose value for the patient as a function of the individualized modeling equation and a non-invasive spectral scan generated by a remote spectral device. If the spectral scan falls within the range of the modeling equation, the predicted blood glucose level is output to the patient. If the spectral scan falls outside the range of the modeling equation, regeneration of the model is required, and the patient takes a number of noninvasive scans and an invasive blood glucose level determination. The computer regenerates the individualized modeling equation as a function of the set of spectral scans and corresponding blood glucose values. Excerpt(s): The present invention relates to the field of near infrared spectrometry for predicting patient blood glucose levels. There are roughly four million people in the United States currently diagnosed with Diabetes Mellitus. This disease causes blindness, loss of extremities, heart failure, and other complications over time. There is no "cure" for the disease, which is caused by either the failure of the pancreas to produce insulin or the body's inability to use insulin, but rather only treatment, most commonly with insulin injections in order to change the blood-glucose level. The majority of patients with Type I diabetes, as well as people with Type II diabetes or diagnosed as prediabetic, need to frequently monitor their blood glucose levels, establishing an individual blood glucose profile in order to adjust diet, medication, exercise, or to lower the blood glucose while avoiding hypoglycemia (low blood-sugar). In well-regulated patients, two or three blood samples are tested for glucose daily and are usually sufficient. In new or difficult patients, or when monitoring for hypoglycemia is required, blood samples may be required in rapid (every few minutes) succession. Web site: http://www.delphion.com/details?pn=US06675030__
150
•
Blood Glucose
Non-invasive measurement of blood analytes using photodynamics Inventor(s): Rice; Mark J. (Johnson City, TN), Routt; Wilson (Lexington, KY) Assignee(s): Fovioptics, Inc. (Lexington, KY) Patent Number: 6,650,915 Date filed: October 22, 2001 Abstract: The determination of blood glucose in an individual is carried out by projecting illuminating light into an eye of the individual to illuminate the retina with the light having wavelengths that are absorbed by rhodopsin and with the intensity of the light varying in a prescribed temporal manner. The light reflected from the retina is detected to provide a signal corresponding to the intensity of the detected light, and the detected light signal is analyzed to determine the changes in form from that of the illuminating light. For a biased sinusoidal illumination, these changes can be expressed in terms of harmonic content of the detected light. The changes in form of the detected light are related to the ability of rhodopsin to absorb light and regenerate, which in turn is related to the concentration of blood glucose, allowing a determination of the relative concentration of blood glucose. Other photoreactive analytes can similarly be determined by projecting time varying illuminating light into the eye, detecting the light reflected from the retina, and analyzing the detected light signal to determine changes in form of the signal due to changes in absorptivity of a photoreactive analyte. Excerpt(s): This invention pertains to the field of non-invasive in vivo measurement of blood analytes. The measurement of blood glucose by diabetic patients has traditionally required the drawing of a blood sample for in vitro analysis. The blood sampling is usually done by the patient himself as a finger puncture, or in the case of a child, by an adult. The need to draw blood for analysis is undesirable for a number of reasons, including discomfort to the patient, resulting in many patients not testing their blood as frequently as recommended, the high cost of glucose testing supplies, and the risk of infection with repeated skin punctures. Many of the estimated three million Type 1 (juvenile) diabetics in the United States are asked to test their blood glucose six times or more per day in order to adjust their insulin doses for tighter control of their blood glucose. As a result of the discomfort, many of these patients do not test as often as is recommended by their physician, with the consequence of poor blood glucose control. This poor control has been shown to result in increased complications from this disease. Among these complications are blindness, heart disease, kidney disease, ischemic limb disease, and stroke. In addition, there is recent evidence that Type 2 (adult-onset) diabetics (numbering over 10 million in the United States) may reduce the incidence of diabetes-related complications by more tightly controlling their blood glucose. Accordingly, these patients may be asked to test their blood glucose as often as the Type 1 diabetic patients. Web site: http://www.delphion.com/details?pn=US06650915__
•
Optical spectroscopy pathlength measurement system Inventor(s): Diab; Mohamed K. (Mission Viejo, CA) Assignee(s): Masimo Corporation (Irvine, CA) Patent Number: 6,640,116 Date filed: August 9, 2001
Patents 151
Abstract: A physiological monitor utilizes Faraday rotation measurements to estimate mean photon pathlengths through tissue. These pathlength estimates, along with corresponding optical spectroscopy measurements allow the noninvasive monitoring of blood constituent concentrations. The technique is particularly applicable to noninvasive blood glucose measurements. The physiological monitor has a polarized light source for illuminating tissue and a magnetic field generator which creates a magnetic field within the tissue during illumination. The magnetic field imparts a Faraday rotation in the plane of polarization of the incident light beam as it propagates through the tissue and emerges as a transmitted light beam. A polarimeter is used to measure the rotation of the transmitted light. A signal processor then computes an estimate of the mean pathlength from the polarimeter output. The polarized light source has a multiple wavelength optical emitter and, in conjunction with the polarimeter detector, also functions as a spectrometer. The signal processor combines spectroscopic measurements at various wavelengths with corresponding mean pathlength estimates to compute blood constituent concentrations. Excerpt(s): Various optical spectroscopic measurement systems have been developed for the noninvasive monitoring of blood constituent concentrations. In such systems, light of multiple wavelengths is used to illuminate a thin tissue portion of a person, such as a fingertip or earlobe, to obtain a spectrum analysis of the light absorbed by blood flowing through the tissue site. Pulse oximetry systems, which perform such measurements to monitor blood oxygenation of hemoglobin constituents, have been particularly successful in becoming the standard of care. Extending this technology to the noninvasive monitoring of other blood constituents, such as blood glucose, is highly desirable. For example, current methods for accurately measuring blood glucose involve drawing blood from the subject, which can be onerous for diabetics who must take frequent samples to closely monitor blood glucose levels. If the medium is a tissue portion of a person, such as a fingertip, it includes a number of constituents that absorb light. Some of the principal absorbing constituents in tissue include water, oxyhemoglobin, reduced hemoglobin, lipids, melanin and bilirubin. A drawback to applying the Beer-Lambert Law to determine the concentrations of absorbing constituents, however, is that tissue is a turbid media, i.e. strongly scatters light, which violates an underlying assumption of equation (1). Scattering in tissue is due, in part, to the variations in refractive index at the boundaries of cells or other enclosed particles, such as collagen fibers, mitochondria, ribosomes, fat globules, glycogen and secretory globules. where c.sub.v is the speed of light in a vacuum and n.sub.s is the refractive index of the sample. Web site: http://www.delphion.com/details?pn=US06640116__ •
Peptide agonists of GLP-1 activity Inventor(s): Larsen; Bjarne Due (Br.o slashed.nsh.o slashed.j, DK), Mikkelsen; Jens Damsgaard (Lyngby, DK), Neve; S.o slashed.ren (Lyngby, DK) Assignee(s): Zealand Pharma A/S (Glostrup, DK) Patent Number: 6,528,486 Date filed: July 12, 2000 Abstract: The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.
152
Blood Glucose
Excerpt(s): The present invention relates to novel peptide agonists of GLP-1 activity. More specifically the invention relates to novel peptides that lower blood glucose levels comprising variants of the exendin-4 polypeptide sequence and peptide conjugates comprising variants of the GLP-1 or the exendin-4 polypeptide sequences which are pharmacologically active and stable, and as agonists of GLP-1 activity are useful in the treatment of diseases that benefit from regulation or excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders. The present invention also relates to methods of preparing said novel peptides, a composition, e.g., a pharmaceutical composition, comprising a peptide of the invention and a physiologically acceptable carrier, to said peptide for use in therapy, a method of treating a disorder and to the use of said peptide for the manufacture of a pharmaceutical composition for use in therapy. A number of hormones that lower blood glucose levels are released from the gastrointestinal mucosa in response to the presence and absorption of nutrients in the gut. These include gastrin, secretin, glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The most potent substance known is GLP-1 (.O slashed.orskov, 1992, Diabetologia 35:701711). Glucagon-like peptide 1 (GLP-1) is a product of proglucagon, a 180 amino acid peptide (Drucker, 1998 Diabetes 47:159-169). The overall sequence of proglucagon contains the 29-amino acid sequences of glucagon, the 36 or 37 amino acid sequence of GLP-1 and the 34 amino acid sequence of glucagon-like peptide-2 (GLP-2), an intestinotrophic peptide. GLP-1 has a number of functions. It is a physiological hormone that enhances the effect on insulin secretion in normal humans and is therefore an incretin hormone. In addition, GLP-1 also lowers glucagon concentrations, slows gastric emptying, stimulates (pro)insulin biosynthesis, and enhances insulin sensitivity (Nauck, 1997, Horm. Metab. Res. 47:1253-1258). The peptide also enhances the ability for the.beta.-cells to sense and respond to glucose in subjects with imparted glucose tolerance (Byrne, 1998, Eur. J. Clin. Invest. 28:72-78). The insulinotropic effect of the GLP-1 in humans increases the rate of glucose disappearance partly because of increased insulin levels and partly because of enhanced insulin sensitivity (D'Alessio, 1994, Eur. J. Clin. Invest. 28:72-78). This has placed GLP-1 as a promising agent for treatment of type II diabetes. Active fragments of GLP-1 have been found to be GLP-1(736) and GLP-1(7-37). However, a major pharmacological problem with native GLP-1 is its short half-life. In humans and rats, GLP-1 is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV) into GLP-1(9-36)amide, acting as an endogenous GLP-1 receptor antagonist (Deacon, 1998, Diabetologia 41:271-278). Several strategies circumventing this problem have been proposed, some using inhibitors of DPP-IV and other DPP-IV resistant analogues of GLP-1(7-36)amide (Deacon, 1998, Diabetologia 41:271-287; Deacon et al., 1998, Diabetes 47:764-769; Ritzel, 1998, J. Endocrinol. 159:93-102; U.S. Pat. No. 5,545,618; Pederson, 1998, Diabetes 47:1253-1258). Exendins, another group of peptides that lower blood glucose levels have some sequence similarity (53%) to GLP-1[736]NH.sub.2 (Goke et al., 1993, J. Biol. Chem. 268:19650-55). The exendins are found in the venom of Helodermatidae or beaded lizards (Raufman, 1996, Reg. Peptides 61:1-18). Exendin-3 is present in the venom of Heloderma horridum, the Mexican beaded lizard and exendin-4 is present in the venom of Heloderma suspectum, the Gila monster. Exendin-4 differs from exendin-3 at just positions two and three. The cDNA encoding the exendin-4 precursor protein, a 47 amino acid peptide fused to the amino terminus of exendin-4 has been cloned and sequenced (Pohl et al., 1998, J. Biol. Chem. 273:9778-9784 and WO98/35033). Both exendin-3 and exendin-4 stimulate an increase in cellular cAMP production in guinea pig pancreatic acinar cells by interacting with exendin receptors (Raufman, 1996, Reg. Peptides 61:1-18). Exendin-3 causes a biphasic increase in cellular cAMP production, but a monophasic increase in amylase release in pancreatic acinar
Patents 153
cells. In contrast, exendin-4 causes a monophasic increase in cAMP production and does not alter amylase release. Web site: http://www.delphion.com/details?pn=US06528486__ •
Protein domains in the hepatic glycogen-targetting subunit of protein phosphatase 1 and methods of making and using the same Inventor(s): Armstrong; Christopher George (Dundee, GB), Cohen; Patricia Townsend Wade (Invergowrie, GB), Doherty; Martin John (Edinburgh, GB) Assignee(s): Medical Research Counsel (GB) Patent Number: 6,710,026 Date filed: September 26, 2001 Abstract: The present invention relates to compounds useful for treating disorders associated with abnormal blood glucose levels in mammals, such as Type I and Type II diabetes. The invention also relates to methods of making and using such compounds. Excerpt(s): The present invention relates to compounds useful in the treatment of disorders associated with abnormal blood glucose levels, particularly in the prevention of phosphorylase-a binding to the glycogen targeting subunit (G.sub.L) of protein phosphatase 1 (PP1). Such compounds are useful for increasing glycogen synthesis and thereby reducing blood glucose levels. The compounds find utility in the treatment of disorders, such as type I and type II diabetes, associated with higher than normal levels of blood glucose (hyperglycaemia). Most of the adverse physiological consequences in type I and type II diabetes arise from the higher than normal levels of blood glucose. Although high blood glucose levels can be reduced by administration of insulin in type I diabetes and by dietary restrictions in the case of type II diabetes, a drug which aids reduction of blood glucose levels would be advantageous in the treatment of these disorders. The liver, which is the main organ regulating glucose homeostasis, is able to store glucose in the form of glycogen and the synthesis of hepatic glycogen from glucose is under the control of hepatic glycogen synthase. Protein phosphatase 1 is major protein serine/threonine phosphatase in eukaryotic cells, which regulates numerous distinct cellular processes. This is achieved by the interaction of die catalytic subunit of PP1 (PP1C) with a diverse range of targeting subunits that localise PP1 C to specific sites within the cell, modulate its activity towards particular substrates and allow its activity to respond to extracellular signals. Web site: http://www.delphion.com/details?pn=US06710026__
•
Recombinant vector for use in gene therapy for insulin-dependent diabetes mellitus and therapeutic composition thereof Inventor(s): Suh; Dongsang (Department Genetic Engineering, Sungkyunkwan University, Chunchun-dong, Jangan-ku, Suwon, Kyonggi-do, KR 440-746) Assignee(s): none reported Patent Number: 6,596,515 Date filed: February 5, 2001 Abstract: Disclosed are a recombinant vector for use in gene therapy for insulindependent diabetes mellitus and a therapeutic composition thereof. Following the
154
Blood Glucose
injection of a.beta.-galactosidase expression vector having a K14 promoter gene, along with a Drosophola's P transposase expression helper vector, into murine skin in a liposome-mediated manner, the.beta.-galactosidase gene is expressed in the keratinocyte layer from 24 hours to 20 weeks after injection as measured by X-gal staining. With the enhancement effect and tissue specificity, the K14 promoter is applied for the expression of a human insulin gene in keratinocytes, thereby suggesting a new gene therapy method for treating insulin-dependent diabetes mellitus. When, in combination with the P-element expression helper vector, a human insulin expression vector with the K14 promoter is injected into the skin of diabetic mice, which lack insulin-producing.beta.cells of the pancreas, their blood glucose levels are maintained in a normal range. Excerpt(s): The present invention relates to a recombinant vector suitable for use in gene therapy for insulin-dependent diabetes mellitus and a pharmaceutical composition comprising the recombinant vector as an effective ingredient. More particularly, the present invention relates to a gene therapy system for effectively and safely treating insulin-dependent diabetes mellitus by taking advantage of the gene delivery capacity of Drosophila's P-transposon and the tissue specificity and expression enhancement of a K14 promoter. Gene therapy offers a new paradigm for curing human diseases. Rather than altering disease phenotypes by using agents that interact with gene products or are themselves gene products, gene therapy theoretically can modify specific genes, which results in a cure following a single administration. Initially, gene therapy was envisioned for the treatment of genetic disorders, but is currently studied for a broad spectrum of diseases, including cancer, peripheral vascular disease, arthritis, neurodegenerative disorders and other acquired diseases. Further, in combination with the Human Genome Project, gene therapy is expected to make a great progress in the treatment of far more diseases. With gene therapy, the delivery of genes into cells and their expression therein can be artificially regulated, so that the mutated genes of patients can be corrected by genetic recombination. There are disclosed patents regarding gene therapy. For instance, PCT publication No. 1997-27310 claims a retrovirus vector which can be used in gene therapy and PCT publication No. 199734009 discloses a recombinant adenovirus vector for gene therapy for human tumors. Virus vectors are, however, limited to only the treatment of hereditary diseases, owing to safety concerns and highly complex procedures. Also, the gene therapy utilizing virus vectors, as in such patents, suffers from the disadvantage of requiring much time and high expense. In prior arts, non-viral insulin vectors have been disclosed nowhere yet. Web site: http://www.delphion.com/details?pn=US06596515__ •
Saliva-monitoring biosensor electrical toothbrush Inventor(s): Kuo; Youti (88 Foxbourne Rd., Penfield, NY 14526) Assignee(s): none reported Patent Number: 6,623,698 Date filed: March 12, 2001 Abstract: A biosensor electrical toothbrush having a brush head with a test channel and a renewable biosensor system within the test channel for performing routine saliva tests. The brush head stimulates saliva production and collection in the test channel where measurement signals are produced by sensors. The signals are transmitted for storage and analysis to a microprocessor that provides readable data signals reflective of the presence or quantitative level of a specific component of saliva. The brush handle contains the micro-processor, a display means, a battery, a motor and a reservoir for
Patents 155
storing a reagent which is supplied in controlled quantities to the channel during saliva testing. The toothbrush is used to detect fertility periods, pregnancy, labor onset, alcohol concentration, blood glucose concentration and indicators that signal a need for comprehensive HIV testing. A test head without bristles may be used in place of a brush head to provide a saliva-monitoring oral device which performs the same saliva tests as the electrical toothbrush. The bristles are replaced by an oral thermometer, a gum massage element or other element used for medical or dental functions. Excerpt(s): There is a growing need for a home diagnostic system for monitoring various personal physical health conditions and for the early detection of health problems. Such systems are typically used to determine fertility periods, pregnancy, labor onset, alcohol levels, glucose levels of diabetic persons and indicators that signal a need for comprehensive HIV testing. Home diagnostics systems are desirable because they are convenient to use and reduce health care costs. The present invention relates to salivamonitoring oral devices including saliva-monitoring electrical toothbrushes. Several patents describe various systems for collecting and diagnosing the contents of saliva. Some of the prior art diagnostic purposes and collection and testing procedures are summarized below. Web site: http://www.delphion.com/details?pn=US06623698__ •
System and methods for blood glucose sensing Inventor(s): Bell; Douglas E. (Coral Springs, FL), Neel; Gary T. (Weston, FL), Voss; Houston F. (Fort Lauderdale, FL), Wong; T. Philip (Coral Springs, FL) Assignee(s): Home Diagnostics, Inc. (Fort Lauderdale, FL) Patent Number: 6,743,635 Date filed: November 1, 2002 Abstract: A system for measuring a glucose level in a blood sample includes a test strip and a meter. The test strip includes a sample chamber, a working electrode, a counter electrode, fill-detect electrodes, and an auto-on conductor. A reagent layer is disposed in the sample chamber. The auto-on conductor causes the meter to wake up and perform a test strip sequence when the test strip is inserted in the meter. The meter uses the working and counter electrodes to initially detect the blood sample in the sample chamber and uses the fill-detect electrodes to check that the blood sample has mixed with the reagent layer. The meter applies an assay voltage between the working and counter electrodes and measures the resulting current. The meter calculates the glucose level based on the measured current and calibration data saved in memory from a removable data storage device associated with the test strip. Excerpt(s): The present invention relates to electrochemical sensors and, more particularly, to systems and methods for sensing blood glucose levels electrochemically. Many people, such as diabetics, have a need to monitor their blood glucose levels on a daily basis. A number of systems that allow people to conveniently monitor their blood glucose levels are available. Such systems typically include a test strip where the user applies a blood sample and a meter that "reads" the test strip to determine the glucose level in the blood sample. Among the various technologies available for measuring blood glucose levels, electrochemical technologies are particularly desirable because only a very small blood sample may be needed to perform the measurement. In electrochemical-based systems, the test strip typically includes a sample chamber that contains reagents, such as glucose oxidase and a mediator, and electrodes. When the
156
Blood Glucose
user applies a blood sample to the sample chamber, the reagents react with the glucose, and the meter applies a voltage to the electrodes to cause a redox reaction. The meter measures the resulting current and calculates the glucose level based on the current. Web site: http://www.delphion.com/details?pn=US06743635__ •
System for delivering insulin Inventor(s): Houben; Richard P. M. (Berg & Terblijt, NL), Renirie; Alexis C. M. (Berg en Dal, NL), Weijand; Koen J. (Hoensbroek, NL) Assignee(s): Medtronic, Inc. (Minneapolis, MN) Patent Number: 6,558,345 Date filed: April 17, 2000 Abstract: There is provided an implantable system and method for monitoring pancreatic beta cell electrical activity in a patient in order to obtain a measure of a patient's insulin demand and blood glucose level. A stimulus generator is controlled to deliver stimulus pulses so as to synchronize pancreatic beta cell depolarization, thereby producing an enhanced electrical signal which is sensed and processed. In a specific embodiment, the signal is processed to determine the start and end of beta cell depolarization, from which the depolarization duration is obtained. In order to reduce cardiac interference, each stimulus pulse is timed to be offset from the QRS signal which can interfere with the pancreas sensing. Additionally, the beta cell signals are processed by a correction circuit, e.g., an adaptive filter, to remove QRS artifacts, as well as artifacts from other sources, such as respiration. The thus obtained insulin demand signal is used either to control delivery of insulin from an implanted insulin pump, or to control ongoing pancreatic stimulation of a form to enhance insulin production. Excerpt(s): This invention relates to systems for treatment of non-insulin-dependent diabetes mellitus and, in particular, systems for stimulating the pancreas to enhance sensing of beta-cell electrical activity, from which a measure of patient blood glucose level is obtained. It is known, from statistics published in 1995, that the number of diabetes patients in the United States is 7.8 million, or about 3.4% of the total U.S. population. This number has been steadily rising over the last 25 years. Approximately 90%, or about 7 million, are non-insulin-dependent diabetes mellitus (NIDDM) patients, in whom the sensitivity to rising glucose levels, or the responsiveness of insulin, is compromised to varying degrees. About 30%, or 2.3 million these patients, use insulin, and about 25% of these insulin users take daily measures of blood glucose levels. As a general proposition, most NIDDM patients are candidates for blood glucose level measurements and/or injections of supplemental insulin. The percentage of NIDDM patients receiving insulin treatment increases with the duration of NIDDM, from an initial rate of about 25% to about 60% after 20 years. For this population of patients, there is a need for a flexible and reliable system and method for measuring glucose level and supplying insulin when and as needed. The human pancreas normally provides insulin for metabolic control. Basically, the insulin acts to promote transport of glucose in body cells. The pancreas has an endocrine portion which, among other functions, continuously monitors absolute blood glucose values and responds by production of insulin as necessary. The insulin-producing cells are beta cells, which are organized with other endocrine cells in islets of Langerhans; roughly 60-80% of the cells in an islet are such beta cells. The islets of Langerhans in turn are distributed in the pancreatic tissue, with islets varying in size from only about 40 cells to about 5,000 cells.
Patents 157
Web site: http://www.delphion.com/details?pn=US06558345__ •
Test strip for blood glucose determination Inventor(s): Cole; Gilbert W (Charlotte, NC), Phillips; Kevin J (Lancaster, SC) Assignee(s): ABB Diagnostics, Ltd. (Slough Berkshire, GB) Patent Number: 6,518,034 Date filed: June 25, 1998 Abstract: A test strip for determining blood glucose concentration includes a test strip and a photometer. The test strip comprises a substrate formed with an aperture, a polymeric membrane adhered to the aperture and in registration with the aperture, having a quantity of reagent on its bottom surface of the membrane. The polymeric membrane is adhered to the bottom of the substrate by double sided tape. The placement of the reagent on the bottom surface of the membrane allows filtration of the red blood cells from plasma before the glucose in the blood reaches the reagent and carries with it oxygen to drive the glucose-reagent reaction to completion. The photometer includes an infrared LED for detecting glucose components in the reacted test strip and simple, one-button operation. Excerpt(s): The present invention relates generally to blood glucose testing. In particular, the present invention advances a testing method and apparatus for use in determining blood glucose concentrations. The fast and accurate determination of one's blood glucose level is crucial to those with diabetes, especially for individuals who are insulin dependent. Failure to monitor blood glucose levels frequently and adequately can lead to severe health problems, diabetic coma, and, in some cases, death. Given the importance of monitoring blood glucose levels, the prior art includes devices for selfmonitoring. Self-monitoring permits diabetic patients to measure their own glucose level in a non-laboratory setting and at relatively low cost. Thus, self-monitoring improves the ability of diabetics, including those who have busy schedules and who travel frequently, to regulate their blood glucose levels. Web site: http://www.delphion.com/details?pn=US06518034__
•
Visual blood glucose test strip Inventor(s): Chang; Carol (San Francisco, CA), Dao; Mimi Diemmy (San Jose, CA), Jurik; Franklin A. (Pleasanton, CA), Stubbs; Andrea (Palo Alto, CA) Assignee(s): Lifescan, Inc. (Milpitas, CA) Patent Number: 6,531,322 Date filed: November 27, 2000 Abstract: A visual blood glucose test strip has two membranes that each incorporate a reagent that reacts with glucose in a blood sample applied to the membranes to cause a color change. One of the membranes also includes an inhibitor and a dye. A blood sample applied to the strip causes the two membranes to form two different colors. Comparing the colors to a calibrated color chart permits a user to determine the glucose concentration in the blood sample. Excerpt(s): This invention relates to a dry reagent strip that measures blood glucose concentration; more particularly, a strip that makes the glucose measurement without
158
Blood Glucose
requiring a meter. Many visual test devices have been developed for measuring the concentration of certain analytes in biological fluids. These devices have, for example, measured glucose, cholesterol, proteins, ketones, phenylalanine, or enzymes in blood, urine, or saliva. Among the devices that are in most widespread use today is the blood glucose monitor. In the U.S. alone, there are estimated to be more than 14 million people with diabetes. In order to avoid serious medical problems, such as vision loss, circulatory problems, kidney failure, etc., many of these people monitor their blood glucose on a regular basis and then take the steps necessary to maintain their glucose concentration in an acceptable range. Web site: http://www.delphion.com/details?pn=US06531322__
Patent Applications on Blood Glucose As of December 2000, U.S. patent applications are open to public viewing.9 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to blood glucose: •
Acceptance testing method for sets of multiple colored workpieces Inventor(s): Chang, Carol F.; (San Francisco, CA), Hoang, Vinh; (San Jose, CA), Jurik, Franklin A.; (Pleasanton, CA), Sharma, Manoj; (Milpitas, CA) Correspondence: Mayumi Maeda; Lifescan, INC.; 1000 Gibraltar Drive; Milpitas; CA; 95035; US Patent Application Number: 20030235923 Date filed: June 21, 2002 Abstract: A method for the acceptance testing of a set of multiple colored workpieces (e.g., paired color pads of a calibrated color chart or paired membranes of visual blood glucose test strip). The method includes first measuring a plurality of color parameters (e.g., L*a*b* color parameters) associated with the set of multiple colored workpieces, followed by conversion of the plurality of color parameters into a single response parameter. Next, the single response parameter for the set is compared to a predetermined single response parameter specification for the set and acceptance of the set of multiple colored workpieces determined based on the comparison. The method can be easily employed in conjunction with multiple (e.g., paired) membrane test strips used to measure, for example, glucose, cholesterol, proteins, ketones, phenylalanine or enzymes in blood, urine, saliva or other biological fluid and/or sample fluid characteristics such as pH and alkalinity. Excerpt(s): This invention relates, in general, to methods for the acceptance testing of colored workpieces and, in particular, to methods for the acceptance testing of sets of multiple colored workpieces, such as paired color pads of a calibrated color chart or paired membranes of a visual blood glucose test strip, based on color parameter data. In the manufacturing of colored objects (i.e., colored workpieces), it is often necessary to perform acceptance testing based on the color(s) of the colored workpiece. Such acceptance testing typically relies on any of a variety of standard color definition systems that specify color parameters for individual colors (e.g., one of the color systems
9
This has been a common practice outside the United States prior to December 2000.
Patents 159
defined by the Commission Internationale de l'Eclairage [CIE] including the systems based on the L*a*b* color space and L*C*h* color space) or visual evaluation. Acceptance testing of colored workpieces is frequently performed by obtaining CIE L*, a* and b* colorimetric parameter data (hereinafter referred to as "L*a*b*" color parameters) on individual (i.e., single) colors of the colored workpiece and then comparing each of the three L*a*b* color parameters to an associated color parameter specification. Alternatively, the L*a*b* color parameters can be used to compute a.DELTA.E*.sub.ab value with respect to a color reference standard using methods known to one skilled in the art. Such a.DELTA.E*.sub.ab value is an absolute quantity indicative of the difference of a single color of the colored workpiece undergoing acceptance testing to the color reference standard. The.DELTA.E*.sub.ab value, however, merely represents the magnitude of color difference but does not identify the direction of bias from the color reference standard. Acceptance testing of colored workpieces can also be similarly performed by using other color systems. Using these conventional methods, an individual color of a colored workpiece can be compared to color parameter specifications or a color reference standard and the colored workpiece either rejected or accepted based on that comparison. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Amphiphilic networks, implantable immunoisolatory devices, and methods of preparation Inventor(s): Isayeva, Irada S.; (Akron, OH), Kennedy, Joseph P.; (Akron, OH) Correspondence: Renner, Kenner, Greive, Bobak, Taylor & Weber; Fourth Floor; First National Tower; Akron; OH; 44308; US Patent Application Number: 20030232925 Date filed: April 1, 2002 Abstract: The present invention provides high mechanical strength amphiphilic polymeric networks and implantable biological devices made therefrom that are capable of encasing and, thus, immunoisolating biological material from an immunological response of a host individual. The present invention also provides methods for making the amphiphilic networks and implantable biological devices. The present invention also provides a method for the treatment of type I diabetes mellitus comprising the steps of encasing a sufficient amount of islet of Langerhans cells within said biological device, wherein said biological device is capable of immunoisolating said encased islet cells upon implantation into an individual; implanting said biological device into a diabetic host individual; allowing said implanted biological device to remain implanted in said diabetic individual for a time sufficient to normalize the blood glucose level in said diabetic individual. Excerpt(s): The present invention relates to amphiphilic polymer networks and methods for their preparation. The networks comprise the reaction product of hydrophobic crosslinking agents and hydrophilic monomers. The present invention is more particularly related to an amphiphilic polymer network comprising the reaction product of multi-arm multi-telechelic polyisobutylene stars as hydrophobic crosslinking agents and acrylate or methacrylate hydrophilic monomers. Applications include implantable biological devices comprising the amphiphilic networks that are capable of encapsulating and immunoisolating biologically active moieties, such as cells, from the immune response of a host individual. Many medical deficiencies and diseases result from the inability of cells to produce normal biologically active moieties. Many of these
160
Blood Glucose
deficiencies can be remedied by implanting the needed biologically active moieties or pharmacological agents into the individual having the deficiency. A well known disease that can be remedied by implanting biological material or a pharmacological agent is Type I diabetes mellitus, wherein the production of insulin by pancreatic Langerhans islet cells is substantially deficient, impaired, or nonexistent. Encapsulating human islet cells or tissues within a biologically compatible device followed by implanting the device into a host individual has been proposed as a means for providing insulin to an individual with Type I diabetes. However, an individual's immune response frequently attacks foreign biological material such as cells, tissues, and organs. And the response severely limits the effectiveness of methods that involve implanting foreign biological material. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
ANTIDIABETIC AGENTS Inventor(s): Bigge, Christopher F.; (Ann Arbor, MI), Schaum, Robert P.; (Ann Arbor, MI) Correspondence: Heidi M. Berven; Warner-Lambert Company, Llc; 2800 Plymouth Road; Ann Arbor; MI; 48105; US Patent Application Number: 20030220381 Date filed: March 17, 2003 Abstract: Compounds of formula I: 1wherein X, Y, B, E, J, K, L, Z, and R.sub.9-R.sub.12 have any of the meanings described herein, their pharmaceutically acceptable salts, lower blood glucose levels and are useful for treating diseases in mammals such as Non-Insulin Dependent Diabetes Mellitus. Also disclosed are pharmaceutical compositions, processes for preparing compounds of formula (I) and intermediates useful for preparing compounds of formula I. Excerpt(s): This application claims benefit of priority from U.S. Provisional Application Serial No. 60/369,787 filed on Apr. 3, 2002. The present invention relates to compounds that are useful as antidiabetic agents. Type II diabetes, or non-insulin dependent diabetes (NIDDM) is a significant healthcare problem whose incidence is on the rise. Between 1990 and 1998, the prevalence of NIDDM in the United States increased by 33 percent, to about 13 million persons. An additional 5 million persons are presumed to have undiagnosed NIDDM, while another 14 million persons have impaired glucose tolerance. Direct medical costs associated with diabetes were $44 billion in 1997, due mainly to hyperglycemia-related diabetic complications, including diabetic angiopathy, atherosclerosis, diabetic nephropathy, diabetic neuropathy, and diabetic ocular complications such as retinopathy, cataract formation, and glaucoma. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 161
•
Antidiabetic preparation for oral administration Inventor(s): Kato, Nobuo; (Tokyo, JP), Makino, Chisato; (Kawasaki-Shi, JP), Ninomiya, Nobutaka; (Kawasaki-Shi, JP), Orita, Haruo; (Kawasaki-Shi, JP), Sakai, Hidetoshi; (Kawasaki-Shi, JP), Shioya, Shigeru; (Tokyo, JP), Yabuki, Akira; (Kawasaki-Shi, JP) Correspondence: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.; 1940 Duke Street; Alexandria; VA; 22314; US Patent Application Number: 20040002544 Date filed: June 28, 2002 Abstract: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide, repaglinide, or mitiglinide (KAD-1229). Excerpt(s): The present invention relates to an antidiabetic, particularly to a preparation for directly controlling, namely decreasing both a post prandial blood glucose level and a fasting blood glucose level of diabetic patients with one preparation to make these levels close to normal levels. Ordinary antidiabetics are antidiabetics for decreasing either a post prandial blood glucose level or a fasting blood glucose level to make it close to a normal level. As antidiabetics for decreasing a post prandial blood glucose level to make it close to a normal level, nateglinide has been developed, and it is described in, for example, Japanese Patent Publication No. 15,221/1992 or Japanese Patent Laid-Open No. 194,969/1998. Further, antidiabetics for decreasing a fasting blood glucose level to make it close to a normal level are described in, for example, Kondo Nobuo, Nippon Rinsho, vol. 55, 1997, extra ed., p. 159 and the like. In recent years, for treating diabetes, it has been considered important that both a post prandial blood glucose level and a fasting blood glucose level are decreased to make them close to normal levels. However, there have been no preparations for decreasing both levels to make them close to normal levels. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Apparatus and method for monitoring blood glucose levels including convenient display of blood glucose value average and constituent values Inventor(s): Ginsberg, Barry H.; (Wyckoff, NJ) Correspondence: Stacey J. Longanecker; Roylance, Abrams, Berdo & Goodman, L.L.P.; Suite 600; 1300 19th Street, N.W.; Washington; DC; 20036; US Patent Application Number: 20040059201 Date filed: September 10, 2003 Abstract: A method of presenting glucose data to a person with diabetes from a blood glucose meter is provided in which an effective meal average (EMA) value is presented, followed by two or more of the individual values that make up the EMA, to provide improved feedback data for clinical decisions by patients who need to alter their dose of insulin. The EMA can also comprise a measure of the variability of its constituent
162
Blood Glucose
values. The EMA encompasses those values that occur at specified times such as 1 hour before and 1 hour after a specified meal time. The EMA is calculated over a limited number of days previous to the calculation (e.g., 3 days) and has a minimum number of values that must be obtained within the time and date ranges. An algorithm allows for exclusion of any given reading from the average (e.g., post-prandial or control solution readings). Patients can use 1 to 8 EMA on any given date range (e.g., preferably 4, that is, breakfast, lunch, supper and bedtime snack). Excerpt(s): This application claims priority from U.S. Provisional Application Serial No. 60/409,965 filed Sep. 11, 2002, the contents of which are expressly incorporated herein by reference in their entirety. Related subject matter is disclosed in a copending U.S. patent application of Gordon et al, entitled "A System and Method for Integrating Data with Guidelines to Generate Displays Containing the Guidelines and Data", Ser. No. 09/985,173, filed Nov. 1, 2001; and in a copending U.S. patent application of Gordon, entitled "System and Method for Assessment and Corrective Action Based on Guidelines", Ser. No. 10/153,883, filed May 24, 2002; the entire contents of both applications being incorporated herein by reference. The invention relates generally to blood glucose meters and glucose monitoring for managing diabetes and, more particularly, to presentation of glucose data to a user in a convenient format, including an effective meal average and its constituent values and/or a measure of variability among the constituent values. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Apparatus and method for pattern delivery of radiation and biological characteristic analysis Inventor(s): Yen, Brian; (Portola Valley, CA) Correspondence: Squire, Sanders & Dempsey L.L.P; 600 Hansen Way; Palo Alto; CA; 94304-1043; US Patent Application Number: 20040087844 Date filed: October 8, 2003 Abstract: The present invention uses a high signal to noise ratio method and apparatus to analyze a characteristic of a biological object, such as blood glucose level. The method and apparatus can also have surgical applications, such as coagulation or ablation of a pattern on a biological object. Excerpt(s): This application claims benefit of and incorporates by reference U.S. patent application Ser. No. 60/423,345, entitled "System and Method for Pattern Delivery of Radiation and Glucose Detection," filed on Nov. 1, 2002, by inventor Brian Yen. This invention relates generally to radiation delivery and characteristic analysis, and more particularly, but not exclusively, provides a system and method for characteristic analysis using pattern delivery of radiation to a biological object. Diabetes is a disease of the pancreas in which the pancreas produces little or no insulin or when the body does not respond properly to insulin ("insulin resistance"). There is no cure for diabetes and diabetics must generally manage the disease on a daily basis. One aspect of management includes injecting insulin, such as Lantus, multiple times a day or dispensing it continuously via a pump. Improper administration of insulin can lead to severe side effects including hyperglycemia in which blood glucose levels are too high, which can lead to damage to nerves, blood vessels, and other body organs. Improper administration can also lead to hypoglycemia, in which blood glucose levels are too
Patents 163
low, which can lead to passing out and even coma in worst case scenarios. Accordingly, as the amount of insulin dispensed needs to be varied based on blood glucose levels, diabetics must frequently monitor their blood glucose levels. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Atraumatic insertion of a subcutaneous device Inventor(s): Sabra, Mads C.; (Copenhagen N, DK) Correspondence: Reza Green, ESQ.; Novo Nordisk Pharmaceuticals, INC.; 100 College Road West; Princeton; NJ; 08540; US Patent Application Number: 20030225361 Date filed: March 19, 2003 Abstract: The invention relates to a concept for placing a subcutaneous device such as a sensor at a selected site within the body of a patient, e.g. to obtain blood glucose readings. In a first aspect, an insertion needle comprises an oblong needle body and a distal end portion, the distal end portion having a pointed distal tip allowing the needle to be introduced subcutaneously and a distally facing generally smooth surface, the body comprising along a portion thereof a longitudinal groove adapted to at least partially accommodate the subcutaneous device. In a second aspect, a combination of an insertion needle and a subcutaneous device form an oblong body portion and a distal end portion formed by either of the members or in combination by the two members, the distal end portion having a pointed distal tip and a distally facing generally smooth surface. By the above configuration, a concept is provided reducing the severity of the body response following transcutaneous placement of a device as well as reducing the pain associated with the insertion. Excerpt(s): The present invention relates generally to the insertion of subcutaneous devices. More specifically, the invention relates to an insertion device for placing a subcutaneous device at a selected site within the body of a patient, a needle-formed subcutaneous device as well as combinations of such devices. Especially, the invention relates to insertion means for easy transcutaneous placement of a sensor of the type used, for example, to obtain blood glucose readings. In the treatment of patients it would often be desirable to monitor a given parameter indicating the actual state of the treatment, e.g. monitoring the concentration of a drug dispensed to the patient or a body substance influenced by the drug. A given monitor system for measuring the concentration of a given substance may be based on invasive or non-invasive measuring principles. An example of the latter would be a non-invasive glucose monitor arranged on the skin surface of a patient and using near-IR spectroscopy, however, the present invention is concerned with the introduction of a transcutaneous device such as a sensor element. In recent years, a variety of electrochemical sensors have been developed for a range of applications, including medical applications for detecting and/or quantifying specific agents in a patient's blood. As one example, glucose sensors have been developed for use in obtaining an indication of blood glucose levels in a diabetic patient. Such readings can be especially useful in monitoring and/or adjusting a treatment regimen which typically includes regular administration of insulin to the patient. In this regard, blood glucose readings are particularly useful in conjunction with feedback controlled medication infusion devices, e.g. of the external type carried by the patient. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
164
•
Blood Glucose
Automated mechanical mechanism for a blood glucose sensor dispensing instrument Inventor(s): Brown, Michael K.; (Elkhart, IN), Micinski, Russell J.; (South Bend, IN), Miller, Norman S.; (Elkhart, IN), Whitson, Robert C.; (Elkhart, IN) Correspondence: Jerome L. Jeffers, ESQ.; Bayer Corporation; P. O. Box 40; Elkhart; IN; 46515-0040; US Patent Application Number: 20040069793 Date filed: October 15, 2002 Abstract: A sensor dispensing instrument adapted to handle a sensor pack containing a plurality of sensors and to perform a test using one of the sensors. The sensor dispensing instrument includes an outer housing and a disk drive mechanism contained therein for rotating the sensor pack and ejecting one of the sensors from the sensor pack and through a sensor opening on the housing. The disk drive mechanism of the sensor dispensing instrument is operated by pressing a button which activates a motor. The motor moves a disk drive pusher in a first direction to rotate the sensor pack, and then moves the disk drive pusher in a second direction to eject a sensor from the sensor cavity and through the sensor opening. Excerpt(s): The present invention generally relates to a fluid monitoring system, and, more particularly, to a new and improved instrument for handling multiple sensors that are used in analyzing blood glucose or other analytes contained therein. People suffering from various forms of diabetes routinely need to test their blood to determine the level of blood glucose. The results of such tests can be used to determine what, if any, insulin or other medication needs to be administered. In one type of blood glucose testing system, sensors are used to test a sample of blood. Such a sensor may have a generally flat, rectangular shape with a front or testing end and a rear or contact end. The sensor contains biosensing or reagent material that will react with blood glucose. The testing end of the sensor is adapted to be placed into the fluid being tested, for example, blood that has accumulated on a person's finger after the finger has been pricked. The fluid is drawn into a capillary channel that extends in the sensor from the testing end to the reagent material